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ABSTRACT 
Background: HIV-positive patients have a significantly weakened immune system which 
makes them highly susceptible for opportunistic infections, requiring additional treatment.  
Cryptococcal meningitis and oropharyngeal candidiasis are treated with oral fluconazole.  A 
great potential for drug-drug interactions (DDIs) between fluconazole and antiretrovirals 
(ARVs), efavirenz, nevirapine, and lopinavir/ritonavir, exists due to interference in common 
metabolic pathways.  The outcome may result in the development of adverse drug reactions 
or drug resistance and treatment failure. 
Aim: The primary aim of this thesis was to evaluate the effect of fluconazole on the 
pharmacokinetics of efavirenz, nevirapine and lopinavir/ritonavir in HIV-infected patients 
diagnosed with cryptococcal meningitis or oropharyngeal candidiasis. 
Methods: A prospective study was conducted in 80 HIV-positive, treatment experienced 
adults (≥18 years old) treated in three different outpatient clinics in the Western Cape region.  
Patients were subdivided according to ARV regimen and the use of fluconazole.  A sparse 
sampling design was used and corresponding ARV serum concentrations were determined by 
established HPLC and GC methods.  Fluconazole serum concentrations were determined by a 
newly developed HPLC method.  Patient characteristics, concomitant medications, clinical 
test data and ARV serum concentrations were included in a NONMEM generated, one-
compartment, open pharmacometric model with first order elimination to detect any drug-
drug interactions between fluconazole and the studied ARVs.  The secondary outcome was to 
establish which patient characteristics influence ARV pharmacokinetics. 
Results: From 80 outpatients, a total of 276 ARV serum samples (137 efavirenz, 67 
nevirapine and 72 lopinavir) were collected for pharmacokinetic evaluation.  Efavirenz 
clearance was correlated with race and concomitant use of rifampicin.  No significant 
covariates were established in the nevirapine model.  In the lopinavir model, concomitant use 
of clotrimazole and the antituberculosis combination isoniazid, pyrazinamide and rifampicin 
were identified as significant covariates. 
Discussion: No significant effects of fluconazole on the pharmacokinetics of any of the 
studied ARVs were observed.  Varying efavirenz plasma concentrations in different ethnic 
populations may be due to differences in gene expression particularly CYP2B6.  Coloured 
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patients had significantly lower efavirenz serum concentrations (56.8% decrease in 
clearance), which has not been previously described in the South African context.  Although 
gender was not a significant covariate in the nevirapine model, female patients tended to have 
higher nevirapine serum concentrations.  TB treatment in all patients receiving lopinavir 
consisted of a combination of isoniazid, pyrazinamide and rifampicin, each with different 
effects on CYP isoenzymes. The exact contributing factor of each drug in the ultimate 
decrease in lopinavir clearance (46.4%) can therefore not be established. 
Conclusions: Given the limitations of the sample size in the present study, no statistical 
significant effect of fluconazole on the pharmacokinetics of the investigated ARVs could be 
demonstrated.  A retrospective analysis of the data showed various co-factors that influence 
the pharmacokinetics of the investigated ARVs.  This data needs to be confirmed in a 
prospective study as the identified covariates are appropriate in the management of HIV-
infected patients in the South African context. 
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ABSTRAK 
Agtergrond: HIV-positief pasiënte het ‘n aansienlike verswakte immuunstelsel, wat hul 
hoogs vatbaar tot opportunistiese infeksies maak, en dus, addisionele behandeling benodig. 
Cryptococcal meningitis en orofaringeale kandidiase word met orale flukonasool behandel. 
As gevolg van middeling in algemene metaboliese paaie is daar ‘n groot moontlikheid van 
middel-middel interaksies tussen flukonasool en die antiretrovirale (ARV) middels, 
efavirenz, nevirapine, en lopinavir/ritonavir. Die uitkomste hiervan mag tot die ontwikkeling 
van nadelige middel-middel interaksies of middelweerstandigheid en mislukte behandeling 
lei. 
Doel: Die primêre doel van hierdie tesis was om die effek van flukonasool op die 
farmakokinetika van efavirenz, nevirapine en lopinavir/ritonavir in HIV geïnfekteerde 
pasiënte met gediagnoseerde cryptococcal meningitis en orofaringeale kandidiase te evalueer. 
Metodes: Die studie was met 80 HIV-positief, behandeling-ervare volwassenes (≥18 jaar) 
onderneem. Voorafgenoemde was in drie verskillende buitepasiëntklinieke in die Wes-Kaap 
behandel. Pasiënte was volgens ARV regimen en die gebruik van flukonasool, of dan nie, 
verder verdeel. ‘n Beperkte steekproef ontwerp was gebruik, en ooreenstemmende ARV 
serum konsentrasies is deurgevestigde HPLC en GC metodes vasgestel. Flukonasool serum 
konsentrasies was deur ‘n nuutontwikkelde HPLC metode vasgestel. Pasiëntkenmerke, 
gepaardgaande medikasie, kliniesetoets data en ARV serum konsentrasies was by ‘n 
NONMEM genereerde, een-kompartement, oop farmakometriese model met eerste orde 
eliminasie ingesluit om enige middel interaksies tussen flukonasool en die bestudeerde ARVs 
op te tel. Die sekondêre uitkomste was om vas te stel watter pasiënt kenmerke ARV 
farmakokinetika beïnvloed. 
Resultate:Uit 80 buitepasïente was ‘n totaal van 276 ARV serum monsters (137 efavirenz, 
67 nevirapine en 72 lopinavir) vir farmakokinetiese evaluasie gekollekteer. Efavirenz 
opruiming was met ras gekorreleer asook gepaardgaande gebruik van rifampisien. Geen 
betekenisvolle ko-variante was in die nevirapine model vasgestel nie. In die lopinavir model 
het die gepaardgaande gebruik van clotrimazole en die anti-tuberkulose kombinasie 
isoniazied, pyrazinamied en rifampisien, lopinavir opruiming verminder. 
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Bespreking: In hierdie studie is geen betekenisvolle effekte van flukanosool op die 
farmakokinetika van enige van die bestudeerde ARVs waargeneem nie. Afwisselende 
efavirenz plasma konsentrasies in verskillende etniese populasies mag aan verskille in 
geenuitdrukking, veral CYP2B6, toegeskryf word. Kleurling pasïente het betekenisvolle 
verlaagde efavirenz serum konsentrasies getoon (56.8% verlaging in opruiming). Hierdie 
bevinding is nog nooit voorheen in die Suid-Afrikaanse konteks beskryf nie. Alhoewel geslag 
nie ‘n beduidende ko-variant in die nevirapine model was nie, het vroulike pasïente geneig 
om hoer nevirapine serum konsentrasies te hê. TB behandeling, in alle pasïente wat lopinavir 
ontvang het, het uit die volgende kombinasie bestaan: isoniazied, pyrazinamied en 
rifampisien, elk met hul eie effekte op CYP isoensieme. Die presiese bydra van elke middel 
in die uiteindelike verlaging (46.4%) in lopinavir opruiming kan dus nie vasgestel word nie. 
Gevolgtrekking: Gegewe die beperkings van die steekproef in die huidige studie, kon geen 
statistiese beduidende effek van flukonazool op die farmakokinetika van die betrokke ARVs 
gedemonstreer word nie. ‘n Retrospektiewe analise van die data het gewys dat verskeidene 
ko-faktore die farmakokinetika van die betrokke ARVs beïnvloed. Hierdie data moet in ‘n 
prospektiewe studie bevestig word omdat die geidentifiseerde covariates die bestuur van 
MIV-positiewe pasiente in die Suid-Afrikaanse konteks te verbeter. 
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1.0 LITERATURE REVIEW 
 
1.1 Burden of HIV/AIDS 
The human immunodeficiency virus (HIV) has been known since the 1980s (Pomerantz et 
al., 2003).  Evolutionary scientists, however, believe that the virus was present years before it 
became public knowledge.  A cross-species transfer of the simian immunodeficiency virus 
from primates to humans has led to the development of one of the deadliest epidemics of 
humankind (Maher, 2010). 
 
1.2 HIV and Associated Opportunistic Infections 
In developing countries, HIV positive patients with late stage disease significantly contribute 
to the total burden of disease.  There is an estimated 5.5 million South-Africans living with 
HIV; contributing 17% to the global HIV/AIDS epidemic (Jarvis et al., 2010).  The 
compounding problem is late stage patients that are likely to develop a variety of 
opportunistic infections as the virus, characterized by a reduction in T-lymphocytes, renders 
the host immunocompromised and susceptible to a variety of pathogens.  Opportunistic 
infections (OIs) are defined as diseases caused by pathogens, albeit bacteria, fungi, viruses or 
parasites, that would rarely result in disease in healthy individuals.  People infected with the 
human immunodeficiency virus (HIV), however, have a significantly weakened immune 
system which compromises their ability to keep such infections under control.  Although the 
occurrence of OIs has decreased significantly after the emergence of combination 
antiretroviral therapy (cART) in developed countries, OIs still pose a major hurdle with 
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regards to morbidity and mortality in HIV-infected individuals in developing countries such 
as South Africa (Ruhnke, 2004).  Furthermore, late presentations of disease as well as HIV-
treatment failure are reasons why OIs remain troublesome and a significant cause of death in 
HIV-infected individuals (Willemot et al., 2004). 
 
Mycobacterium tuberculosis causes Tuberculosis (TB),the most deadly infection arising in 
patients living with HIV/AIDS (Sánchez et al., 2010, Elsherbiny et al., 2009).  Globally in 
2007, one out of three HIV-positive people were co-infected with TB (WHO, 2009).  
Tuberculosis was diagnosed in 27%-34% of HIV-infected adults admitted to tertiary hospitals 
in Kwa-Zulu Natal, South Africa during 2001 (Holmes et al., 2003).  Since 2001 the number 
of patients co-infected with HIV and TB has increased, with Cape Town having the second 
largest patient population.  Other OIs such as pneumocystis pneumonia (PCP), caused by the 
fungus Pneumocystis jiroveci, remains a common life-threatening infection seen in both 
treatment-naive and treatment-experienced patients (Enomoto et al., 2010).  PCP typically 
affects patients with a CD4 count of less than 200, however, patients with a CD4 count of 
less than 300 and a history of previous OIs, are also at risk and may require prophylactic 
treatment (Hull et al., 2008). 
 
The yeast, candida albicans, is present in the system of most people.  In 
immunocompromised patients, however, the body’s immune system cannot keep the fungus 
at bay resulting in disease (candidiasis).  Candida can occur in the mouth, throat or vagina 
and is one of the more common opportunistic infections seen during the early stages of 
infection (Pappas et al., 2004).  The parasite toxoplasma gondii causes an infection known as 
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toxoplasmosis which frequently manifests in the brain resulting in encephalitis.  Patients with 
CD4 count of less than 100 are at risk. 
 
Oropharyngeal candidiasis (OPC) and cryptococcal meningitis are the two most prevalent 
infections seen in late stage HIV/AIDS patients (Gallant et al., 1994).  Although OPC is 
usually treated topically, severe forms are treated systemically and this necessitates further 
treatment or prophylaxis with antifungal agents, such as fluconazole (FCZ).  A great potential 
for drug-drug interactions (DDIs) therefore exists in treated HIV/AIDS patients which in turn 
increases a patient’s probability of experiencing adverse drug events (ADEs) or treatment 
failure (Seden et al., 2009). 
 
1.2.1 Oropharyngeal candidiasis 
The most commonly encountered opportunistic infection in patients with HIV/AIDS, OPC, is 
reported to occur in approximately 90% of infected patients (Hamza et al., 2008).  Moreover, 
OPC remains the most frequent HIV-associated oral disease in sub-Saharan Africa in patients 
with a CD4 count of < 250 cells/µl (Durden et al., 1997). 
 
OPC is a fungal infection of the tongue and oral mucosa usually caused by Candida albicans, 
however, non-Candida species have recently also been found to result in OPC more 
frequently (Jenkinson et al., 2002).  It is diagnosed by observing the following symptoms: 
white, furry patches on the tongue and oral cavity; painful or burning red patches on the 
tongue; an unpleasant taste in the mouth; decreased appetite and intolerance of certain foods.  
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The development of oropharyngeal candidiasis in a patient is an indicator of progressive 
immunosuppression and therefore worsening of the condition. 
 
OPC is generally treated with oral fluconazole, either given as single dose (750mg) or as 2-
week therapy (150mg/day).  Studies have found that there is no statistically significant 
difference in efficacy between these two regimens (Hamza et al., 2008). 
 
1.2.2 Cryptococcal meningitis 
Cryptococcal meningitis (CM) is a life-threatening fungal infection commonly seen in 
patients with HIV and is one of the key indicators of the development of acquired 
immunodeficiency syndrome (AIDS) (Sloan et al., 2009).  The infection is diagnosed by 
performing a lumbar puncture.  The disease generally affects adult patients and patients with 
a CD4 cell count of 100 cells/µl or less.  The incidence of such life-threatening opportunistic 
infections has declined following large scale ART roll-out, but patients are still diagnosed 
with CM due to late presentation (Pappas, 2010). 
 
Current South African guidelines outline three treatment categories for cryptococcal 
meningitis in HIV patients (McCarthy et al., 2007): 
• A 2 week induction phase with amphotericin B (IV) at a dose of 1-1.5 mg/kg/day 
• The consolidation phase consists of oral FCZ, 400 mg given daily for 8 weeks 
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• Secondary prophylaxis (long term maintenance) with oral FCZ 200 mg/day for life or 
until CD4 count is greater than 200 cells/mm
3
 for more than 6 months on cART (at 
least 12 months on FCZ in total) 
 
The prevalence of HIV in the Sub-Saharan Africa region is approximately 22 500 000 cases 
with a reported incidence estimated at 720 000 cases of cryptococcal meningitis per year, 
which demonstrates the impact of the disease (WHO, 2009; Sloan et al., 2009).  The annual 
approximation of death due to HIV-related cryptococcal meningitis is 600 000 (Pappas, 
2010).  Research has also shown that in HIV infected individuals, the cryptococcal infection 
has a very high rate of relapse (30-50 %) following treatment (Ruhnke, 2004).  Management 
of the infection in patients therefore routinely involves lifelong antifungal therapy in addition 
to the antiretroviral therapy.  With the emergence of immune reconstitution inflammatory 
syndrome (IRIS), a condition seen in cART-treated patients, there is a paradoxical 
deterioration in the patients’ clinical status as the recovering immune system responds to a 
previously acquired opportunistic infection which in turn worsens the symptoms of infection 
(Ruhnke, 2004).  Management for this condition includes continuation of both antifungal 
therapy and cART. 
 
1.3 Drug-drug interactions (DDIs) 
Polypharmacy or the prescription of a cocktail of drugs to treat one or multiple pathologies 
has become common practice.  Consequently the threat of DDIs has become more evident.  
Knowledge of the occurrence and the extent of such interactions are crucial to research, the 
health care provider and the patient to improve prescribing practices and avoid adverse drug 
reactions (ADRs) (Mehta et al., 2007; Lazarou et al., 1998).  The World Health Organization 
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(WHO) defines ADRs as “any noxious, unintended and undesired effect of a drug, which 
occurs at doses used in humans for prophylaxis, diagnosis, or therapy”.  ADRs are a 
significant contributor towards hospital admissions (Pirmohamed et al., 2004).  A meta-
analysis of hospital admissions in the USA, between 1966 and 1996, shows that 45 770 
patients were admitted to hospital due to an ADR and 17 753 (39%) of these admissions 
resulted in death (Lazarou et al., 1998).  In the age of HIV/AIDS and tuberculosis, 
developing countries such as South Africa have also observed an increase in hospital 
admissions due to ADRs.  A prospective, observational study of 655 patients admitted to the 
New Somerset Hospital in Cape Town, South Africa, found that a total of 96 patients (14%) 
experienced at least one adverse drug reaction; 41 patients were admitted to hospital because 
of the ADR, 41 patients developed an ADR after admission and 14 patients were hospitalized 
for other medical conditions (Mehta et al., 2007).  The two drug classes that contributed 
mainly to hospital admission were cardiovascular and antiretroviral agents.  Whereas ADRs 
that developed after patient admission were mostly attributed to drugs used to treat various 
opportunistic infections (antifungals, anti-tuberculosis drugs and antibiotics). 
 
DDIs are a major cause of adverse drug reactions and the potential risk factors for developing 
DDIs are extensive (Pirmohamed et al., 2004).  High pill burden, concomitant diseases, 
gender, race (genetic variation) and age are the main risk factors cited for developing DDIs 
(Evans-Jones et al., 2010; Lazarou et al., 1998).  The relationship between experiencing a 
DDI and age is however disproportionate.  Elderly patients are more likely to have altered 
drug plasma levels because of physical changes that affect drug disposition and metabolism 
(Routledge et al., 2003; Gurwitz et al., 1991).  An increase in body fat content can result in 
an increased volume of distribution and changes in renal and hepatic function may affect the 
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metabolism and excretion of drugs.  All of these factors contribute to possible overdosing of 
elderly patients with standard dosages of a drug (Gurwitz et al., 1991). 
 
DDIs are unavoidable and often overlooked especially in HIV-positive populations (Patel et 
al., 2011).  Adverse reactions caused by concomitant use of antiretrovirals and contra-
indicated co-medication account for 5.2% of hospital admissions (Evans-Jones et al., 2010).  
It is known that HIV-positive patients can develop a number of HIV-associated opportunistic 
infections, as discussed earlier, which requires additional treatment.  Moreover, effective 
management of the disease requires life-long ART.  HIV has therefore become a chronic 
illness and the HIV-patient population is ageing.  With age comes a multitude of other 
illnesses that also require further treatment and therefore polypharmacy is commonly 
practiced in this patient population (Seden et al., 2009; Tseng et al., 1997). 
 
Drug interactions are broadly defined as an event that occurs between co-administered drugs, 
drugs and food or drugs and lifestyle (such as smoking or drinking).  DDIs specifically may 
affect the pharmacokinetic profile (absorption, distribution, metabolism and elimination) of a 
pharmaceutical agent as well as its efficacy and side effect profile (Robertson et al., 2005; 
Dresser et al., 2000).  DDIs are not limited to oral administration of agents, but may also 
occur after drug administration via any other route i.e.: topical, rectal, inhalation.   
 
Considerable variation exists in the reported prevalence of clinically significant DDIs (Patel 
et al., 2011; Seden et al., 2009; Stockley, 2002).  This could be attributed to different 
definitions of clinical significant drug interactions, study methodology and the specific 
population studied (Stockley, 2002).  DDIs are stratified into 4 different groups: drugs should 
not be co-administered; potential for interaction exists; no clinically significant interaction 
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expected or too little or no clear data available on possible interaction (Patel et al., 2011; 
Seden et al., 2009; Robertson et al., 2005).  Moreover, DDIs are subdivided into either 
pharmacodynamics (PD) or pharmacokinetic (PK) interactions, according to their specific 
mechanism of interaction (Back et al., 2003; de Maat et al., 2003; Piscetelli et al., 2001; 
Tseng et al., 1997). 
 
1.3.1 Pharmacodynamic Interactions 
Pharmacodynamic interactions arise from an additive, synergistic or antagonistic effect that 
occurs at the sites of action in response to co-administration of drugs (de Maat et al., 2003).  
An alteration in the pharmacological response (efficacy and/or toxicity) may result.  The 
polyene antifungal amphotericin B is used mainly in the treatment of life-threatening 
systemic fungal infections (such as cryptococcal meningitis), as it has a narrow therapeutic 
index.  Interactions between amphotericin B and antiretrovirals (ARVs) are 
pharmacodynamic in nature and may result in nephrotoxicity, blood dyscrasias and 
hypokalaemia (Albengres et al., 1998).  Other general examples of pharmacodynamic DDIs 
include: alcohol and antidepressants (synergism); ACE inhibitors and non-steroidal anti-
inflammatory drugs (additive); thiazides and non-steroidal anti-inflammatory drugs 
(antagonism). 
 
1.3.2 Pharmacokinetic Interactions 
Most DDIs are pharmacokinetic in nature. This results in a change in either of the drugs 
blood concentration or its tissue distribution, thereby affecting the drug concentration at the 
targeted site of action.  These effects are attributed to the drugs interaction with processes 
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such as absorption, distribution, metabolism and excretion (Robertson et al., 2005; Back et 
al., 2003; Dresser et al., 2000).  Pharmacokinetic DDIs have a number of possible outcomes.  
Drug levels of either the concomitant medications may be lowered thereby achieving sub-
therapeutic levels which may lead to treatment failure as well as the development of drug 
resistance.  Alternatively, DDIs may elevate the concentrations of co-administered 
medications resulting in drug toxicity and an increase in the severity and risk of developing 
adverse effects. 
 
1.3.2.1 Drug interactions in absorption 
Drug absorption is defined as the movement of a pharmaceutical agent across an epithelial 
barrier, from the gastrointestinal tract to the circulatory system.  Concomitant administration 
of drugs or the combination of drugs and food can alter the gastrointestinal absorption of a 
drug resulting in decreased circulating drug concentrations (bioavailability) and drug effect 
(Welling, 1984).  Absorption of a drug may be affected by various factors and a distinction is 
made between the total amount of drug absorbed and the rate of absorption (de Maat et al., 
2003).  According to de Maat et al. (2003) drugs that are taken as part of life-long or long-
term therapy, HIV treatment being a case in point, the amount of drug absorbed is more 
important than the rate of absorption. 
 
The bioavailability of a drug may significantly be augmented by the presence of food.  This 
could be beneficial to increase the absorption of certain agents (ARVs such as 
lopinavir/ritonavir, atazanavir, nelfinavir; beta blockers; itraconazole) or to prevent unwanted 
effects such as gastric irritation (NSAIDs such as aspirin and ibuprofen; corticosteroids; 
penicillins) (Piscitelli et al., 2001; Tseng et al., 1997).  Patients may be advised to take 
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certain drugs (e.g. efavirenz, diuretics, nitrates) away from food in order to limit increased 
drug absorption and resulting plasma concentrations which may be associated with adverse 
effects (Robertson et al., 2005).   
 
Chelation reactions between certain drugs and cations (e.g. metal ions and tetracyclines, 
cholestyramine and oral contraceptives, digoxin or Vitamin K) may decrease absorption of 
the specific pharmaceutical agent when taken concomitantly (Welling, 1984).  Another factor 
that may influence drug absorption is the pH of the gastrointestinal tract.  The absorption of a 
variety drugs, including two different antifungals ketoconazole and itraconazole, is pH 
dependent, whereas FCZ absorption seems  to be unaffected by gastrointestinal pH (Piscitelli 
et al., 2001; Tett et al, 1995).  The resulting absorption of ketoconazole and itraconazole then 
relies on the physiological pH of the gut as well as whether the concerned drug is an acid or a 
base (physiochemical properties).  Furthermore, absorption of a drug may be altered by the 
use of antacids which could impair absorption of co-administered agents as well as 
decreasing gastric acidity (de Maat et al., 2003).  Absorption of FCZ and nevirapine is 
unaffected by the concomitant use of antacids (Diflucan® package insert; Viramune® package 
insert). It is, however, recommended to take an antacid one to two hours before or after 
taking efavirenz or lopinavir/ritonavir as the co-administration of these combinations may 
lead to decreased absorption of the antiretroviral agents (Kaletra® package insert; Sustiva® 
package insert).  A co-formulation of didanosine and magnesium antacid is known to 
decrease ciprofloxacin’s (fluoroquinolone) area under the curve (AUC) by 80 percent (Sahai 
et al., 1993).  This interaction can be avoided by taking the fluoroquinolone either 2 hours 
before or 6 hours after the antacid formulation.  The new, enteric-coated didanosine 
formulation does not pose this problem however. 
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1.3.2.2 Drug interactions in distribution 
The most important considerations for distribution interactions between drugs are the degree 
of protein binding of each drug and its mechanism of distribution throughout the body.  It is 
known that only the fraction of drug that is not bound to plasma proteins, albeit albumin, 
lipoproteins or glycoproteins, is pharmacologically active and able to elicit a response (de 
Maat et al., 2003).  It is also this fraction that undergoes metabolism and is excreted.  The 
fraction of drug bound to plasma proteins acts as a reservoir of that drug.  In the event of an 
interaction between two drugs normally bound to the same plasma protein, some competition 
and displacement may occur (Robertson et al, 2005).  Theoretically this could increase the 
unbound fraction of one of the drugs leading to higher plasma concentrations thereby 
enhancing the drug effect.  However, homeostatic control ensures that changes in the 
unbound drug fraction do not alter plasma concentrations by increasing the elimination of 
unbound drug, thereby maintaining equilibrium (Robertson et al., 2005; de Maat et al., 2003).  
Clinically significant DDIs, as a result of protein binding, are uncommon and clinically not 
considered relevant (Sansom et al., 1995).  This is true unless displacement results in 
increased plasma concentrations of drugs that have a high hepatic extraction ratio or drugs 
that have a narrow therapeutic window, long half-life and relatively small volume of 
distribution (Vd) such as phenytoin or tolbutamide (de Maat et al., 2003; Stockley, 2002; 
Sansom et al., 1995).   
 
The ARVs have varying degrees of plasma protein binding; nevirapine (60%), 
lopinavir/ritonavir (98-99%) and efavirenz (99%) (Cvetkovic et al., 2003; Smith et al., 2001).  
No significant interactions, with regards to protein binding, have been reported with the 
ARVs or FCZ (11-12%) respectively (Robertson et al., 2005). 
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The distribution of certain drugs is also regulated by specific transporters such as P-
glycoprotein (P-gp), a multi-drug resistant (MDR) protein (Zhang et al., 2001).  P-gp is an 
ATP-dependent efflux transporter widely distributed throughout the body.  P-gp is located in 
hepatocytes, renal tubules, epithelium lining the small and large intestines, lymphocytes and 
endothelial cells of various barriers (blood-brain -, blood-testes – and maternal-fetal barrier) 
(Christians, 2004; de Maat et al., 2003).   
 
The protease inhibitors, including lopinavir/ritonavir, are substrates of P-gp and their 
distribution may be affected by the concomitant use of agents that also affect this efflux 
transporter (Table 1).  Moreover, lopinavir/ritonavir and efavirenz also act as inducers of this 
efflux transporter and transport of co-administered agents and corresponding drug 
concentrations may be affected (Zhang et al., 2001) 
 
Table 1:  Selected substrates, inducers and inhibitors of P-gp.  Adapted from Zhang et al. 
(2001) 
P-gp substrates  P-gp Inducers P-gp Inhibitors   
     
Amytriptyline Indinavir Amytriptyline Amiodarone Haloperidol 
Amoxicillin Lopinavir Dexamethasone Atorvastatin Ketoconazole 
Atorvastatin Morphine Efavirenz Clarithromycin Itraconazole 
Carbamazepine Phenytoin Lopinavir Cyclosporin Quinidine 
Corticosteroids Quinidine Phenobarbital Erythromycin Ritonavir 
Cyclosporin Verapamil Ritonavir Grapefruit juice Saquinavir 
Digoxin  Rifampicin Garlic Simvastatin 
Estradiol    St. John's wort Green tea Verapamil 
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1.3.2.3 Drug interactions in metabolism 
DDIs are often caused by the interaction of drugs in their common metabolic pathways.  
Metabolism of drugs results in the conversion of lipophilic drug compounds to a more 
ionized or polar form which can more easily be excreted (Attia, 2010).  Metabolism of drugs 
occurs by two separate processes.  Phase I reactions involve processes such as oxidation, 
addition of a hydroxyl group as an oxygen moiety to an organic molecule; reduction and 
hydrolysis, in order to convert the drug to a more polar compound (Guengerich, 2008; Zhang 
et al., 2001).  Phase II reactions, which are commonly referred to as conjugation reactions, 
involve the addition of amino acids, glucuronic acid, glutathione or sulphonates to the phase I 
functional groups resulting in metabolites of the specific drug (Attia, 2010; de Maat et al., 
2003).  With rare exceptions, phase II metabolites are no longer pharmacologically active and 
can readily be excreted via the kidney.   
 
Several enzyme systems are involved in drug metabolism, however, the majority of drugs are 
metabolised by via the cytochrome P450 isoenzyme system (CYPs) (Guengerich, 2008; 
Nebert et al., 2002).  CYPs are localised in the smooth endoplasmic reticulum of the liver and 
the gastrointestinal tract, the main metabolising sites, as well as the stomach, lungs, kidneys 
and the small and large intestines (Zhang et al., 2001).  This system is a superfamily of 57 
genes that code for the various CYP enzymes (Guengerich, 2008).  The enzymes are further 
subdivided into so-called families and subfamilies with regards to their amino acid sequence 
homology and the molecules that they metabolise (Nebert et al., 2002).  The most important 
human CYP isoforms with regards to drug metabolism are: CYP1A2, CYP2A6, CYP2B1, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (Figure 1) (Guengerich, 2008; Back 
et al., 2003).  CYP3A4 is the most prominent isoenzyme involved in drug metabolism.  It 
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contributes 30% to the total amount of CYP enzyme and is responsible for the metabolism of 
roughly 50% of all marketed drugs (Figure 1) (Back et al., 2003; Zhang et al., 2001). 
 
 
 
 
 
 
 
 
Figure 1: (a) Relative abundance of Cytochrome P450 isoenzymes in the human liver and (b) the 
relative contribution of specific isoenzymes to the metabolism and clearance of 403 marketed drugs. 
Adapted from Tozer et al. (2006). 
 
 
A drug is a substrate of a CYP enzyme, when it relies on this enzyme system for metabolism.  
Moreover, drugs can be inhibitors or inducers of one or more CYP isoenzymes (Robertson et 
al., 2005; Back et al., 2003; de Maat et al., 2003).  Inhibition and induction of drug 
metabolism are two distinct processes.  Inhibitors of CYP isoenzymes result in increased drug 
plasma concentrations of co-administered agents and increase the risk of experiencing ADRs 
(Table 2).  Inhibition is a direct and immediate effect of the co-administered agent on the 
responsible metabolising enzymes of the affected agent (Tseng et al., 1997).  Inhibition is 
either competitive (co-medicated agents compete for the active site of the enzyme) or non-
competitive (inhibitor binds to the enzyme-substrate complex resulting in a non-functional 
drug-enzyme complex) and reversible (once the co-medicated drug is discontinued) or 
irreversible (Piscitelli et al., 2001).  Inhibition is commonly a rapid process and the full effect 
may be evident after a couple of days (de Maat et al., 2002; Tseng et al., 1997). 
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Furthermore, the administration of multiple doses, HIV-infected patients a case in point, can 
lead to accumulation of the drug due to incomplete metabolism.  This may result from a 
genetic deficiency of the particular CYP isoenzyme responsible for drug metabolism or due 
to the inhibitory interaction of a co-administered agent and toxicity may develop 
(Guengerich, 2008).   
 
Induction of metabolic enzymes is a more complicated process.  The outcome of CYP 
enzyme induction is an increase in transcription of CYP-encoding DNA, synthesis of the 
corresponding CYP enzyme and consequently increased activity of the metabolizing enzyme 
(Mohutsky et al., 2010).  This is achieved via a signal transduction pathway once the enzyme 
inducer has achieved steady-state concentrations and therefore the time course of induction is 
lengthier and the affects may only be seen after 2-3 weeks (Tseng et al., 1997).  Enzyme 
induction accelerates metabolism of the co-administered agent and results in decreased 
plasma concentrations and increased clearance from the body (Table 3).  Certain drugs are 
also known to be auto-inducers.  These drugs (eg nevirapine, rifampicin, phenytoin, 
carbamazepine) have the ability to increase the rate of their own metabolism, but only for a 
specific time period (Mohutsky et al., 2010).  Hence, the specific drug is given at a lower 
dose when initialising therapy and the dose is subsequently increased to achieve appropriate 
plasma concentrations. 
 
Induction of CYP3A isoenzymes, specifically, is mediated by a ligand-activated transcription 
factor known as the pregnane-X receptor (PXR), belonging to the nuclear hormone receptor 
family (Back et al., 2003; Nebert et al., 2002; Zhang et al., 2001).  When a drug molecule 
binds to the PXR, transcription of the associated CYP gene occurs which eventually leads to 
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an increase in enzyme production and an associated decrease in the plasma concentration that 
is metabolised by the specific enzyme (Back et al., 2003; Nebert et al., 2002) 
Table 2:  Selection of CYP isoenzymes and their corresponding inhibitors. 
CYP Isoenzyme Inhibitor - ARVs Inhibitor - Non-ARVs 
   
2B6 efavirenz, ritonavir, nelfinavir ticlopidine, curcumin 
   
2C9 efavirenz, etravirine, delavirdine fluconazole, amiodarone 
   
2C19 efavirenz, etravirine, delavirdine Omeprazole 
   
2D6 ritonavir, delavirdine, maraviroc quinidine, paroxetine, bupropion 
   
3A4 lopinavir/ritonavir, other PIs, fluconazole, ketoconazole, 
 delavirdine erythromycin, grapefruit juice 
      
 
 
 
Table 3:  Selection of CYP isoenzymes and their corresponding inducers. 
CYP Isoenzyme Inducer - ARVs Inducer - Non-ARVs 
   
2B6 nevirapine phenobarbital, rifampicin 
   
2C9 efavirenz, lopinavir/ritonavir Rifampicin 
   
2C19 efavirenz, lopinavir/ritonavir carbamazepine, rifampicin 
   
2D6 ~ dexamethasone, rifampicin 
   
3A4 efavirenz, nevirapine rifampicin, rifabutin, phenytoin, 
  glucocorticoids, St. John's wort 
      
 
1.3.2.4 Drug interactions in renal excretion 
Firstly, unbound, active drug or drug metabolites are filtered through the glomerular 
membranes of the kidney upon which the drug reaches the lumen of the renal tubules.  The 
rate of this filtration process is related to the flow of blood through the glomeruli.  
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Prostaglandins produced in the kidney indirectly control the flow of blood through the kidney 
(Stockley, 2002).  Drugs that inhibit prostaglandins, such as NSAIDs, may therefore alter 
blood flow and subsequent renal filtration of a drug.  No clinically significant DDIs occur at 
this level. 
 
Not all drugs rely on metabolism for excretion.  Certain drugs, including FCZ (excreted 
mainly as unchanged drug in the urine), depend on renal clearance for their elimination.  
These drugs are mainly polar, non-lipophilic agents that are actively transported from the 
blood across tubular epithelium for excretion in the urine (Robertson et al., 2005).  
Interactions may occur when co-administered agents inhibit, promote or compete for this 
transport mechanism.  The trimethoprim-sulfamethoxazole (TMP-SMX) combination and 
probenecid are competitive inhibitors of renal tubular secretion (Piscitelli et al., 2001).  It is 
known that acyclovir and penicillin levels are elevated when co-administered with 
probenecid and the concomitant use of TMP-SMX and lamivudine results in increased 
plasma lamivudine concentrations (de Maat et al., 2003; Piscitelli et al., 2001).  The 
aforementioned interaction is however not deemed clinically significant as elevated 
lamivudine concentrations are not correlated to the development of adverse effects (Piscitelli 
et al., 2001).  Furthermore, the acidity of a drug can also influence its excretion when used 
together with pH altering agents.  Weak acids, such as salicylates, are more readily excreted 
when the urine is alkalanised. 
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1.3.3 Drug-drug interaction studies 
The armamentarium of therapeutic agents is constantly enlarging and evolving, therefore 
obtaining formal data with regards to potential DDIs for all drug combinations observed 
during clinical use is not possible.  When information with regards to a particular drug 
combination is unavailable, predictions are made on the basis of extensive in vitro and/or in 
vivo pharmacokinetic and pharmacodynamic data (Tseng et al., 1997).  Drug interactions 
may be similar within the same class of drugs or they may vary between drugs belonging to 
the same drug class (eg. simvastatin vs primvastatin) and therefore predicting DDIs may not 
be a simple procedure (Stockley, 2002).  
 
Formal DDI studies during drug development are typically designed as randomized, 
controlled, cross-over studies in healthy volunteers.  The data gathered from these studies 
provide information on the tested drug (A) and its potential DDI with the co-administered 
compound (B).  More specifically, pharmacokinetic parameters describing the rate and extent 
of drug absorption, such as the maximum plasma concentration (Cmax), time to maximum 
concentration (tmax) and area under the time-concentration curve (AUC), are determined from 
these studies.  These parameters can then be compared for each patient when taking the test 
product alone (A) or concomitantly with another drug (A+B).  Each patient in this case acts 
as his/her own control.  A significant DDI is usually present if the 90% confidence interval 
for the ratio between both test conditions falls outside the 80-125% range.  
 
DDIs, clinically significant or not, must be confirmed in patient cohorts for whom the drug is 
indicated (Fletcher, 2010).  When comparing the pharmacokinetic parameters of a drug 
Stellenbosch University http://scholar.sun.ac.za
Literature review                                                                 40 
 
between healthy volunteers and affected patients, differences are commonly seen as a result 
of disease-related modifications (Tseng et al., 1997).  Dickinson et al. (2008) report 
differences in pharmacokinetic parameters of the protease inhibitors (saquinavir, tipranavir 
and atazanvir) in healthy individuals and patients.  When comparing atazanavir and tipranavir 
concentrations, HIV-infected patients had lower plasma concentrations than the cohort of 
healthy volunteers.  Conversely, saquinavir concentrations were higher in HIV-positive 
patients, especially HIV-infected women (Fletcher, 2010; Dickinson et al., 2008).  Another 
example is the interaction between rifabutin and lopinavir/ritonavir.  Concentrations of 
rifabutin were lower in HIV-TB co-infected patients (AUC0-48 4.42 µg.h/L) than in healthy 
volunteers (AUC0-48 7.20 µg.h/L) when co-administered with lopinavir/ritonavir (Boulanger 
et al., 2009).   
 
Furthermore, a DDI study between the antiretrovirals etravirine and raltegravir in healthy 
subjects only showed a modest effect of etravirine on raltegravir pharmacokinetics; 11% 
decrease in Cmax and 10% decrease in AUC (Anderson et al., 2008).  However, when this 
combination was investigated in four cases following co-administration in HIV-positive 
patients, it became evident that significant DDI may result (Mènard et al., 2009).  Mènard 
and colleagues observed that in all four patients a combination of standard etravirine and 
raltegravir (400 mg bd.) doses resulted in markedly reduced raltegravir trough concentrations 
(Cmin) ranging from 5 – 30 ng/ml.  The recommended therapeutic concentration for 
raltegravir ranges between 29 ng/ml and 118 ng/ml.  Following therapeutic drug monitoring 
in these patients, a dosage adjustment of raltegravir to 1200 mg per day seemed to 
compensate for the DDI between etravirine and raltegravir in HIV-infected patients (Do et 
al., 2011; Mènard et al., 2009). 
Stellenbosch University http://scholar.sun.ac.za
Literature review                                                                 41 
 
 
Industry DDI studies are performed within a limited time period, whereas in a clinical setting, 
patients are often prescribed co-administered agents for an indefinite period of time (Fletcher, 
2010).  The conclusion drawn from all these studies is that controlled industry trials involve 
homogeneous, healthy subjects and the results obtained cannot always be generalised to the 
patient population.  Moreover, DDIs may also be more prevalent or more extensive within 
HIV-positive patients. 
 
The need exists for such studies to be performed in the target population in order to ascertain 
the complete potential of interaction between drug and disease or drug and co-administered 
agents.  The present study focuses on potential DDI within a HIV-infected patient cohort in 
the Western Cape, South Africa. 
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1.4 Antiretroviral agents 
Effective treatment of the human immunodefiency virus (HIV) has become more complicated 
over the years as patients require antiretroviral regimens that consist of a combination of 
agents that target different stages of the viral replication cycle.  Combination antiretroviral 
therapy (cART) involves concomitant administration of three or more agents from different 
pharmacological classes (Kis et al., 2009; Seden et al., 2009).  Most of these agents are 
inducers or inhibitors, as well as substrates of the human CYP enzyme system in the liver 
and/or the gastrointestinal mucosa, and can therefore influence or alter the metabolism of co-
administered agents resulting in DDIs (Kakuda et al., 2008).  Numerous different classes of 
antiretrovirals exist (Table 4).  The available treatment strategies for HIV-infected patients in 
South Africa are outlined in Table 5.  
 
Table 4:  Classes of antiretroviral drugs  
Class Agents available 
Nucleoside reverse  
transcriptase inhibitors 
zidovudine, didanosine, stavudine, lamivudine, 
tenofovir, zalcitabine, abacavir, emtricitabine 
Non-nucleoside  
reverse transcriptase inhibitors 
nevirapine, efavirenz, delavirdine*, etravirine*, 
rilpivirine* 
Protease inhibitors 
lopinavir/ritonavir, saquinavir, indinavir,  
nelfinavir, amprenavir 
Fusion inhibitors/Entry inhibitors maraviroc*, enfuvirtide* 
Integrase inhibitors raltegravir 
CCR5 receptor antagonists aplaviroc*, vicriviroc* 
Maturation inhibitors alpha interferon* 
* Drugs not available in South Africa 
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Table 5: Standardised national antiretroviral therapy (ART) regimens for adults and 
adolescents. Adapted from the National Department of Health, South African 
Guidelines (2010) 
1st line therapy 
  EFV is preferred in TB co-infection 
All new patients  NVP is preferred in pregnant women, 
requiring treatment 
TDF + 3TC/FTC + 
EFV/NVP women of child bearing age and  
    women not on reliable contraception 
Currently on d4T-based    Remain on d4T if well tolerated. Switch  
regimen with no side  early with any toxicity. Substitute TDF if 
effects 
d4T + 3TC +EFV/NVP 
at high risk of toxicity (older, high BMI, 
    female, TB treatment) 
Contra-indication to TDF    
renal disease 
AZT + 3TC + EFV/NVP 
  
2nd line therapy 
  Virological failure followed by intensive  
Failing on a d4T or AZT- adherence management. If repeat VL 
based 1st line regimen 
TDF + 3TC/FTC + LPV/r 
remains >1000 in 3 months despite 
    adherence intervention, switch. 
    Virological failure followed by intensive  
Failing on a TDF-based adherence management. If repeat VL 
1st line regimen 
AZT + 3TC + LPV/r 
remains >1000 in 3 months despite 
    adherence intervention, switch. 
Salvage therapy 
  Virological failure on protease inhibitors 
  is almost always due to non-adherence. 
  Intensively explore and address issues 
Failing any 2nd line relating to causes of non-adherence 
regimen 
Specialist referral 
most often lead to resuppression. If VL 
  remains high, refer where possible, but 
    maintain on failing regimen. 
*Abbreviations:  3TC Lamivudine; AZT Zidovudine; d4T Stavudine; EFV Efavirenz; FTC Emtracitabine;  
  LPV/r Lopinavir/ritonavir; NVP Nevirapine; TDF Tenofovir; VL Viral load 
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1.4.1 Nevirapine 
Nevirapine (Viramune®) belongs to the group non-nucleoside reverse transcriptase inhibitors 
(NNRTI’s); one of the five existing classes of antiretroviral agents available in South Africa.  
Nevirapine was the first NNRTI widely introduced into clinical practice following approval 
by the US Food and Drug Administration (FDA) in 1996 (Pomerantz et al., 2003).  The drug 
is structurally classified as a dipyridodiazepinone and has a molecular weight (MW) of 266.3; 
the structural formula is given in Fig. 2 (Havlir et al., 1995). 
N
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Figure 2:  Chemical structure of nevirapine 
 
1.4.1.1 Indications 
Nevirapine is most effective when used in combination with other antiretroviral agents for the 
treatment of Human Immunodeficiency Virus Type 1 (HIV-1).  The drug commonly forms 
the backbone of combination antiretroviral therapy (cART) in both treatment-naive and 
treatment-experienced HIV patients (Kappelhoff et al., 2005).  Because of its accessibility 
and cost nevirapine is extensively used in first line treatment regimens in resource-limited 
settings, such as South Africa (Elsherbiny et al., 2009; Vrouenraets et al., 2007; Sanna et al., 
2005). 
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Due to potential serious adverse events initiation of therapy with nevirapine, in adults 
specifically, is indicated in women with a CD4 count of less than 250cells/mm
3
 and in men 
with a CD4 count of less than 400cells/mm
3 
(South African Treatment Guidelines, 2010; 
Knobel et al., 2008).  This general guideline is followed unless the benefits to the patient 
outweigh the risks. 
 
Furthermore, mother-to-child transmission of HIV is also a significant contributor to the 
incidence of disease in third world countries such as Africa (Moodley et al., 2003; Luzuriaga 
et al., 1997).  Numerous studies have demonstrated nevirapine’s efficacy in reducing vertical 
transmission of HIV (Luzurgia et al., 1997).  The HIV-Net 012 clinical trial run in Uganda 
showed that a single 200 mg nevirapine dose during labour and a single 2 mg/kg to their 
newborn within 72 hours of birth significantly decreases to risk of HIV-transmission (Kunz et 
al., 2009).  These results were compared to a similar study done with zidovudine, which  
however showed no significant effect.  Not only is nevirapine superior in clinical efficacy, 
but the treatment is also markedly cheaper which makes the nevirapine regimen the better 
quality option, especially in developing countries (Vrouenraets et al., 2007).  It therefore also 
remains the drug of choice in women of child-bearing age (South African Treatment 
Guidelines, 2010). 
 
1.4.1.2 Mechanism of action 
Nevirapine inhibits the viral reverse transcriptase enzyme and hence the replication of the 
HIV Type-1 virus.  Unlike the nucleoside analogues (NRTIs), which bind to the enzymes 
active site, nevirapine non-competitively targets the viral enzyme by binding to an allosteric 
site (Pomerantz et al., 2003, Havlir et al., 1995; Richman et al., 1994).  This results in a 
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conformational change in the HIV reverse transcriptase, which renders the enzyme unable to 
convert single stranded viral RNA to double stranded DNA for incorporation into human 
DNA (Figure 3) (Dahri et al., 2007; Smith et al., 2001).  This inhibition thus prevents further 
multiplication of the virus (de Clercq, 2004). 
 
 
Figure 3:  Mechanism of action of (a) NRTIs which require intracellular activation and (b) NNRTIs 
(mechanism described in text). Modified from R.J. Pomerantz et al., 2003. 
 
1.4.1.3 Pharmacokinetics 
Nevirapine is administered as an oral dose in adults and utilised in combination with other 
antiretroviral agents.  In order to account for the drugs auto-inducing capabilities on the CYP 
metabolising enzyme system, initiation with nevirapine consists of a two week lead-in period 
of a 200 mg once daily dose (South African Treatment Guidelines, 2010; Mohutsky et al., 
2010).  Continuous therapy is then dosed as 200 mg nevirapine twice daily.  Following oral 
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administration, the drug is well absorbed (absolute bioavailability >90%) in both healthy 
subjects as well as HIV-1-infected patients (Smith et al., 2001).  Absorption of nevirapine 
occurs almost completely within 4 hours after drug intake (Havlir et al., 1995). Absorption 
may be delayed by food intake, but bioavailability of the drug is not affected.  Peak plasma 
concentrations of 5.74 µg/ml (5.00 -7.44 µg/ml) (median and interquartile range) are obtained 
within 2 hours following a 200 mg twice daily nevirapine dose (van Heeswijk et al., 2000).  
The recommended therapeutic concentration for the drug is a trough concentration greater 
than 3.4 µg/ml (Dahri et al., 2007). 
 
Nevirapine is a small, lipophilic molecule that is mainly unionized at physiological pH 
(pH=7.4) (Back et al., 2003).  The drug is therefore widely distributed throughout the body 
including breast milk (Kunz et al., 2009, Moodley et al., 2003).  It crosses the placenta and is 
classified as a category B medication in pregnancy.  Cerebrospinal fluid (CSF) penetration of 
nevirapine is moderate, concentrations reaching up to approximately 30% of the 
corresponding plasma concentration (Yazdanian et al., 1999).  Nevirapine is 60% plasma 
protein bound; the majority being bound to albumin (Smith et al., 2001). 
 
The elimination half life of nevirapine following a single 200 mg dose is 45 hours (van 
Heeswijk et al., 2000).  This decreases considerably following multiple dosages, ranging 
from 25 to 30 hours for patients at steady state (Smith et al., 2001).  Nevirapine undergoes 
extensive hepatic metabolism.  The two main isoenzymes involved are CYP3A4 and 
CYP2B6 with limited contribution by the isoenzymes CYP2D6 and CYP2C9 (Elsherbiny et 
al., 2009; de Maat et al., 2003).  Nevirapine is metabolised to 4 different metabolites namely 
2-, 3-, 8- and 12-hydroxynevirapine, the 12-hydroxy form being the only active metabolite 
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(Elsherbiny et al., 2009).  The primary route of elimination is as glucoronidated metabolites 
(2-,3- and 12-hydroxynevirapine glucuronide) in the urine.  Only a small fraction (±3%) of 
the drug is excreted unchanged in the urine. 
 
1.4.1.4 Side effects 
Nevirapine is relatively well-tolerated in most patients and has a reasonable safety profile 
(Pomerantz et al., 2003; Bershoff-Matcha et al., 2001; Havlir et al., 1995; Richman et al., 
1994).  The two most serious adverse events associated with the drug are hepatotoxicity and 
severe hypersensitivity reactions.  Following a retrospective investigation of the Boehringer 
Ingelheim databases, researchers identified particular risk factors for the development of 
hepatotoxicity.  Sanna et al. (2005) and Stern et al. (2003) independently showed that gender 
and CD4 count on commencement of nevirapine treatment were the major determining 
factors.  Their results showed that women with a CD4 count of more than 250 cells/µl were 
much more likely to have abnormal liver function tests and develop symptoms of 
hepatotoxicity.  Moreover, male patients with a CD4 count of greater than 400 cells/µl were 
at higher risk for developing hepatic symptoms.  It is estimated that between 6 and 30% of 
patients on a nevirapine containing regimen experience serious adverse effects involving the 
liver and this may lead to the discontinuation of therapy (Sulkowski et al., 2002). 
 
A mild-to-moderate rash is the most common treatment-limiting side effect experienced in 
nevirapine-treated patients (Bersoff-Matcha et al., 2001; Havlir et al., 1995).  The rate of 
nevirapine associated rash is estimated at 17% (Carr et al., 2000).  The mechanism of 
nevirapine-associated rash remains unclear.  It has been demonstrated, however, that taking a 
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100 mg daily nevirapine dose for a two week introductory period decreases the risk of rash 
development (de Maat et al., 2002). 
1.4.1.5 Nevirapine drug-drug interactions 
DDIs involving nevirapine are mainly due to interference with the CYP enzyme system, i.e. 
the CYP3A4 and CYP2B6 isoenzymes (Cohen et al., 2007, Back et al., 2003). 
 
Rifampicin, a commonly utilised antimycobacterial agent, is a potent inducer of CYP3A and 
CYP2B6 (Elsherbiny et al., 2009; Ribera et al., 2001).  The inducing properties of rifampicin 
overcome that of nevirapine’s and the net result is a decrease in nevirapine plasma 
concentrations due to an increase in the ARVs metabolism.  This interaction has been 
extensively described in cohorts of both healthy volunteers and HIV-infected patients.  
Results from a small Spanish study (n=10) showed significant mean reductions of 31% 
(maximum reduction of 41%) and 36% in the area under the time-concentration curve 
(AUC0-12) and the Cmax, respectively (Ribera et al., 2001).  There was no significant 
difference found when comparing the minimum nevirapine concentrations (Cmin).  Cohen et 
al. (2007) found similar results in a South African study (n=16) with significant decreases in 
both the AUC0-12 and Cmax in those patients treated with a nevirapine-based regimen and in 
the continuation phase of antituberculosis therapy with rifampicin.  In addition to this, the 
South African study found that almost 38% of the patients had a significant reduction in the 
Cmin-values to below the recommended therapeutic trough concentration of 3.4 µg/ml.  This is 
associated with an increased risk of drug resistance and ultimately treatment failure.  
Increasing the nevirapine dose to 300 mg twice daily has been suggested to overcome this 
problem (Ramachandran et al., 2004).  However, nevirapine pharmacokinetics is highly 
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variable and this may then result in excessive plasma concentrations potentially resulting in 
adverse effects. 
The use of nevirapine in HIV-infected individuals is often accompanied by other drugs used 
to treat specific co-morbidities.  Significant interactions are seen between nevirapine and a 
variety of concomitant medications which can alter the pharmacokinetics of the co-
administered agent which then results in altered drug levels.  This includes, but is not limited 
to, the drugs listed in Appendix A.  Drugs that are contraindicated with nevirapine use or 
require close monitoring, according to the drugs package insert, include: cimetidine, 
clarithromycin, fluconazole, ketoconazole, methadone, oral contraceptives, rifampicin, 
rifabutin, St. John’s wort and warfarin. 
 
The DDI between nevirapine and FCZ has not been extensively described and there are 
conflicting results found by various research groups (Wakeman et al., 2010; Geel et al., 2004; 
Kishimoto et al., 2000).  In theory the competition for shared metabolic isoenzymes may 
result in elevated nevirapine levels as FCZ is an inhibitor of both CYP2C9 and CYP3A4 
(Albengres et al.,1998).  Increased nevirapine plasma concentrations may in turn lead to an 
increase in side effects including hepatotoxicity (Wakeman et al., 2010). 
 
In vitro data suggest that inhibition of CYP isoenzymes by FCZ is the weakest when 
compared to other azoles such as ketoconazole, miconazole and itraconazole (Kishimoto et 
al., 2000; Albengres et al., 1998).  It has, however, been established that due to the low 
degree of protein binding (11-12%) of FCZ, its in vivo plasma concentration is approximately 
10 times greater than that of itraconazole (Albengres et al., 1998).  Similar results were found 
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during in vitro studies in rat liver microsomes.  When comparing the effect of ketoconazole 
and FCZ on nevirapine metabolism using rat liver microsomes, the inhibitory constants (Ki-
values) were 1.59 µM and 11.5 µM for ketoconazole and FCZ respectively (Kishimoto et al., 
2000).  This shows that in vitro inhibition by ketoconazole is appreciably stronger.  When 
looking at in vivo data from the same study however, nevirapine’s area under the plasma 
concentration-time curve (AUC) increases almost 7.4 times when co-administered with 20 
mg/kg FCZ and increases only 2.1 times when taken with the same dose of ketoconazole.  
Normal steady state plasma concentrations of a 400 mg daily dose and 100 mg daily dose for 
ketoconazole and FCZ respectively are 7.64 ± 3.87 µg/ml and 4.39 ±3.33 µg/ml (Force et al., 
1995).  The conclusion drawn from this by Kishimoto et al. (2000) was that inhibition of 
ketoconazole is drastically decreased in vivo because of its small unbound fraction of drug, 
3% compared to the 89% unbound fraction of FCZ. 
 
Wakeham et al. (2010) conducted a pharmacokinetic study on 49 HIV-infected Ugandans.  
All the participants were treated with nevirapine 200 mg twice daily and further randomly 
subdivided into two groups; 22 patients were assigned a placebo and 27 patients were placed 
on active FCZ treatment.  A total of four blood samples were collected over an 8 hour period 
and these samples were then analysed to determine the nevirapine concentration at each time 
point.  The mean trough concentrations were 3.865 µg/ml and 5.141 µg/ml in the placebo and 
FCZ groups respectively.  When comparing the maximum nevirapine concentrations (Cmax), 
the FCZ group had a median value of 6.546 µg/ml (95% CI 6.040 - 7.974 µg/ml) whereas the 
placebo group had a mean value of 5.126 µg/ml (95% CI 4.739 -5.773 µg/ml).  The 
corresponding increase in nevirapine AUC0-8 was approximately 29% and clearance of the 
drug was also significantly reduced (median values: 5.58 L/hr versus 4.34 L/hr).  Altogether 
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61 participants, 27 in the FCZ group and 34 in the placebo group, withdrew from the study 
due to significantly increased alanine amino transaminases (> 5X ULN).  Furthermore, 11/27 
and 20/22 patients on FCZ and the placebo, respectively, experienced a rash.  One FCZ 
patient developed Stevens-Johnson syndrome. 
 
Manosuthi et al. (2007) conducted a retrospective study in nevirapine-initiated patients with 
and without co-adminstered FCZ.  The outcome was that concomitant use of nevirapine and 
FCZ led to significantly increased nevirapine plasma trough concentrations versus nevirapine 
alone (11 400 ± 6 100 ng/ml versus 6 500 ± 3000 ng/ml).  It was also established that the 
nevirapine-FCZ combination was, however, well tolerated in most patients, despite have 
significantly higher nevirapine concentrations.  Clinical hepatitis developed in only 2.4% of 
the nevirapine and fluconazole treated patients. 
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1.4.2 Efavirenz  
Like nevirapine, efavirenz (Sustiva®, Stocrin®) is a non-nucleoside reverse transcriptase 
inhibitor.  Efavirenz is a trifluoro-derivative with a molecular weight (Mw) of 315.68 g/mol 
(Figure 4).  The drug is a potent and selective inhibitor of HIV-1 and widely used in patient 
populations as a part of combination antiretroviral therapy.  Efavirenz was granted FDA 
approval in September 1998 (Vrouenraets et al., 2007).  Prospective, controlled studies 
showed that regimens containing efavirenz, in combination with two nucleoside reverse 
transcriptase inhibitors (NRTIs) or a protease inhibitor (PI) were as effective in achieving 
viral load suppression as a PI-based regimen without efavirenz (Dahri et al., 2007). 
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Figure 4:  Chemical structure of efavirenz. 
 
1.4.2.1 Indications 
For the management of patients with HIV-1 infection, efavirenz is most often combined with 
agents belonging to the nucleoside reverse transcriptase inhibitor (NRTIs) or protease 
inhibitor (PIs) class.  The drug is prescribed to both newly diagnosed and treatment-
experienced patients (Sustiva® package insert).  However, efavirenz, in many cases, is the 
drug of choice for initial therapy in treatment-naive patients as first-line therapy (Table 3) 
(Dahri et al., 2007; Vrouenraets et al., 2007). 
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According to current South African treatment guidelines, adults are dosed with a 600 mg 
efavirenz coated tablet once daily.  Efavirenz is teratogenic in non-human primates 
(Vrouenraets et al., 2007).  It is therefore contraindicated during pregnancy or in women with 
child-bearing potential (16-45 yrs) and labelled as a category D agent in pregnancy by the 
FDA (Sustiva® package insert).  Yet in daily practice efavirenz is still prescribed to pregnant 
women. 
 
Efavirenz is given as post-exposure prophylaxis (PEP) to non-infected individuals who may 
have accidentally come into contact with the virus.  This is often the case with health care 
workers treating infected patients. 
 
1.4.2.2 Mechanism of action 
Efavirenz, like all non-nucleoside reverse transcriptase inhibitors, acts by inhibiting the viral 
reverse transcriptase enzyme (Fig 3).  The mechanism of action of efavirenz is similar to that 
of nevirapine which was discussed earlier. 
 
1.4.2.3 Pharmacokinetics 
Efavirenz is orally administered; available as a tablet (50 mg, 100 mg, 200 mg or 600 mg) or 
an oral solution (30 mg/ml).  It is recommended for the drug to be taken on an empty stomach 
at bedtime in order to minimise possible central nervous system and psychiatric side effects 
(Lopez-Cortes et al., 2006).  The drug is 99% protein bound, the majority of this to albumin 
(Smith et al., 2001).  Efavirenz is well absorbed from the gastrointestinal tract and peak 
plasma concentrations (Cmax) are reached within three to five hours after taking the dose.  In a 
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study conducted with healthy volunteers the Cmax ranged from 0.51 to 2.9 µg/ml following 
administration of efavirenz in doses of 100 mg up to 1600 mg (Sustiva® package insert).  The 
suggested therapeutic window for efavirenz in HIV-infected is a plasma concentration 
between 1 and 4 µg/ml (Dahri et al., 2007).  
 
Efavirenz has a long half-life (t1/2); 52 to 76 hours after a single dose.  Half-life decreases to 
values between 40 and 55 hours during multiple dose administration (Smith et al., 2001).  
Due to the long half-life, it takes approximately 6 to 10 days for a patient to reach steady state 
efavirenz plasma levels.  Metabolism of efavirenz occurs in the liver via the CYP enzyme 
system.  The primary isoenzyme responsible for this process is CYP2B6 with some 
involvement of CYP 3A4 (Ståhle et al., 2004; Back et al., 2003).  The resulting metabolites 
are hydroxylated to form 8-hydroxyefavirenz (major) and 7-hydroxyefavirenz (minor), the 
products of primary metabolism (Ward et al., 2003).  Subsequent glucoronidation produces 
8,14-dihydroxyefavirenz, the product of secondary metabolism, which is no longer active 
(Ward et al., 2003).  A large proportion of efavirenz (16 – 61%) is excreted as unchanged 
drug in the faeces; the remaining 14-34% is excreted as metabolites in the urine (Smith et al., 
2001).  A very small percentage (± 1%) is excreted as unchanged drug in the urine 
(Vrouenraets et al., 2007).  Dosage adjustments in patients with renal insufficiencies are 
therefore not needed.  Due to genetic differences in the expression of CYP proteins 
responsible for drug metabolism, large inter-individual variability occurs in efavirenz 
metabolism (Ståhle et al., 2004).  This may warrant therapeutic drug monitoring to assess an 
individual patients plasma drug concentration.   
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1.4.2.4 Side effects 
Efavirenz is tolerated relatively well in most adult patients when the drug is taken at the 
recommended dosage of 600 mg daily.  Adverse effects commonly encountered with 
efavirenz based regimens include nausea, vomiting, dyspepsia, diarrhoea, rashes as well as 
certain nervous system effects (Adkins et al., 1998).  A multicenter, randomized trial 
investigated and compared the safety profile of efavirenz based regimens (efavirenz in 
combination with zidovudine and lamivudine or efavirenz in combination with only 
indinavir) to a regimen consisting of indinavir, zidovudine and lamivudine (Staszewski et al., 
1999).  The researchers observed a significant difference between patients on the 
abovementioned regimens when investigating the incidence of nervous system effects and 
rash; efavirenz based regimens had a higher prevalence of both the adverse effects (48 and 
54% respectively versus 21%).  When looking at the incidence of nausea and vomiting, 
however, it was established that both efavirenz based regimens were superior to that of the 
comparator regimen.  Other side effects experienced with efavirenz include elevated levels of 
triglycerides or cholesterol (hyperlipidemia), neutropenia as well as altered fat distribution 
(Fontas et al., 2004; Zapor et al., 2004).  
 
Efavirenz, unlike other NNRTIs, is associated with various neuropsychiatric central nervous 
system adverse effects (Hawkins et al., 2005).  These effects include headaches, dizziness, 
impaired concentration, somnolence, insomnia, abnormal dreams, confusion and 
hallucinations (Hasse et al., 2005; Hawkins et al., 2005; Adkins et al., 1998).  In many cases 
these effects are minor, but they may lead to poor compliance and ultimately discontinuation 
of the drug (Zapor et al., 2004).  Neuropsychiatric symptoms normally appear within the first 
two weeks of therapy and resolve within a period of 6 to 10 weeks, though in certain patients, 
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these effects may persist and result in severe depression, anxiety, suicidal tendencies, 
aggressive behaviour or paranoia depending on the plasma concentration of efavirenz 
(Hawkins et al., 2005). 
 
Allergic reactions to efavirenz are relatively common, but the severity of the reaction varies 
considerably.  The more harmless skin reactions, such as maculopapular rash, occur regularly 
(10%), whereas serious, potentially life-threatening allergic responses arise less frequently 
(<5 %) (Carr et al., 2000; Adkins et al., 1998).  The more serious events are associated with 
the development of blisters, loss of skin or the formation of cutaneous sores (Montesorri et 
al., 2004).  This may be accompanied by fever and eventually lead to severe infections, sepsis 
and possibly death if left untreated. 
 
1.4.2.5 Drug-drug interactions 
Efavirenz is known to induce hepatic isoenzyme CYP3A as well as inhibit isoenzymes 2C9, 
2C19 and 3A4 (Vrouenraets et al., 2007; Back et al., 2001).  Co-administered agents that are 
metabolised via these pathways may have altered plasma concentrations due to interference 
in common metabolic pathways.  Drugs such as methadone; cyclosporine, tacrolimus; 
atorvastatin and simvastatin; nifedipine, diltiazem and verapamil and hormonal 
contraceptives such as ethinyl estradiol are primarily metabolised by CYP3A.  Induction of 
this isoenzyme by efavirenz may result in significantly decreased levels of these agents and 
dose adjustments may be necessary (Sustiva® package insert).  On the other hand, drugs that 
rely on CYP2C9, CYP2C19 or CYP3A4 for their metabolism may have elevated plasma 
concentrations by way of efavirenz’s inhibitory effect on these isoenzymes.  Inhibition of 
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CYP3A4, when compared to induction of the same enzyme by efavirenz, is a more rapid 
process and the effect can be seen after one or two co-administered doses (Flexner, 2004).  
Phenytoin and warfarin are drugs that fall into the latter category (rely on CYP metabolism) 
and care must be taken to avoid possible adverse effects.  Furthermore, phenytoin and 
warfarin both potentially result in a bi-directional DDI with efavirenz (Sustiva® package 
insert).  This means that the blood concentrations of both the co-administered drugs are 
affected by one another.  Such an interaction is very difficult to predict and interpatient 
variability is high.   
 
Co-administered drugs that induce CYP2B6 and CYP3A, the isoenzymes responsible for 
efavirenz metabolism, would increase the clearance of efavirenz and result in decreased 
efavirenz plasma concentrations (Elsherbiny et al., 2009; Ribera et al., 2001).  The 
concomitant use of efavirenz and the antimycobacterial agent, rifampicin, is a commonly 
encountered combination.  Rifampicin is a potent inducer of both the aforementioned 
isoenzymes and may therefore decrease efavirenz plasma concentrations which may result in 
treatment failure and the development of drug resistance (Elsherbiny et al., 2009).  The 
Centre for Disease Control and Prevention have suggested an increase in the efavirenz dose 
from 600 mg daily to 800 mg daily to overcome the induction by rifampicin, however, 
Manosuthi et al (2006) found that such a dose increase was not necessary to achieve adequate 
virological suppression.  Researchers investigating the use of the higher efavirenz dose have, 
however, found that patients experience higher incidences as well as severity of side effects 
(Manosuthi et al., 2006).  Such dose adjustments are consequently not commonly done in the 
clinical setting.  Still efavirenz remains the drug of choice for the antiretroviral backbone 
when treating HIV-TB co-infected patients (South African Treatment Guidelines, 2010).   
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Other drugs that may induce efavirenz metabolism include carbamazepine, phenobarbital, 
phenytoin; and warfarin (Adkins et al., 1998).  According to the efavirenz package insert 
concomitant use of the following drugs is contraindicated: astemizole, midazolam, triazolam 
or ergot derivatives.  A comprehensive list of efavirenz-associated DDIs can be seen in 
Appendix A. 
 
Co-administration of voriconazole, a novel triazole antifungal agent, and efavirenz at the 
standard doses (EFV 600 mg daily and VCZ 200 mg twice daily) is contra-indicated 
(Catanzaro et al., 2004).  Liu et al. (2008) evaluated the pharmacokinetics of both agents in 
healthy male subjects during a two phase study period.  Results showed that mean steady 
state efavirenz concentrations increased significantly following concomitant use with 
voriconazole.  The maximum plasma concentration (Cmax) increased from 3.85 µg/ml to 5.26 
µg/ml and the area under the plasma concentration-time curve (AUC) increased from 57.8 
µg.hr/ml to 83.3 µg.hr/ml.  This could most likely be explained by voriconazole’s strong 
inhibition of CYP3A4.  On the contrary, voriconazole levels significantly decreased when 
taken with efavirenz; Cmax decreased from 3.06 µg/ml to 1.15 µg/ml with a corresponding 
decrease in AUC (26.3 µg.hr/ml to 5.71 µg.hr/ml) due to efavirenz’s enzyme induction 
capabilities.  The same pattern of interaction was found in numerous other studies including 
cohorts of HIV-positive patients (Catanzaro et al., 2004;).  Guidelines now recommend 
adjusted doses of both agents (EFV 300 mg daily and VCZ 400 mg twice daily) when used 
concomitantly (Damle et al., 2007). 
 
When compared to voriconazole and ketoconazole, FCZ is a less potent inhibitor of 
CYP3A4, although the interaction between efavirenz and FCZ has not been well established 
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(Dahri et al., 1998).  In theory there is a potential for interactions as the drugs share a 
common metabolic pathway via CYP3A4 and 2C9, but FCZ has a greater affinity for fungal 
CYP than mammalian CYP isoenzymes.  Robertson et al. (2005) and de Maat et al. (2003) 
concluded that there is no clinical significant interaction between these agents, although 
isolated case reports outline interactions between efavirenz and FCZ that have resulted in 
significantly altered plasma concentrations.  A case described by Hasse et al. (2005) was a 
native Thai, HIV-positive woman diagnosed with cryptococcal meningitis.  She presented at 
the local hospital with severe psychotic episodes.  The patient was confused, experienced 
spells of dizziness and incidences of child-like behaviour and aggression.  These 
neuropsychiatric symptoms were linked to toxic levels of efavirenz which was later 
confirmed after measurement of her plasma level; efavirenz measurements was 59 400 µg/ml 
which is approximately 30 times the normal limit.  Following genetic testing the patient was 
found to be homozygous for the CYP2B6 G516T allele and therefore a poor metaboliser of 
drugs utilising the CYP2B6 pathway.  In addition, the increase in drug efavirenz levels most 
likely was aggravated by a DDI between efavirenz and FCZ. 
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1.4.3 Lopinavir/ritonavir 
Lopinavir (Kaletra®, Aluvia®) (Figure 5) belongs to the class of antiretroviral agents known 
as protease inhibitors and was approved by the FDA in 2000.  Lopinavir is never used as a 
single protease inhibitor, but co-administered with a low, non-therapeutic dose of another 
protease inhibitor, ritonavir.  The reason for combining these two agents is that ritonavir 
inhibits the rapid and extensive CYP 3A4-mediated metabolism of lopinavir (Cvetkovic et 
al., 2003).  This prevents lopinavir’s rapid clearance from the body, enhancing its 
bioavailability and activity against the viral protease.  Another advantage of the co-
formulation is the decrease in pill burden and the knowledge that both agents are taken 
concomitantly.  The lopinavir/ritonavir combination is available as a fixed-dose formulation 
of 200/50 mg (4:1 lopinavir/ritonavir ratio) for oral administration as a tablet. 
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Figure 5:  Chemical structure of (a) and lopinavir (b) ritonavir. 
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1.4.3.1 Indications 
Lopinavir/ritonavir is indicated for use in the management of HIV-1 infected patients in 
combination with additional antiretroviral agents.  Lopinavir/ritonavir is commonly added to 
nucleoside analogues as first line therapy in both treatment experienced and treatment naive 
patients (Cvetkovic et al., 2003).  However in the African setting, lopinavir/ritonavir is more 
frequently prescribed as a part of salvage therapy in patients that have failed first line 
regimens (Table 5).  According to the South African Treatment Guidelines (2010) virological 
failure is defined as a viral load of more than 1000 copies/ml after 3 months despite 
adherence intervention and may be caused by the development of drug resistance. 
 
1.4.3.2 Mechanism of action 
A polypeptide chain is formed following translation of viral RNA.  This chain consists of 
essential proteins (reverse transcriptase-, protease- and integrase enzymes) that are needed by 
the virus to mature and produce new, infective virus particles.  Before maturation can occur, 
the abovementioned proteins must be cleaved from the polypeptide chain in order to become 
functional (Pomerantz et al., 2003).  This is the responsibility of HIV-1 viral protease.  In all 
retroviruses, the essential ingredient needed for the production of new virus particles is an 
active viral protease enzyme.  The HIV-1 protease is homodimeric; comprised of a 99 amino 
acid sequence protein (Cvetkovic, 2003; Eron, 2000).  The protease inhibitors, including 
lopinavir/ritonavir, are highly selective for the active site and thus potent inhibitors of the 
viral protease enzyme (Figure 6).  Consequently preventing cleavage of the functional 
proteins needed for growth and maturation.  The net result is thus production of immature, 
non-infective viral molecules (Pomerantz et al., 2003). 
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Figure 6:  Mechanism of action of the protease inhibitor class of drugs. 
 
1.4.3.3 Pharmacokinetics 
The pharmacokinetic properties of the lopinavir/ritonavir combination have been investigated 
in both HIV-positive adult patients and healthy adults with no significant differences in the 
pharmacokinetics between these two populations (Cvetkovic et al., 2003). 
 
In a pharmacokinetic study performed in patients who were in steady state for 
lopinavir/ritonavir treatment at a dose of 400/100 mg twice a day together with food, mean 
peak plasma concentration (Cmax) was 9.8 ±3.7 µg/ml (Bertz et al., 2001).  The time required 
to reach the maximum concentration was approximately 4 hours.  Absorption and subsequent 
bioavailability of the drug can significantly increase when taken with a moderate-to-high fat 
meal (Gustavson et al., 2000).  Lopinavir is approximately 98-99% protein bound.  Binding 
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occurs with both albumin and alpha-1-acid glycoprotein (AAG); the majority of the drug 
being bound to the latter (Boffito et al., 2003).   
 
Both lopinavir and ritonavir undergo extensive first pass metabolism in the gut which leads to 
a decrease in plasma concentration (Kumar et al., 2004).  The main pathway of metabolism 
of this drug is via oxidative, hepatic metabolism via the CYP enzyme system.  
Lopinavir/ritonavir is almost solely metabolised by the CYP3A isoenzyme, with a small 
contribution from CYP2D6 which is involved in ritonavir metabolism (Kumar et al., 1999).  
The half-life of the co-formulated drug is 5-6 hours, which results in twice daily dosing. 
 
The largest percentage of the dose (80.1 - 85.1%) is recovered in the urine or faeces as 
metabolites (Kaletra® package insert).  The remaining lopinavir is excreted as unchanged 
drug in the urine (±2.2%) and the faeces (±19.8%) (Cvetkovic et al., 2003).  Since the renal 
clearance of the drug is insignificant, no dosage adjustments are needed in patients with renal 
insufficiency.  Seeing as the drug is metabolised and eliminated primarily by the liver, 
caution should be taken in patients with hepatic impairment or failure (Kaletra® package 
insert). 
 
1.4.3.4 Side effects 
Possible side effects with lopinavir/ritonavir are similar to those experienced with the 
majority of marketed drugs.  This includes nausea, vomiting, diarrhoea, headache, rash, fever 
and abdominal pain (Dios et al., 2002).  An adverse effect commonly observed with protease 
inhibitors, is a change in the body fat composition known as lipodystrophy (Carr et al., 1998; 
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Danner et al., 1995).  The pattern of fat redistribution is similar to that seen in patients with 
hypercortisolism.  In such cases fat tends to accumulate in the abdomen and trunk, which is 
referred to as a ‘crix belly’ or ‘protease paunch’, and a fat pad develops behind the neck.  
Furthermore, peripheral fat loss is characteristic in these patients.  The limbs are normally 
thin accompanied by loss of fat in the face, especially the cheek area, which then results in an 
identifiable gaunt appearance associated with HIV stigmatisation. 
 
Other troubling adverse effects associated with lopinavir/ritonavir therapy are the 
development of metabolic abnormalities such as increased hypercholesterolemia, 
hypertriglyceridemia as well as hyperglycaemia (Fontas et al., 2004; Carr et al., 1998).  In 
certain patients this may result in clinical manifestation of diabetes mellitus.  An increased 
risk of bleeding in patients with haemophilia has been observed and caution must be taken in 
patients with heart disease or a history of arrhythmias as the drug can cause a prolongation of 
the QT interval (Chinello et al., 2007; Carr et al., 1998).  Moreover, lopinavir/ritonavir has 
been associated with abnormal liver function tests.  Randomised control trials conducted to 
obtain FDA approval for the combination PI, illustrated that hepatotoxicity occurred in 1 - 
9.5% of patients taking the drug (Canta et al., 2005; Sulkowski, 2004).  Patients with a 
history of hepatitis or abnormal liver functioning should be closely monitored as the 
condition may worsen when continuing with therapy (Canta et al., 2005).  The drug has been 
classified as a category C agent in pregnancy by the FDA. 
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1.4.3.5 Drug-drug interactions 
In certain circumstances DDIs could be advantageous.  The fixed-dose co-formulated 
lopinavir and ritonavir is an example of utilising DDIs in order to favourably alter a drugs 
pharmacokinetic profile (Cvetkovic et al., 2003). 
 
The source of many of these DDIs could be due to sharing common metabolic pathways.  As 
previously mentioned, the drug is metabolized mainly in the liver via CYP enzymes; 
particularly CYP3A, which is also responsible for the metabolism of approximately 50% of 
all marketed drugs (Back et al., 2003).  In addition to this, lopinavir/ritonavir is both a strong 
inhibitor of the CYP3A4 isoenzyme and an inducer of the CYP1A2, CYP2C9 and CYP2C19 
isoenzymes (Yeh et al., 2006).  Interaction studies between lopinavir/ritonavir and an array of 
co-medications have been performed in both small groups of patients as well as healthy 
volunteers (Decloedt et al., 2011; Yeh et al., 2006; la Porte et al., 2004; Cato et al., 1997).  
Concomitant use of lopinavir/ritonavir and agents that rely greatly on the abovementioned 
isoenzymes for their metabolism is contraindicated or must be monitored as elevated levels of 
the co-administered agent may result in serious adverse effects.  The list of contraindicated 
drugs, according to the Kaletra® package insert, include: astemizole, ergonovine, ergotamine, 
flecainide, propafenone; midazolam, triazolam, pimozide and simvastatin.  The herbal 
product, St. John’s Wort, induces lopinavir/ritonavir metabolism.  Its use together with 
lopinavir/ritonavir is not recommended, as it may drastically decrease plasma concentrations 
of the ARVs.  This may possibly result in virological failure and ultimately drug resistance.  
Appendix A outlines various potential DDIs experienced with lopinavir/ritonavir use. 
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Potential interactions due to the concomitant use of lopinavir/ritonavir and antimycobacterial 
agents such as rifampicin, which is a potent inducer of CYP3A4, must be taken into account 
prior to treatment (la Porte et al., 2006).  Numerous studies have illustrated that the 
aforementioned combination leads to sub-therapeutic levels of lopinavir/ritonavir and 
diminished virological response.  According to Decloedt et al. (2011) doubling the 
lopinavir/ritonavir dose in healthy individuals was sufficient to surmount the increased 
metabolism of the protease inhibitor.  Moreover, there is a decreased incidence of 
hepatotoxicity in the HIV-infected cohort when compared to healthy subjects (Decloedt et al., 
2011).  Subsequent follow up studies have, however, shown that these patients were more 
likely to develop hepatotoxicity associated with elevated lopinavir/ritonavir levels. 
 
Co-administration of lopinavir/ritonavir and FCZ is common practice in HIV-infected 
patients as they are likely to develop a variety of opportunistic fungal infections.  The 
potential mechanism of DDI is thought to be the inhibition of CYP3A4 by FCZ.  Following 
ritonavir’s approval by the FDA as both a single agent and a part of combination therapy, 
Cato et al. (1997) performed a randomized, cross over study in thirteen healthy volunteers to 
evaluate potential interactions between these two agents.  In essence each participant acted as 
their control; receiving ritonavir followed by a wash out period and then crossed over to the 
ritonavir and FCZ combination.  Serial blood samples were taken once patients reached 
steady state for the drug or drugs taken and these samples were then analysed to obtain the 
ritonavir concentration.  Five volunteers (1 male and 4 female) discontinued the study after 
developing adverse reactions commonly seen with ritonavir.  It was speculated that the 
increased ritonavir levels in women may be due to the difference in body size; these values 
were however not reported in the study.  For the remaining eight volunteers that completed 
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the study, results showed that there were only minor differences in the resulting ritonavir 
plasma concentration and pharmacokinetic parameters.  The 0-24 hour period Cmax and AUC 
parameters were significantly different between the ritonavir alone (8.95 ± 2.41 µg/ml and 
151 ± 36 µ.hr/ml respectively) and the ritonavir plus FCZ (10.25 ± 2.69 µg/ml and 169 ± 41 
µ.hr/ml respectively).  There was no significant difference in the time to maximum ritonavir 
concentration (tmax) in either group, 3.9 ± 1.1 hr (ritonavir alone) versus 4.1 ±1.0 hr (ritonavir 
plus FCZ). The conclusion drawn from this study by Cato et al (1997) was that the 
interaction between ritonavir and FCZ is minor with no clinical relevance or need for dose 
adjustment. 
 
The potential for DDIs to occur between co-formulated lopinavir and ritonavir and FCZ 
exists as lopinavir, like ritonavir, is metabolized mainly by CYP3A4.  FCZ is a moderate 
inhibitor of CYP3A4 and concomitant use may lead to increased levels of lopinavir/ritonavir.  
This combination has been evaluated in clinical practice, results mostly showing that there is 
no significant interaction between these agents.  The ‘boosting’ of lopinavir with ritonavir 
may assist the drug from overcoming any possible interactions. 
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1.5 Antifungal agents 
The antifungal therapies currently available fall into three broad categories: systemic 
preparations for systemic infections as well as oral and topical preparations for 
mucocutaneous infections (Katzung, 1998).  Furthermore, antifungal agents can be divided 
into three distinct classes: polyenes consisting of amphotericin B and nystatin; the fluorinated 
pyrimidine analogue, flucytosine and the azole antifungals (Dismukes, 1988).
 
 
The azole antifungals are synthetic compounds and can be further classified, according to 
their structure, into imidazoles and triazoles (Ringel, 1990).  The imidazoles consist of one or 
more 5-membered rings, known as the azole ring, containing two nitrogen atoms, whereas the 
triazoles contain three nitrogen atoms in the azole rings (Dismukes, 1988).  Structural 
differences between the two categories lead to differences in the absorption and efficacy of 
the drug. 
 
1.5.1 Fluconazole 
Fluconazole (Diflucan®) is a synthetic azole-derived antifungal agent.  FCZ (Mw 306.3 Da), 
belonging to the triazole group, contains three nitrogen atoms in the five-membered azole 
ring (Figure 7). 
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Figure 7:  Chemical structure of fluconazole. 
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1.5.1.1 Discovery 
FCZ has been in use since 1990 following approval from the Food and Drug Administration 
(FDA) (Terrell, 1999).  Since then FCZ has been utilized for its broad-spectrum of 
applications in the treatment of both superficial and systemic fungal infections.  More recent 
research has reported the use of the newer triazole antifungals, such as FCZ and itraconazole, 
for a variety of indications rather than ketoconazole as discussed below (Terell et al., 1992; 
Saag et al, 1988).  This is due to the triazoles broader spectrum of activity and reduced 
toxicity when compared to ketoconazole (Dismukes, 1988). 
 
1.5.1.2 Indications 
FCZ has shown activity against a variety of pathogens both in vitro and in vivo.  Susceptible 
organisms illustrating in vitro activity against the agent include: Candida albicans; non-
albicans Candida species such as Candida glabrata; Histoplasma capsulatum; Coccidioides 
immitis; Blastomyces dermatitidis and Cryptococcus neoformans (Chen et al., 2007).  Good 
activity has especially been seen in a variety of Candida species as well as Cryptococcus 
neoformans in clinical situations.  FCZ, therefore, remains a valuable and low-cost drug 
alternative for the treatment of oropharyngeal candidiasis, amongst others, and cryptococcal 
meningitis (Zobios et al., 2008). 
 
The dosage for the consolidation phase of active cryptococcal meningitis is 400mg daily oral 
FCZ for a period of 8 weeks (McCarthy et al., 2007).  This is then followed by long term 
maintenance or prophylactic therapy where FCZ is dosed at 200 mg daily.  There are two 
schools of thought about the time period of prophylactic treatment.  The first is that 
maintenance therapy is necessary until the patient has a CD4 count that is greater than 200 
Stellenbosch University http://scholar.sun.ac.za
Literature review                                                                 71 
 
cells/mm
3
 for more than 6 months on antiretroviral therapy following a minimum of 12 
months treatment with FCZ.  The second argument is that prophylactic therapy with 200 mg 
daily FCZ is a part of lifelong treatment, irrespective of the associated CD4 counts.  
Researchers supporting the first mentioned hypothesis argue that lifelong treatment with FCZ 
may result in the development of drug resistance (Hamza et al., 2008; Vanden et al., 1998; 
Johnson et al., 1995).  Furthermore, resistance to the drug is also encountered in certain non-
albicans Candida species such as C. Krusei and some isolates of C.glabrata (Chen et al., 
2007). 
 
Vaginal candidiasis, osophogeal candidiasis and urinary tract infections caused by C. 
albicans, candidemia and disseminated candidiasis are the other main indications of FCZ 
(Guo et al., 2010; Wildfeuer et al., 1997). 
 
1.5.1.3 Mechanism of action 
Many antifungal agents are known and target different components of the fungal cell.  The 
mechanism of action for all azoles is similar (Terrell et al., 1992).  According to Kyle et al. 
(2004) both imidazole and triazole antifungal agents have a fungistatic effect at low and 
therapeutic concentrations. 
 
FCZ’s antifungal properties have been attributed to the inhibition of the synthesis of an 
important fungal cell membrane component, ergosterol (Figure 8).  This mode of action 
involves the selective inhibition of fungal sterol-14α-demethylase, a critical CYP isoenzyme 
required for the synthesis of ergosterol (Guo et al., 2010; Terell, 1999; Kelly et al., 1995).  
Stellenbosch University http://scholar.sun.ac.za
Literature review                                                                 72 
 
Disruption of this fungal CYP isoenzyme (sterol-14α-demethylase) leads to inhibition of the 
conversion of an ergosterol precursor, lanosterol, to ergosterol via a demethylation process 
(Ringel, 1990).  This interference, attributed to the formation of a toxic sterol intermediate 
(methylsterols) which is inserted into the membrane instead of ergosterol, leads to an 
alteration in fungal cell membrane composition which gives rise to impaired cell membrane 
integrity and fungal cell functioning (Sheehan et al., 1999).  This ultimately results in the 
inhibition of fungal cell growth and further replication (Thompson et al., 2009). 
 
FCZ, as well as another triazole agent itraconazole, has an increased affinity for the fungal 
P450 enzyme system rather than its mammalian counterpart (Sheehan et al., 1999; Grant et 
al., 1990).  FCZ, when compared with ketoconazole/the older imidazoles, therefore does not 
result in a large extent of toxicity due to the interaction with mammalian sterols (Ringel, 
1990). 
 
 
 
 
 
 
 
 
 
 
Figure 8:  A schematic representation of fluconazole’s mechanism of action. 
 
KEY:              Fluconazole              Sterol-14α-demethylase                 Ergosterol  
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1.5.1.4 Pharmacokinetics 
FCZ has been an important drug in the antifungal armamentarium because of its favourable 
pharmacokinetic profile.  Within the African setting it remains the most prescribed new age 
antifungal.  The triazoles, including FCZ, are highly hydrophilic molecules (Grudzien et al., 
2009; Brammer et al., 1990).  FCZ can therefore be administered orally as well as by an 
intravenous infusion.  Following oral administration the drug is well and almost completely 
absorbed within 2 hours.  FCZ is widely distributed throughout the body and has a 
bioavailability of >90% (Roos et al., 2008; Chen et al., 2007).  This pattern of distribution 
has been observed in both healthy volunteers and HIV-positive patients (Wildfeuer et al., 
1997).  Due to the small size of the molecule, FCZ shows excellent distribution into the 
central nervous system compartments.  Numerous studies suggest that FCZ cerobrospinal 
fluid (CSF) concentrations are about 80% compared to the corresponding plasma 
concentrations (Wildfeuer et al., 1997).  Its absorption is not greatly affected by food or the 
absence of gastric acid, therefore FCZ can be taken away from food (Diflucan® package 
insert).  The half-life (t1/2) of the drug following oral administration ranges from 20 to 50 
hours, with a mean t1/2 of roughly 30 hours (Debruyne et al., 1993).  Steady state plasma 
levels are reached within 4-5 days.  Following a 200 mg oral dose, steady state concentrations 
of approximately 4.6 mg/L ± 1.1 mg/L are achieved.  The time to reach maximum plasma 
concentration ranges between 2.4 and 3.7 hours (Debruyne, 1997).   
 
FCZ blood concentrations display a very low degree of interpatient variability because of its 
favourable PK profile and as distribution of the drug amounts to total body water which 
shows relatively little variation (Wildfeuer et al., 1997).  Consequently variation in plasma 
drug concentrations is limited (±20 % CV) in healthy individuals.  A good linear relationship 
between the dose administered and the resulting plasma concentration has been demonstrated 
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in both healthy subjects and immunocompromised patients (Debruyne, 1997; Wildfeuer et 
al., 1997; Brammer et al. 1990).  Roos et al. (2008) however, demonstrated that a larger 
degree of variation exists in patients diagnosed with HIV/AIDS as a result of disease 
interactions and DDIs (which will be discussed below). 
 
FCZ is primarily cleared by renal elimination. Approximately 91% of the dose is excreted in 
the urine; 80% as unchanged drug and the remaining 11% as a combination of glucoronidated 
and nitrogen oxide drug metabolites (Chen et al., 2007; Debruyne et al., 1993; Brammer et 
al., 1990).  The aforementioned metabolites are no longer active following hepatic 
metabolism by CYP3A4 isoenzymes. Because FCZ relies almost solely on renal elimination, 
dosage adjustments may be necessitated in patients with impaired renal function (Chen et al., 
2007; Wildfeuer et al., 1997).  Debruyne (1997) showed that the elimination half-life of FCZ 
could increase up to 98 hours in renal impaired patients with a creatinine clearance of less 
than 20 ml/min. 
 
1.5.1.5 Side effects 
When oral FCZ therapy was first introduced in the early 1990s, it was thought that the drug 
was devoid of serious adverse effects.  Continuous research regarding FCZ and its safety has 
largely shown this to be true.  As previously mentioned FCZ has a greater affinity for the 
fungal CYP enzyme system and therefore boasts with an improved safety profile.  In most 
patients FCZ is well tolerated in dosages up to 1600 mg/day (Debruyne, 1997).  It is however 
recommended that a maximum daily dose of 1600 mg should not be exceeded in order to 
avoid possible neurological side effects such as hallucinations, vivid dreams and insomnia.  
According to Grant et al. (1990) the incidence of adverse events in patients treated with FCZ 
is approximately 16%.  For oral FCZ dosages of 100 mg up to 400 mg, the most common 
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side effects experienced involved the gastrointestinal system (Chen et al., 2007).  Nausea, 
vomiting, diarrhoea, abdominal pain, skin rash and headache are side effects frequently 
encountered in patients taking FCZ (Chen et al., 2007; Sheehan et al., 1999).  The only 
caveat in FCZ’s armour is the potential risk of developing hepatotoxicity in certain patients as 
well as the possibility of causing QT prolongation which may result in arrthymias (Guo et al., 
2010; Albengres et al., 1998).  Impaired hepatic functioning is normally identified following 
abnormal liver functions tests (LFTs). 
 
Even though patients using FCZ experience less adverse effects than when treated with 
ketoconazole, plasma concentration levels should, in certain situations, be monitored due to 
its interaction with the CYP enzyme system.   
 
1.5.1.6 Drug-drug interactions 
A retrospective cohort study performed by Yu and colleagues (2005) at a tertiary care 
teaching hospital in Boston, Massachuchetts followed patients admitted to the hospital within 
a four year period between July 1997 and June 2001.  The study included patients treated 
with oral FCZ, itraconazole or ketoconazole; during this period 3953 patients admitted were 
treated with FCZ.  The researchers’ findings were that 2716 patients on FCZ experienced a 
DDI and approximately 711 of these were serious DDIs.  The population of HIV infected 
patients within this cohort was small (n=170) and only 4.3% of these patients experienced an 
interaction between FCZ and their antiretroviral therapy.  The need for additional 
medications in HIV patients is common, however, and complex DDIs may result. 
Significant DDIs between FCZ and co-administered medications have been observed in 
healthy volunteers and patients.  From the drugs investigated in this pharmacokinetic study, 
FCZ is not highly bound to plasma proteins (11-12%) which explains that no interactions 
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involving protein binding have been reported (Robertson et al., 2005).  The main mechanism 
of drug interaction is due to FCZ’s inhibitory effect on mammalian CYP enzymes, mainly 
CYP2C9, CYP2C19 and CYP3A4 to a lesser extent (Piscitelli et al., 2001).  In this manner 
FCZ would decrease the clearance of the co-administered agent resulting in increased plasma 
concentrations of these agents.  Elevated drug concentrations may lead to serious adverse 
effects as well as discontinuation of therapy.  The main DDIs experienced with FCZ, as 
indicated in the Diflucan® package insert, includes: certain benzodiazepines including 
diazepam, cyclosporine and tacrolimus, hydrochlorothiazide, midazolam, phenytoin, 
rifampicin and rifabutin, sulfonylureas, theophylline and warfarin.  A more extensive list of 
potential DDIs with FCZ is presented in Appendix B. 
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2.0 Gaps in research 
• Data pertaining to ARV pharmacokinetic drug interaction studies is restricted in 
resource limited countries such as South Africa. 
 
• Knowledge of DDIs between FCZ and the ARVs is limited; this includes the effect of 
FCZ on the pharmacokinetics of nevirapine, efavirenz and the lopinavir/ritonavir 
combination. 
 
• Knowledge of patient characteristics or covariates that influence the pharmacokinetics 
of efavirenz, nevirapine and lopinavir/ritonavir is limited within specific, local patient 
populations. 
 
• The use of pharmacometrics to model and simulate pharmacokinetic data of the 
investigated ARVs and their potential DDI with FCZ in the treated local patient 
population. 
 
2.1 Aim of the study 
The primary aim of this thesis was to evaluate the effect of FCZ on the pharmacokinetics of 
efavirenz, nevirapine and lopinavir/ritonavir in HIV-infected patients diagnosed with 
cryptococcal meningitis or oropharyngeal candidiasis.  There is a large degree of inter- and 
intraindividual variation with regards to serum drug concentrations due to individual 
differences in the expression of metabolizing enzymes.  Therefore a population 
pharmacokinetic approach has been applied to study the pharmacokinetics (alteration in PK) 
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and potential DDIs between FCZ and the ARVs nevirapine, efavirenz, lopinavir/ritonavir in 
adult patients.  In addition to this, population PK data of the investigated ARVs were also 
obtained. 
 
The results of this study provide evidence based guidance for the combined antiretroviral-
antifungal treatment in patients with cryptococcal meningitis and oropharyngeal candidiasis 
as well as information about relevant covariates/patient characteristics that may influence 
optimal therapy. 
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3.0 Materials and methods 
3.1 Clinical method 
 
3.1.1 Subjects  
A prospective study was conducted in HIV-positive, treatment experienced adult (≥18 years 
old) patients (N=80) which were subdivided into two separate groups.  The first group 
(n=54), which will further be referred to as the control group, consisted of patients treated 
with one of the antiretroviral agents (ARVs) investigated; efavirenz, nevirapine or 
lopinavir/ritonavir, but not with FCZ.  The cohort of patients (n=26) in the second group, also 
referred to as the treatment group, comprised of patients treated with one of the ARVs 
investigated as well as the antifungal, FCZ.  FCZ was used in the patients for the treatment of 
oropharyngeal candidiasis (n=5), cryptococcal meningitis (n=21).  Patients were recruited 
from three established infectious diseases outpatient clinics in the Western Cape area; 
Tygerberg Hospital, Karl Bremer Hospital and the T.C. Newman Clinic in Paarl.  Patients 
under the age of 18 years and those with nausea and vomiting or severe anaemia were 
excluded from the study. 
 
3.1.2 Protocol 
This study was approved by the Health Research Ethics Committee at Stellenbosch 
University (N10/06/212) and conducted according to the ethical guidelines and principles of 
the international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice (GCP) and the Medical Research Council (MRC) Ethical Guidelines for Research.  
The study also received approval from the Department of Health (DOH) as well as 
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authorisation from the heads of the three respective clinics.  The final version of the protocol 
is provided in Appendix C. 
 
Written informed consent was obtained from each patient after details of the study, including 
the risks and benefits of the study, had clearly been explained to them in a language that the 
patient was comfortable with.  Furthermore, all patients were informed that the study was 
entirely voluntary and they could leave the study at any point in time with no prior notice or 
reason.  In addition to this they were also provided with the telephone number of one of the 
clinics doctors to answer any questions.  The patient information and consent forms were 
available in English, Afrikaans and Xhosa (Appendix D-F).  Detailed patient information and 
characteristics were recorded in 2 separate case record forms (CRFs) at each visit (Appendix 
G-H). 
 
Patients were treated according to the regular standard of care.  FCZ was prescribed by the 
patients’ physicians.  
 
3.1.3 Study design 
The study was designed as a prospective, open, uncontrolled pharmacokinetic study with 
sparse sampling in an HIV-infected cohort.  All participants had been at steady state for the 
respective antiretroviral regimens containing either 200 mg nevirapine twice daily, 600 mg 
efavirenz nocturnally or two tablets lopinavir/ritonavir (2 x 400/100 mg) twice daily.  Patients 
recruited to the treatment group were also at steady state for FCZ.  All patients had been at 
steady state for FCZ, in other words on treatment for more than 5 days. 
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3.1.4 Sample collection 
The blood sampling schedule for the purpose of the study was to collect four (4) random 
blood samples of 5 ml each (total 20 ml) from each study participant.  These samples were 
collected over the span of two visits (2 blood samples per visit) to the outpatient clinic and a 
minimum time period of one hour between blood draws was maintained (Figure 9).  When 
possible, these extra blood samples were taken at the time of routine clinical venepuncture so 
as to minimize discomfort to the patient. 
 
 
 
 
 
 
 
 
 
Figure 9:  Flow diagram of blood sampling schedule in study participants. 
 
There were a number of deviations from the planned sampling schedule due to loss to follow-
up or unwillingness of a patient to complete the required number of blood draws.  Following 
an interim analysis of the pharmacokinetic data, the protocol was amended to include serial 
blood sampling from consenting patients.  This amendment was approved by the Ethics 
Committee.  For these patients (n=4), blood samples were collected at times indicated in 
Figure 10 or as close to these times as possible.   
 
> 1 hour 
> 1 hour 
Dose taken 
(documented 
by patient) 
Visit 1 
Visit 2 
Sample 1 
Sample 3 
Sample 2 
Sample 4 
Stellenbosch University http://scholar.sun.ac.za
Materials & Method                                                                    82 
 
 
 
 
 
 
 
Figure 10:  Flow diagram of serial blood sampling schedule performed in four patients. 
 
Exact doses, dosing times, and blood sampling times were carefully recorded for each patient 
during each visit.  Adherence during the week prior to blood sampling was assessed by means 
of a pill count.   
 
Blood was collected in 7.5 ml Vacuette tubes containing serum separating clot activator.  The 
blood samples were centrifuged at 1.789 g for 10 minutes to obtain serum.  The serum was 
then promptly harvested and placed in a heated water bath (57°C) for an hour.  After the 
serum samples were left to cool, they were stored in the -80°C freezer in the Division of 
Pharmacology, Stellenbosch University until they were shipped to the Therapeutic Drug 
Monitoring (TDM) Scientific Laboratory (Infectious Diseases), Wuerzburg, Germany for 
further analysis.  All samples were analysed by validated high performance liquid 
chromatography (HPLC) or gas chromatography (GC) methods described below. 
 
3.1.5 Statistical analysis 
The identified independent variables were age, sex, race, body weight, height, BMI and 
concomitant medications. The mean values, standard deviation (SD), coefficient of variance, 
median and range for each parameter were calculated and the results presented in tables and 
Dose taken 
(observed) 
0 
0.25 
0.5 
1.0 
2.0 4.0 6.0 8.0 
Time in hours 
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graphs using Graph Pad Prism version 5.01 (GraphPad software, Inc, San Diego, California).  
Normality of patient characteristics was assessed by Shapiro-Wilks normality tests and the 
significant difference was then established by either an unpaired t-test or a Mann Whitney 
test.  Contingency tables and chi-square tests were used to assess the categorical out  A 
statistically significant difference was defined when p < 0.05. 
 
A stepwise regression approach was used when modelling the data.  This included a forward 
inclusion, by starting with no variables and adding any significant variables one by one, and 
backward elimination which is starting with all potential variables and then removing them 
one by one if not significant. 
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3.2 Experimental method 
3.2.1 Chemicals and reagents 
All reference standards used are free bases. 
3.2.1.1 Efavirenz 
Efavirenz powder was purchased from Sequoia Research Products Ltd (Pangbourne, UK).  
The internal standard used, A86093, was purchased from Abbott Labs (Chicago, IL, USA).  
The following reagents were purchased from Merck (Darmstadt, Germany): potassium 
dihydrogen phosphate (KH2PO4); di-sodium hydrogen phosphate (Na2HPO4); HPLC grade 
methanol (MeOH), diethylether (C2H5)2O and HPLC grade water (H2O).  Fetal calf serum 
(FCS) was obtained from BIOCHROM AG (Berlin, Germany) and analytical grade 
acetonitrile (CH3CN) was purchased from Sigma Aldrich (Steinheim, Germany). 
 
3.2.1.2 Nevirapine  
Nevirapine powder was purchased from Sequoia Research Products Ltd (Pangbourne, UK) 
and the internal standard, scandicaine from Astra Chemicals (Astra GmbH, Wedel, 
Germany).  Analytical grade (C2H5)2O, MeOH, dimethyl sulfoxide (DMSO), HPLC grade 
H2O, sodium dihydrogen carbonate (Na2HCO3) and sodium carbonate (Na2CO3) were 
obtained from Merck (Darmstadt, Germany). 
 
3.2.1.3 Lopinavir 
Lopinavir powder was purchased from Sequoia Research Products Ltd (Pangbourne, UK).  
The lopinavir assay makes use of the same internal standard, A 86093 (Abbott Labs, 
Chicago, Illinois, USA) as used in the efavirenz analysis.  FCS was purchased from 
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BIOCHROM AG (Berlin, Germany) and analytical grade CH3CN was purchased from Sigma 
Aldrich (Steinheim, Germany).  All the other reagents were supplied by Merck (Darmstadt, 
Germany): (C2H5)2O; KH2PO4; Na2CO3; NaHCO3; MeOH; n-hexane and HPLC-grade H2O. 
 
3.2.1.4 Fluconazole 
FCZ powder and the internal standard (IS), phenacetin, were both purchased from Sigma-
Aldrich (Taufkirchen, Germany).  Analytical grade CH3CN was obtained from Sigma 
Aldrich (Steinheim, Germany).  HPLC grade MeOH, sodium hydroxide (0.1N NaOH), 
chloroform (CHCl3), K2HPO4 and HPLC grade H2O were purchased from Merck (Darmstadt, 
Germany).  FCS used to prepare the calibration curves and control samples were obtained 
from BIOCHROM AG (Berlin, Germany).  
 
3.2.2 Preparation of calibration curves and quality controls  
For the preparation of the standard samples an appropriate amount of the working solutions 
and the internal standard (ISTD) were added to blank serum samples to achieve a specific 
range of calibration concentrations (Tables 6, 7, 8 and 9).  All stock solutions were stored at 
4°C and were stable for at least 3 months and the long-term matrix stability is at least 6 
months at 4°C.  The solutions were warmed up to room temperature prior to use. 
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3.2.2.1 Efavirenz  
 
Table 6:  Pipetting scheme for preparation of efavirenz calibration curves and control samples 
No 
EFV concentration 
(ng/ml) 
Solution 
No 
Volume 
pipetted (µl) 
Volume of  
buffer (µl)  
Volume of 
FCS (µl) 
Volume of 
ISTD (µl) 
LLQ 125 WS I 10 500 200 25 
1 250 WS I 20 500 200 25 
2 500 WS I 40 500 200 25 
3 1 000 WS I 80 500 200 25 
4 2 500 SS 20 500 200 25 
5 5 000 SS 40 500 200 25 
6 10 000 SS 80 500 200 25 
ULQ 15 000 SS 120 500 200 25 
       
EFV Stock Solution (SS) 10 mg EFV/100 ml MeOH:KH2PO4 (1:1 v/v)  
Working Solution I (WS I) 10 ml SS/90 ml MeOH:KH2PO4 (1:1 v/v) 
ISTD Solution 10 mg Abbott ISTD A86093/100 ml MeOH:KH2PO4 (1:1 v/v) 
Buffer Sörensen-phosphate buffer (pH 7.0)   
 
3.2.2.2 Nevirapine 
 
Table 7:  Pipetting scheme for preparation of nevirapine calibration curves and control samples 
No 
NVP concentration 
(ng/ml) 
Solution 
No 
Volume 
pipetted (µl) 
Volume of  
buffer (µl)  
Volume of 
NCS (µl) 
Volume of 
ISTD (µl) 
LLQ 150 WS I 75 500 250 25 
1 250 WS I 125 500 250 25 
2 500 WS II 25 500 250 25 
3 1 000 WS II 50 500 250 25 
4 2 500 WS II 125 500 250 25 
5 5 000 SS 25 500 250 25 
6 10 000 SS 50 500 250 25 
ULQ 20 000 SS 125 500 250 25 
       
NVP Stock solution (SS) 5mg NVP/100 ml DMSO/MeOH (1:1 v/v)   
Working Solution I (WS I) 5 µg NVP/10ml DMSO/MeOH (1:1 v/v)   
Working Solution II (WS II) 50 µg NVP/10 ml DMSO/MeOH (1:1 v/v)  
ISTD Solution 4 mg scandicaine/100 ml H2O   
Buffer Sodium carbonate buffer (pH 9.4) 
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3.2.2.3 Lopinavir 
 
Table 8: Pipetting scheme for lopinavir calibration curves and controls samples 
No 
LPV concentration 
(ng/ml) 
Solution 
No 
Volume 
pipetted (µl) 
Volume of  
Na-Ca buffer 
(µl)  
Volume 
of FCS 
(µl) 
Volume 
of ISTD 
(µl) 
LLQ 150.00 WS I 15.0 500 500 25 
1 250.0 WS I 25 500 500 25 
2 500.0 WS I 50 500 500 25 
3 1000.0 WS I 100 500 500 25 
4 2000.0 SS 20 500 500 25 
5 4000.0 SS 40 500 500 25 
6 6000.0 SS 60 500 500 25 
ULQ 1 10000 SS 100 500 500 25 
ULQ 2 20 000 SS 200 500 500 25 
LPV Stock Solution (SS) 10 mg LPV/100 ml H2O/CH3CN (1:1 v/v)  
Working Solution I (WS I) 0.5 mg LPV/100 ml H2O/CH3CN (1:1 v/v)     
ISTD Solution  5 mg Abbott ISTD A86093/100 ml MeOH   
Buffer Sodium carbonate buffer (pH 9.4)   
 
3.2.2.4 Fluconazole 
The FCZ method described below was newly developed in the routine Therapeutic Drug 
Monitoring (TDM) Scientific Laboratory of the Infectious Diseases Centre of Würzburg 
Medical Centre in Würzburg, Germany.   
 
Table 9:  Pipetting scheme for preparation of fluconazole calibration curves and control samples 
No 
FCZ concentration 
(µg/ml) 
Solution 
No 
Volume 
pipetted (µl) 
Volume of  
NaOH (µl)  
Volume of 
FCS (µl) 
Volume of 
ISTD (µl) 
LLQ 0,25 WS I 12,5 200 250 25 
1 0,5 WS I 25 200 250 25 
2 1,0 WS I 50 200 250 25 
3 2,0 WS I 100 200 250 25 
4 4,0 SS 10 200 250 25 
5 10,0 SS 25 200 250 25 
6 20,0 SS 50 200 250 25 
ULQ 40,0 SS 100 200 250 25 
FCZ Stock Solution (SS) 10 mg FCZ in 100 ml MeOH    
Working Solution I (WS I) 0.5 mg FCZ in 100 ml MeOH    
ISTD Solution  5 mg phenacetin in 100 ml MeOH   
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3.2.3 Instrumentation and chromatographic conditions 
 
3.2.3.1 Efavirenz 
For the determination of efavirenz serum levels a Beckman Coulter (Beckman Coulter 
GmbH, Stuttgart, Germany) HPLC system was used.  The system consists of a System Gold 
508 Autosampler, a System Gold Diode Array Detector Module 168 and a System Gold 
Solvent Module 125.  The analytical column used was an XTerra™ RP18 column (2.1X150 
mm I.D., particle size 5µm) from Waters Corporation (Eschborn, Germany). 
 
The chromatographic separation was performed with a gradient elution.  The UV signal was 
monitored at both 245 nm and 255 nm throughout the analysis.  The two mobile phase 
components were as follows: mobile phase A consisted of 1/15 M potassium dihydrogen 
phosphate buffer (KH2PO4): acetonitrile (CH3CN) at a ratio of 60:40 (adjusted to pH 6.7 with 
sodium hydroxide) and mobile phase B consisted of 1/15 M potassium dihydrogen phosphate 
buffer (KH2PO4): acetonitrile (CH3CN) at a ratio of 30:70 (adjusted to pH 6.7 with sodium 
hydroxide).  All solutions were filtered through a 0.45 µm membrane filter (Millipore 
Corporation, Billerica, MA, USA) prior to use.   
 
The total run time for each sample was 30 min and a washing step was completed between 
each measurement in order to ensure complete elution of all substances.  The analysis was 
performed at room temperature (22°C).  The conditions for separation are outlined in Table 
10. 
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Table 10:  Conditions for the mobile phase applied for analytical separation of efavirenz with 
regards to time, mobile phase and flow rate. 
Time (min) 
Flow rate 
(ml/min) 
Mobile phase A
1
 Mobile phase B
2
 Duration (min) 
0 0.20 70 30 2 
2* 0.20 20 80 5 
7~ 0.25 20 80 12 
19* 0.25 70 30 5 
24~ 0.20 70 30 6 
30 0.20 70 30 STOP 
1
  Mobile phase A: 1/15 M KH2PO4:CH3CN (60:40), pH 6.7 
2
  Mobile phase B: 1/15 M KH2PO4:CH3CN (30:70), pH 6.7 
* Change in mobile phase composition occurs within 30 sec 
~ Change in flow rate occurs within 30 sec 
 
3.2.3.2 Nevirapine 
A Hewlett-Packard 5890 series II gas chromatograph was used for analysis.  The system 
consisted of a 7673 autosampler and an HP 3396 series II integrator (Hewlett Packard GmbH, 
Waldbronn, Germany), equipped with a nitrogen–phosphorus-detector (NPD).  
Chromatography was performed with an RTX-5 Amine, 95% dimethyl – 5% diphenyl 
polysiloxane column, 15mX0.32µm 1.0µ film thickness from Restek Chromatography 
products (Restek GmbH, Bad Homburg, Germany).  The carrier gas, helium 5.0, had a 
constant inlet pressure of 7.55 p.s.i and the injection mode was splitless (1 µl) for 0.3 min. 
 
The temperature program was as follows: 120°C at time zero followed by a 10°C increase per 
min up to 310°C, the final temperature. This temperature was maintained for 2 min.  The 
temperature of the injection port and the NPD detector was fixed at 300°C. 
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3.2.3.3 Lopinavir 
Lopinavir levels were determined by an HPLC analytical system consisting of the following: 
a Spark Holland™ Triathlon Autosampler (Emmen, Netherlands); a System Gold Solvent 
Module (Beckman Coulter, Krefeld, Germany); a System Gold 168 detector (Beckman 
Coulter, Krefeld, Germany) and a Jetstream II Plus Column Thermostat from Techlab GmbH 
(Erkerode, Germany).  An XTerra™ RP18 analytical column (2.1X150 mm I.D., particle size 
5µm) from Waters Corporation (Eschborn, Germany) was used. 
 
Lopinavir concentrations were determined by means of a gradient method.  The absorption 
was measured at both 220 nm and 254 nm.  The two mobile phases were as follows: mobile 
phase A consisted of 20 mM potassium dihydrogen phosphate buffer (KH2PO4): acetonitrile 
(CH3CN) at a ratio of 80:20 (adjusted to pH 4.9 with H3PO4) and mobile phase B consisted of 
20 mM potassium dihydrogen phosphate buffer (KH2PO4): acetonitrile (CH3CN) at a ratio of 
30:70 (adjusted to pH 4.9 with H3PO4).  All solutions were filtered through a 0.45 µm 
membrane filter (Millipore Corporation, Billerica, MA, USA) prior to use.  The volume 
injected from each sample vial was 20 µl and the analysis was performed at room 
temperature (22°C).   
 
The total run time for each sample was 30 min and a washing step was completed between 
each measurement in order to ensure complete elution of all substances.  Lopinavir eluted 
after 18.7 min and scandicaine, the internal standard, after 20.1 min.  Table 11 outlines the 
separation conditions. 
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Table 11:  Conditions for the mobile phase applied for analytical separation of lopinavir with 
regards to time, mobile phase and flow rate. 
Time (min) 
Flow rate 
(ml/min) 
Mobile phase A
1
 Mobile phase B
2
 Duration (min) 
0 0.20 65 35 10 
10* 0.20 30 70 8 
18~ 0.25 30 70 5 
23 0.25 65 35 2 
27~ 0.20 65 35 3 
30 0.20 65 35 STOP 
1
  Mobile phase A: 20 mM KH2PO4:CH3CN (80:20), pH 4.9 
2
  Mobile phase B: 20 mM KH2PO4:CH3CN (30:70), pH 4.9 
* Ratio of mobile phases increased linearly over 10 min period 
~ Immediate change in flow rate 
 
 
3.2.3.4 Fluconazole 
The HPLC system consisted of a System Gold 508 Autosampler, a System Gold model 168 
NM Diode Array Detector (DAD) and a System Gold 126 Solvent Module all from Beckman 
Coulter (Krefeld, Germany).  The oven used was a Jetstream II Plus Column Thermostat 
from Techlab GmbH (Erkerode, Germany).  An ASCENTIS Express™ liquid 
chromatography column (C18 2.1x100 nm, 2.7µ particle size), a Supelco product from 
Sigma-Aldrich (Steinheim, Germany) was used. 
 
FCZ was measured by means of an isocratic method.  The mobile phase was prepared by 
mixing filtered 20 mM potassium dihydrogen phosphate (K2HPO4) buffer and acetonitrile 
(CH3CN) at a ratio of 85:15 (v/v) with an adjusted pH of 3.0.  The flow rate was set at 0.3 
ml/min.  The column was heated to 25°C and the volume injected from each sample vial was 
1 injection of 20 µl.  The UV absorption was measured at wavelengths of 210 nm and 260 
nm.  The total run time for each sample was 12 min and a washing step was done between 
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each sample to ensure complete elution of all substances.  The retention times of FCZ and the 
internal standard, phenacetin, were 4.3 and 8.6 min respectively.   
 
3.2.4 Sample extraction 
3.2.4.1 Efavirenz 
Frozen serum samples were firstly thawed to room temperature.  Following this the analytical 
samples were prepared by pipetting 25 µl of the internal standard, 500 µl of Sörensen 
phosphate buffer (41.3:58.7; 1/15 M KH2PO4:1/15 M Na2HPO4; pH 7.0) and 200 µl of serum 
into a 15 ml screw cap test tube.  After this 3 ml of diethyl ether were added to the test tube 
which was then vortexed for 5 min to ensure complete mixing of all substances.  The samples 
were then centrifuged (Eppendorf Centrifuge 5804R, Hamburg, Germany) at 2.264 g for 5 
min.  The upper, organic layer was transferred to a clean conical tube which was evaporated 
to dryness under a gentle stream of nitrogen at 43°C.  The addition of diethyl ether, mixing 
and drying under nitrogen stream following transferral to the conical vial was repeated.  The 
resulting residue was either capped for storage in a refrigerator (4-5°C) until further analysis 
or reconstituted with 300 µl of a dilution mixture (1 1/15 M KH2PO4; 0.5 CH3CN; 0.5 
MeOH).  The solution was vortexed at approximately 30 sec and centrifuged at 2.264 g for 5 
min.  In certain ‘polluted’ samples further separation was needed.  In such a case the sample 
solution was transferred to a 1 ml plastic eppendorf tube (Eppendorf, Hamburg, Germany) 
and mixed in a microcentrifuge (Eppendorf Micro Centrifuge, Hamburg, Germany) at 
15.399g for 5 min.  The sample was then transferred to an autosampler vial with glass insert 
for analysis. 
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3.2.4.2 Nevirapine 
The sample preparation and extraction procedure of nevirapine were identical to the method 
described above for efavirenz, however, different extraction solutions were used.  Sample 
preparation was done by spiking 250 µl of patient serum with 25 µl of internal standard and 
500 µl of sodium carbonate buffer pH 9.4 (46 ml Na2CO3 and 204 ml NaHCO3).  Liquid-
liquid extraction was performed following the method described above.  The nevirapine 
residue was subsequently reconstituted with 300 µl of a DMSO/MeOH (1:1 v/v) solution.   
 
3.2.4.3 Lopinavir 
The sample preparation and extraction procedure of lopinavir were identical to the method 
described above for efavirenz and nevirapine, however, different extraction solutions were 
used.  Samples were prepared by spiking 500 µl of patient serum with 25 µl of internal 
standard and 500 µl of sodium carbonate buffer pH 9.4 (46 ml Na2CO3 and 204 ml NaHCO3).  
In addition to the previously described liquid-liquid extraction method, the lopinavir residues, 
once reconstituted with 220 µl of 20mM KH2PO4:MeOH:CH3CN (1:0.5:0.5 v/v, pH 4.9), 
were washed with 1 ml n-hexane and then centrifuged for 5 min.  The n-hexane was 
subsequently decanted.  
 
3.2.4.4 Fluconazole 
The frozen serum samples obtained from patients were firstly thawed to room temperature 
prior to the extraction procedure.  Once thawed, the samples for HPLC analysis were 
prepared by aliquoting 25 µl of the IS, 200 µl of 0.1 N sodium hydroxide (NaOH) and 250 µl 
of patient serum into a 15 ml screw cap test tube.  FCZ was subsequently extracted (liquid-
liquid extraction) by adding 3 ml of chloroform to the test tube.  The test tube was vortexed 
for 5 min to ensure complete mixing of all substances.  Thereafter the samples were 
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centrifuged (Eppendorf Centrifuge 5804R, Hamburg, Germany) at 2.264 g for 5 min which 
allowed for the complete separation of the two phases.  After centrifugation the organic 
(lower) layer was transferred to a clean conical glass vial.  The vials were then placed under a 
nitrogen stream (43°C) in order to evaporate the organic layer to dryness.  The 
aforementioned procedure was then repeated for a second time in order to ensure optimum 
FCZ extraction.  At this point the samples were either capped then stored in a refrigerator (4-
5°C) for analysing at a later date or the samples were resolved and prepared for HPLC 
analysis. 
 
Following extraction, the FCZ precipitate was resolved in 200 µl of potassium phosphate 
buffer.  This was then again vortexed for approximately 30 sec and centrifuged at 2.264 g for 
5 min before it was transferred to a 2 ml autosampler vial with glass insert. 
 
3.2.5 Validation of the analytical method 
The analytical laboratory provides a routine TDM service, specifically for ARVs and other 
anti-infectives. Although the bioanalytical method has not been strictly validated according to 
FDA and EMA guidelines, the laboratory is accredited and the assays have been sufficiently 
established for clinical use. 
 
3.2.5.1 Specificity and selectivity 
Serum samples were spiked with various substances to ensure that the signal measured by the 
detector comes from the substance of interest and that no other excipients, impurities, 
metabolites or concomitant medications, that may be present in the serum sample, interfere 
with the specific analyte.  Three serum samples spiked with different concentrations of 
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efavirenz, nevirapine, lopinavir/ritonavir and FCZ were analysed for interference with each 
of the compounds listed below. 
 
Efavirenz, nevirapine, lopinavir/ritonavir and fluconazole 
The following compounds were investigated for interference with the analytes: abacavir, 
adefovir, amprenavir, amoxicillin, aspirin, atorvastatin, dapsone, didanosine, efavirenz, 
fluconazole, folinic acid, ganciclovir, indinavir, itraconazole, lamivudine, lopinavir, 
methadone, methotrexate, nelfinavir, M8-metabolite of nelfinavir, nevirapine, oxazepam, 
paracetamol, pyrazinamide, pyrimethamine, ranitidine, rifampin, ritonavir, saquinavir, 
stavudine, sulfamethoxazole, sulfadoxin, tenofovir, trimethoprim, zalcitabine, and 
zidovudine. 
 
No interfering peaks were observed at the retention times of efavirenz, nevirapine, 
lopinavir/ritonavir or FCZ. 
 
3.2.5.2 Accuracy, precision and recovery 
The accuracy and intra-day precision of each method were determined by measuring replicate 
serum samples of the test compound at various concentrations.  The results are shown in 
Table 12.   
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Table 12:  Conditions for determining accuracy and precision of the analytical methods for 
the various test compounds. 
  EFV NVP LPV/r FCZ 
No. of replicate plasma samples 8 6 6 8 
No. of different concentrations 4 3 3 4 
0.2 0.75 1.0 0.5 
2.3 2.5 5.0 4.0 
6.0 5.5 20.0 10.0 
Sample concentration (µg/ml) 
8.5  - -  20.0 
 
Please see Appendix I for an example of fluconazole’s interday precision. 
 
Accuracy was calculated as the relative error of the nominal concentration (Cnom) and the 
mean value of the observed concentrations (Cobs) as follows: accuracy (%) = [(Cnom-
Cobs)/Cnom] x 100.  Precision of each method was expressed in terms of relative standard 
deviation and was calculated from the observed concentrations as follows: precision (%) = 
[standard deviation (SD)/Cobs] x 100.  Calculated accuracy (RE %) and precision (CV %) for 
each method are presented in Table 13. 
 
The recovery of all the tested compounds was estimated by comparing the peak areas in 
extracted spiked serum samples to those of non-processed standard solutions.  There is no 
difference in recovery between the calf serum matrix and that of serum samples.  Recovery 
for efavirenz, nevirapine, lopinavir and FCZ was 96.2 ± 3.0 %, 97.8 ± 3.8 %, 95.1 ± 2.2 % and 
94.9 ± 3.6 % respectively. 
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Table 13:  Accuracy and precision for the analytical methods of efavirenz, nevirapine, 
lopinavir and fluconazole using spiked serum samples: intra-day precision 
(C.V. %) and accuracy (RE %) 
EFV 
No. of replicate serum samples 8 8 8 8 
Sample concentration (µg/ml) 0.2 2.3 6.0 8.5 
Mean concentration found (µg/ml) 0.202 2.275 5.969 8.049 
C.V. % 2.6 3.2 2 3.8 
RE % -1.3 1.1 0.5 5.3 
NVP 
No. of replicate serum samples - 18 18 18 
Sample concentration (µg/ml) - 0.75 2.5 5.5 
Mean concentration found (µg/ml) - 0.7 2.37 5.159 
C.V. % - 4.8 4.6 4.1 
RE % - 6.6 5.1 6.2 
LPV 
No. of replicate serum samples - 8 8 8 
Sample concentration (µg/ml) - 1.0 5.0 20.0 
Mean concentration found (µg/ml) - 1.12 5.09 19.67 
C.V. % - 3.43 0.65 0.41 
RE % - -12 -1.8 1.65 
FCZ 
No. of replicate serum samples 8 8 8 8 
Sample concentration (µg/ml) 0.5 4.0 10.0 20.0 
Mean concentration found (µg/ml) 0.58 4.13 10.12 19.93 
C.V. % 8.8 1.67 0.7 0.9 
RE % -16 -3.25 -1.2 0.35 
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3.2.5.3 Calibration curves 
The specific ranges of calibration concentrations for all of the investigated compounds are 
discussed above (Tables 6, 7, 8 and 9).  The calibration curves, regression equations and 
correlation coefficients (r
2
-values), as determined by the least squares analysis, are shown in 
Figures 11-14. In the following figures (Figure 11-14) the x-axis refers to the serum 
concentration and the y-axis indicates the amount/height quotient. 
 
 
 
 
 
 
 
 
 
Figure 11:  Calibration curves of efavirenz at (a) 245 nm, y = 1320.74 x – 6.67682, r2 = 0.999 and at 
(b) 255 nm, y = 2024.11 x – 12.1730, r
2
 = 0.999. 
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(a)       (b) 
Figure 12:  Calibration curves of nevirapine at (a) 245 nm, y = 1320.74 x – 6.67682, r2 = 0.999 and at 
(b) 255 nm, y = 2024.11 x – 12.1730, r
2
 = 0.999 
 
(a)       (b) 
Figure 13:  Calibration curves of lopinavir at (a) 220 nm, y = 3007.14 x – 21.9032, r2 = 0.999 and at 
(b) 250 nm, y = 26483 x – 67.7264, r
2
 = 0.999 
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(a)       (b) 
Figure 14:  Calibration curves of fluconazole at (a) 210 nm, y = 4.6224 x – 0.172663, r2 = 0.999 and 
at (b) 260 nm, y = 58.4205 x – 0.0911347, r
2
 = 0.999 
 
 
 
 
 
 
3.2.5.4 Stability 
Various storage conditions were investigated for each analyte to ensure stability during the 
analysis.  Spiked serum samples were tested in the following conditions: 30 days at -20°C; 4 
months at -20°C; 7 days at 4°C; 24 hours at room temperature (23-25°C); 60 min at 56°C and 
after four freeze-thaw cycles.  The stability of the drugs was also tested at 57°C which is used 
as the viral inactivation step in sample preparation procedure.  No degradation occurred for 
efavirenz, nevirapine, lopinavir or FCZ in any of the listed stability studies. 
 
Furthermore, all the drugs of interest (efavirenz, nevirapine, lopinavir/ritonavir and 
fluconazole) were stable after extraction for at least 3 months at 4°C. 
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3.3 Population pharmacokinetic analysis 
3.3.1 Datasets used in the model development 
Patients in the control and treatment group were administered either 600 mg efavirenz once 
daily, 200 mg nevirapine twice daily or 800/200 mg lopinavir/ritonavir twice daily.  Patients 
in the treatment group were administered 200 mg FCZ mg once daily.  The serum 
concentration-time data of efavirenz, nevirapine and lopinavir are based on a sparse sampling 
design, where most individuals had at least two blood samples taken.  All available data were 
used for the population pharmacokinetic analysis. 
 
3.3.2 Population Pharmacokinetic Model 
Population pharmacokinetic models were built using a non-linear mixed-effects modeling 
approach.  The first-order conditional maximum likelihood estimation in the NONMEM 
program (double precision, Version 7.1.2, ICON Development Solutions, Elliott City, MD) 
and NM-TRAN pre-processor were used.  Models were run using the G-Fortran Compiler 
(GNU Compiler Collection) on a personal computer under the Microsoft Windows Vista 
operating system (Compaq Presario CQ70).  PerlSpeaksNONMEM 2.3.1 
(http://psn.sourceforge.net/) running activePerl 5.8.9 (ActiveState Software Inc., Vancouver, 
BC, Canada) were used to manage NONMEM batch files.  The subroutines within 
NONMEM were linear mammillary models (ADVAN4 used with TRANS4 in the PREDPP 
library) to investigate a two-compartment, absorption model. 
 
An open-compartment, open model with first order elimination provided the best fit to the 
sparse dataset.  The structural pharmacokinetic model for the two-compartment model 
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consists of the following parameters: absorption rate constant (Ka), oral clearance (CL) and 
volume of the central compartment (V).  Ka is fixed to literature values. All individual V 
assumes the population mean value.  CL was assumed to be log-normally distributed and 
exponential inter-individual variability terms were included in the pharmacokinetic 
parameters in the model (Equation 1).  A proportional residual error model was used 
(Equation 2). 
 
         .......................  Equation 1 
where:  
Pi    =  the true parameter value for individual i 
P    =  the typical value (population mean) of the parameter  
p
iη  =  the difference between the true value for individual, i, and the typical value for the 
population, with a mean of 0 and a variance of ω
2 
 
         .......................  Equation 2 
where: 
Cij     =  the jth measured observation (serum concentration) for individual i 
Ĉij     =  the jth model predicted value (serum concentration) for individual i 
lijε   = the proportional residual error for the jth measurement for individual i, and is normally 
distributed with a mean of 0 and a variance of σ1
2 
ij2ε   =  the additive residual error for the jth measurement for individual i, and is normally 
distributed with a mean of 0 and a variance of σ2
2
 
 w    =   the weighting factor defined as 2ijC  
)exp( pii PP η=
wCC ijijijij •+= )ˆ( 21 εε
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Population pharmacokinetic parameters, without covariates, were estimated.  Estimates of the 
pharmacokinetic parameters for each individual were subsequently obtained using Bayesian 
estimation and were further used in determining their relationship with dose and food state.  
 
3.3.3 Covariate analysis 
Covariate screening was accomplished using stepwise covariate model (SCM) in 
PerlSpeaksNONMEM (PsN). The hypothesis testing to discriminate among alternative 
hierarchical structural models based on the p-values for the forward inclusion and backward 
elimination at 0.05 and 0.01, respectively. Both linear and exponential relationships were 
explored. The resulting model that included all significant covariates was considered the 
“final” population pharmacokinetic model. 
 
3.3.4 Model validation 
A degenerate visual predictive check was performed by the simulation of the parameter 
estimates of the final model to generate 500 individual profiles.  The median and 95% 
prediction intervals for the concentration at each time points were plotted and compared to 
the original data using Xpose4 package running on R (v. 2.13.0) (Figures 28-30). 
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4.0 RESULTS 
4.1 Patient population 
Eighty HIV-positive patients were included in this study.  The control group consisted of fifty 
four patients (n=54) who were taking one of the investigated ARVs as part of their treatment 
regimen.  The treatment group consisted of twenty six patients (n=26) who were taking FCZ 
in addition to one of the investigated ARVs.  Demographic characteristics (age, gender, race, 
weight, height, BMI) are presented in Table 14. 
 
Table 14:  Demographics and baseline characteristics of the study population 
  Control group Treatment group 
 
  (n=54) (n=26) 
Age (years)    
    Mean, SD  39 ± 8 38 ± 8 
    Range  21 – 62 26 - 56 
Gender, no. (%)    
    Male  20 (37%) 8 (31%) 
    Female  34 (63%) 18 (69%) 
Race, no. (%)    
    Black  27 (50%) 14 (54%) 
    Coloured  27 (50%) 11 (42%) 
    White  0 (0%) 1 (4%) 
    Other  0 (0%) 0 (0%) 
Weight (kg)    
    Mean, SD  69.8 ± 15.4 61.8 ± 16.5 
    Range  40.4 - 112,0 38.6 – 107.6 
Height (cm)    
    Mean, SD  165 ± 8 164 ± 9 
    Range  151 – 186 147 - 183 
Body Mass Index (kg/m
2
)    
    Mean, SD  25.8 ± 5.7 22.4 ± 4.8 
    Range  14.4 – 42.7 13.8 – 32.1 
Adherence (%)    
Mean, SD  95 ±11 87 ±13 
Range  59 – 113 56 – 104 
Missing values (n)  7  3 
    
SD standard deviation    
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Fifty six patients (70%) were studied on two occasions as planned and twenty four patients 
(30%) were only studied on one occasion.  The reason for the aforementioned was loss to 
follow-up (16 patients, 66.7%) or unwillingness to further participate in the study (8 patients, 
33.3%). 
 
An unpaired t-test was used to assess whether the two groups were significantly different 
(p<0.05) for patient characteristics that were normally distributed (age, weight and BMI) as 
verified by the Shapiro-Wilks normality test.  The variable height was considered to be not 
normally distributed (p=0.0004, Shapiro-Wilks normality test), therefore the Mann Whitney 
non-parametric test (p=0.96) was used.  Weight (p=0.0022) and BMI (p=0.0006) were 
significantly different between the two groups.  The following box and whisker plots (Figure 
15) illustrate the respective distributions; the whiskers indicating the maximum and minimum 
values of each parameter. 
 
 
(a)                                                                            (b) 
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(c)                                                                           (d) 
Figure 15:  Box and whisker plots of (a) age, (b) weight, (c) height and (d) BMI in the two groups. * 
p < 0.05 
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Clinical Tests 
CD4 count, viral load (VL), serum creatinine (CR), estimated glomerular filtration rate 
(GFR) as determined by the Cockroft & Gault formula (Cockroft et al., 1976) and alanine 
aminotransferase (ALT) are presented in Table 15.  Not all of the abovementioned clinical 
tests were performed for each patient; the number of missing values is also recorded in the 
Table 15. 
Table 15:  Parameters of clinical tests recorded for the study population. 
Clinical Test   
Control group 
(n=54) 
Treatment group 
(n=26) 
p-value 
     
CD4 count (cells/µl)     
    Mean, SD  412 ± 227 227 ± 175 
    Range  8 – 1001 4 - 672 
< 0.0001* 
    Missing values (n, %)  3 (3.2) 1 (2.0)  
Viral load (copies/ml)     
    <40 (n, %)  60 (64.5) 23 (46.0) 
    >40 (n, %)  25 (26.9) 22 (44.0) 
0.0867 
    Range  LDL - 244 151 LDL - 800 000  
    Missing values (n, %)  8 (8.6) 5 (10.0)  
Disease stage (WHO staging)     
Stage I (n, %)  3 (5.6) 0 (0.0)  
Stage II (n, %)  15 (27.8) 1 (3.8)  
Stage III (n, %)  28 (51.9) 2 (7.6)  
Stage IV (n, %)  8 (14.8) 23 (88.4)  
Serum creatinine (µmol/l)     
    Mean, SD  64 ± 19 72 ± 23 
    Range  36 - 124 36 - 129 
0.0987 
    Missing values  18 8  
GFR (ml/min)     
    <60 (n, %)  3 (3.2) 4 (8.0) 
    >60 (n, %)  60 (64.5) 29 (58) 
0.4135 
    Missing values (n, %)  30 (32.3) 17 (34)  
ALT (U/l)     
    Mean, SD  48 ± 68 33 ± 20 
    Range  11 - 320 9 – 84 
0.6214 
    Missing values (n, %)  47 (50.5) 17 (34)  
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* Indicates significance (p < 0.05) 
 
4.1.1 Control group 
4.1.1.1 Patient Characteristics 
Twenty patients (37%) in this group were male.  Their mean age was 42 years (range: 26 to 
62 years), mean body weight was 65.6 kg (range: 41.6 to 86.6 kg), mean height was 171 cm 
(range: 157 to 186 cm) and mean BMI was 22.5 kg/m
2
 (range: 14.4 to 30.0 kg/m
2
).  Thirty 
four (63%) patients were female.  Their mean age was 37 years (range: 21 to 52 years), mean 
body weight was 72.2 kg (range: 40.4 to 112.0 kg), mean height was 161 cm (range: 151 to 
170 cm) and mean BMI was 27.7 kg/m
2
 (range: 17.5 to 42.7 kg/m
2
).  Patients in the control 
group were staged as follows using the WHO staging of HIV/AIDS patients (WHO, 2009): 
three (5.6%) patients were stage 1; fifteen (27.8%) patients were stage 2, twenty eight 
(51.9%) patients were stage 3 and eight (14.8%) patients were stage 4. 
 
The antiretroviral drugs used in these patients consisted of: efavirenz-based regimens (27 
patients, 50%) of 600 mg once daily with an average duration of EFV-based ART of 3 years 
(range: 1-7 years); nevirapine-based regimens (18 patients, 33%) of 200 mg twice daily with 
an average duration of NVP-based ART of 2.5 years (range: 0.5 - 5 years) and 
lopinavir/ritonavir-based regimens (9 patients, 17%) of 400/100 mg twice daily with an 
average duration of LPV/r-based ART of 1.7 years (range: 1- 4 years).  The exact regimens 
are outlined in Figure 16. 
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Drug Regimen 
(a) (b) 
3TC lamivudine; d4T stavudine; DDI didanosine; EFV efavirenz; Lamzid lamivudine/zidovudine; LPV/r 
lopinavir/ritonavir; NVP nevirapine; TDF tenofovir  
 
Figure 16: Percentage of patients in the (a) control group and (b) treatment group receiving various 
efavirenz, nevirapine and lopinavir/ritonavir-based ARV treatment regimens 
 
 
4.1.1.2 Concomitant diseases 
Five (9.3%) patients had active TB and twenty two (40.7%) patients had at least 1 previous 
episode of tuberculosis, but were not currently on antimicrobial therapy.  Hepatic failure was 
found in three (5.6%) patients and hepatitis in one patient (1.9%).  Seventeen (31.5%) 
patients previously had at least one episode of oropharyngeal candidiasis and had received 
FCZ treatment at that time.  The most prevalent concomitant diseases are shown in Figure 17. 
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CONCOMITANT DISEASES 
(a) (b) 
COPD chronic obstructive pulmonary disease; DM diabetes mellitus; HPT hypertension; PN peripheral 
neuropathy; TB tuberculosis 
 
Figure 17: Most prevalent concomitant diseases in (a) the control group and (b) the treatment group, 
given as a percentage of patients 
 
4.1.1.3 Concomitant medications 
All of the patients (n=54) were taking vitamin B complex, 6 patients were prescribed 
pyridoxine (vitamin B6) and 1 patient was given thiamine (vitamin B1) as a supplement.  
Twenty four (44.4%) patients were taking trimethoprim-sulfamethoxazole (TMP-SMX) as 
prophylaxis.  Anti-TB drugs used in 5 patients included: rifampicin (80%), isoniazid (80%), 
pyrazinamide (80%), ethambutol (100%), streptomycin (20%), ciprofloxacin (20%) and 
moxifloxacin (20%).  Nine (16.7%) patients were prescribed an antidepressant, amitryptiline.  
Antidiabetic agents used were metformin (9.3%), gliclazide (5.5%) and human insulin 
(3.7%).  Hydrochlorothiazide (HCTZ), enalapril and amlodipine were given as 
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antihypertensive therapy in 3.7%, 7.4% and 1.9% respectively.  At the time of sampling three 
(5.6%) patients were taking amoxicillin and two (3.7%) patients’ flucloxacillin. 
4.1.2 Treatment group 
4.1.2.1 Patient characteristics 
Eight (30.8%) patients in this group were male.  Their mean age was 41 years (range: 32 to 
50 years), mean body weight was 65.0 kg (range: 41.4 to 107.6 kg), mean height was 171 cm 
(range: 163 to 183 cm) and mean BMI was 22.1 kg/m
2
 (range: 13.8 to 32.1 kg/m
2
).  Eighteen 
(69.2%) patients were female.  Their mean age was 37 years (range: 26 to 56 years), mean 
body weight was 59.0 kg (range: 38.6 to 84.4 kg), mean height was 160 cm (range: 147 to 
174 cm) and mean BMI was 22.6 kg/m
2
 (range: 15.1 to 30.1 kg/m
2
).  Patients in the treatment 
group were staged as follows using the WHO staging of HIV/AIDS patients (WHO, 2009): 
one (3.8%) patient was stage 2, two (7.6%) patients were stage 3 and twenty three (88.4%) 
patients were stage 4. 
 
The ARVs used in the FCZ group consisted of efavirenz-based regimens (13 patients, 50%) 
of 600 mg once daily; nevirapine-based regimens (5 patients, 19.2%) of 200 mg twice daily 
and lopinavir/ritonavir-based regimens of 400/100 mg twice daily (8 patients, 30.8%).  The 
exact regimens are outlined in Figure 16. Two patients receiving lopinavir/ritonavir-based 
regimens received a double dose of the ARV to compensate for co-adminstration.  The 
duration of cART with efavirenz, nevirapine and lopinavir/ritonavir were as follows in the 
treatment group: 4 years (range: 1-8 years); 4 years (range: 1-6 years) and 1.75 years (range: 
0.5-3 years).  
 
4.1.2.2 Concomitant diseases 
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None of the patients had active cryptococcal meningitis at the time of the study.  Seven 
(26.9%) patients had active TB and twelve (46.2%) patients had at least 1 previous episode of 
tuberculosis, but were not currently on antimicrobial therapy.  Drug induced hepatitis was 
found in one (3.8%) patient, one (3.8%) patient was diagnosed with hepatitis B and renal 
failure was observed in two (7.6%) patients.  A weight loss of more than 10% of the patients 
bodyweight was seen in six (23.1%) patients.  The most common concomitant diseases in the 
treatment cohort are shown in Figure 17. 
 
4.1.2.3 Study drug 
Oral FCZ was prescribed to the patients for treatment of either oropharyngeal candidiasis (5 
patients, 19.2%) or maintenance therapy for cryptococcal meningitis (21 patients, 80.8%).  
Twenty five patients (96.2%) were dosed with 200 mg fluconazole per day and one patient 
(3.8%) received 100 mg FCZ per day.  All patients had been at steady state for FCZ, in other 
words on treatment for more than 5 days. 
 
 
4.1.2.4 Concomitant medications 
TB treatment in these patients consisted of a combination of the following agents: rifampicin 
(85.7%), isoniazid (71.4%), pyrazinamide (57.1%), ethambutol (71.4%), streptomycin 
(14.2%), ciprofloxacin (14.2%) and moxifloxacin (14.2%).  Dapsone was prescribed to 4 
patients as prophylaxis for pneumocystis pneumonia (PCP) and twenty one (80.8%) patients 
were taking TMP-SMX as prophylaxis. 
 
4.2 Drug serum concentrations 
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Altogether 276 blood samples were collected from the 80 study participants for 
pharmacokinetic evaluation as follows: 137 efavirenz samples (36.5% efavirenz and FCZ); 
67 nevirapine samples (32.8% nevirapine and FCZ) and 72 lopinavir/ritonavir samples 
(59.7% lopinavir/ritonavir and FCZ).  The drug serum concentrations for each investigated 
ARV and the study drug, FCZ, is shown in Figures 18-21.   
 
The study utilised a random sampling protocol.  Drug intake was not observed in the majority 
of the patients, but the time of dose, as expressed by patient recall, was noted and the exact 
time of blood sampling was recorded.  The time period between drug intake and blood 
sampling for each of the drugs can be seen in Figures 18-21.  The therapeutic ranges (or 
minimum therapeutic plasma concentrations) have been included in Figures 18-21 for 
illustrative purposes, but it should be noted that for nevirapine and lopinavir/ritonavir the 
recommended therapeutic minimum trough concentrations are actually based on trough 
values. 
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Figure 18:  Distribution of efavirenz plasma concentrations in both patient groups corresponding to 
the time between drug administration and blood sampling.  Therapeutic range indicated by dashed red 
lines.   Three outliers (concentrations >30 000 ng/ml) at 08:51, 10:35 and 12:30 hours post-dose have 
not been included in this figure. 
 
 
 
 
 
Figure 19:  Distribution of nevirapine plasma concentrations in both patient groups corresponding to 
the time between drug administration and blood sampling.  Recommended therapeutic minimum 
trough concentration indicated by dashed red line. 
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Figure 20:  Distribution of lopinavir/ritonavir plasma concentrations in both patient groups 
corresponding to the time between drug administration and blood sampling.  Recommended 
therapeutic minimum trough concentration indicated by dashed red line. 
 
 
 
 
Figure 21:  Distribution of fluconazole plasma concentrations in the treatment group, according to 
ARV regimen, corresponding to the time between drug administration and blood sampling.  
Recommended therapeutic minimum concentration indicated by red dashed line.  One outlier 
(concentration >25 000 ng/ml) taken12:45 hours post-dose, has not been included in this figure. 
 
Concentration range 
 
(a)                                                                         (b) 
 
73.4 
13.3 13.3 2.6 
74.4 
23.0 
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Figure 22:  Percentage of efavirenz plasma levels in (a) the control group and (b) the treatment group, 
subdivided according to the sub-therapeutic, therapeutic and toxic concentration range of efavirenz. 
 
 
 
 
Concentration range 
(a)                                                                         (b) 
 
Figure 23:  Percentage of nevirapine plasma samples in (a) the control group and (b) the treatment 
group, subdivided according to the sub-therapeutic and therapeutic nevirapine concentration ranges.  
The recommended therapeutic range is a trough value and is only used for illustrative purposes. 
 
 
 
Concentration range 
(a)                                                                         (b) 
 
17.8 
82.2 
90.0 
26.0 
10.0 
27.3 
72.7 
74.0 
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Figure 24:  Percentage of lopinavir/ritonavir plasma samples in (a) the control group and (b) the 
treatment group, subdivided according to the sub-therapeutic and therapeutic lopinavir/ritonavir 
concentration ranges.  The recommended therapeutic range is a trough value and only used for 
illustrative purposes. 
 
4.3 Population pharmacokinetics 
4.3.1 Base Model 
A one-compartment, open model with first order absorption was fitted to the efavirenz, 
nevirapine and lopinavir steady-state sparse concentration-time data.  The structural 
pharmacokinetic model for the one-compartment model was parameterized on oral clearance 
(CL), volume of the central compartment (V), absorption rate constant (Ka) and F, the oral 
bioavailability which was fixed at 1.  In order to resolve the issue of non-identifiability 
(parameters that cannot be estimated from the available data) due to the sparse sampling 
design, only the absorption parameters were assumed to be log-normally distributed and 
exponential interindividual variability terms were included in the pharmacokinetic parameters 
in the model.  A proportional residual error model was used.  The individual pharmacokinetic 
estimates for each individual were subsequently obtained using Bayesian estimation.  The 
base model parameters are shown in Table 16 along with the final mode parameters following 
inclusion of the covariate model, which will be discussed in the next two sections. 
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Table 16:  Population pharmacokinetic model parameters of the base model and the final 
model incorporating covariate relationship 
†
The covariate parameter was incorporated to the model such that: (1 + θ) CL or (1 + θ) V, where θ = 0. 
‡
Efavirenz final model is based on the forward algorithm. The backward algorithm resulted in the base model. 
 
 
NONMEM Population Model 
Parameter 
Designation Base Model Final Model 
Efavirenz
‡
    
CL (L/h) θ1 12.0 15.8 
V (L) θ2 891 860 
Ka (h
-1
) θ3 0.66 0.66 
CL (rifampicin)
†
 θ6 ~ 0.0236 
CL (race)
†
 θ7 ~ -0.432 
Interindividual variability    
CL ω1 0.785 0.737 
Proportional Error θ4 0.127 0.127 
Additive Error θ5 126 126 
Objective Function  1905.982 1900.322 
Nevirapine    
CL (L/h) θ1 4.56 ~ 
V (L) θ2 1700 ~ 
Ka (h
-1
) θ3 1.66 ~ 
Interindividual variability    
CL ω1 0.065 ~ 
Proportional Error θ4 0.0284 ~ 
Objective Function  -169.736 ~ 
Lopinavir    
CL (L/h) θ1 4.23 4.27 
V (L) θ2 147 1.72 x 10
5
 
Ka (h
-1
) θ3 0.85 0.85 
CL (2C8/9inhibitor TMP-SMX)
†
 θ6 ~ 3.16 
CL (isoniazid & pyrazinamide)
†
 θ7 ~ -0.536 
V (isoniazid & pyrazinamide)
†
 θ8 ~ -1.00 
Interindividual variability    
CL ω1 0.36 0.28 
V ω2 0.54 1.3 
Proportional Error θ4 0.339 0.276 
Additive Error θ5 0.043 0.043 
Objective Function  1157.382 1130.41 
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The distribution of nevirapine concentrations exhibited large variability that rendered the 
population pharmacokinetic model unstable. The individual concentrations were log-
transformed in order to circumvent the problem with model convergence due to the large 
variability in the data. 
 
4.3.2 Covariate Model 
The concomitant medications were categorized based on their effect on specific CYP 
isoenzymes. All concomitant medications were characterized as inhibitor, inducer or 
substrate of a specific CYP isoenzyme or multiple CYP isoenzymes.  These categories were 
set-up to simplify and reduce the number of co-administered drugs in the model.  Only 
known inducers and inhibitors were introduced as categorical variables, substrates were not 
considered.  Table 17 shows the designation for the concomitant medication that patients in 
the study had taken. 
 
Concomitant medications, due to the multitude of drugs taken by the patients were coded, by 
their CYP effect, as dummy variables wherein drugs that are strong inducers or inhibitors of a 
specific CYP isoenzyme were coded as 1 in the CYP variable.  This included the study drug, 
FCZ (Table 17). 
 
Other categorical covariates included sex, race and stage. The dummy variables for sex were 
1 for male and 0 for female; and for race, 0 for black patients and 1 for coloured patients.  
The severity of disease stage, according to WHO staging, had grades from 0 to 4. 
The continuous variables included age, weight, height, body mass index, serum creatinine, 
glomerular filtration rate, and liver function based on ALT values. 
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Table 17:  Concomitant medications with known effects on cytochrome P450 
Concomitant drug Inhibitor Inducer 
TMP-SMX (Bactrim) CYP2C8, 9 ~ 
Amitryptiline CYP2D6 ~ 
Chlorpheniramine CYP2D6 ~ 
Ciprofloxacin CYP1A2, 3A4, 5 ,7 ~ 
Clotrimazole CYP3A4, 5 ,7 ~ 
Diclofenac CYP2C9 ~ 
Flucloxacillin CYP3A4,5,7 ~ 
Fluconazole CYP2C9, 19, 3A4 ~ 
Isoniazid 
CYP2C8,9,19, 1A2, 2A6, 
3A4,5,7 
CYP2E1 
Metformin CYP2D6 ~ 
Promethazine CYP2D6 ~ 
Pyrazinamide CYP2C19 ~ 
Ranitidine CYP2D6 ~ 
Rifampicin ~ 
CYP3A4,5,7, 1A2, 
2B6, 2C8,9,19,2D6 
Theophylline CYP2D6 ~ 
Tryptanol CYP2D6 ~ 
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4.3.3 Final Model 
The model parameters for the final models are listed in Table 16, including the median 
population values, inter-individual variability and residual variability.  The objective 
functions of the final model were 1900.322, -169.736, and 1130.41 for efavirenz, nevirapine 
and lopinavir, respectively.  The stepwise covariate model algorithm in PsN was employed to 
automatically determine influential covariates using forward inclusion at p = 0.05 and 
backward elimination at p = 0.01.  
 
In the efavirenz model, concomitant use of rifampicin and race were significant covariates of 
CL at the 5% level (p = 0.05) for the forward inclusion step.  However, during the backward 
elimination process at p = 0.01 level, both covariates were not considered a significant.  The 
covariate model equation was coded as ( )i1 θ+= baseCLCL , where θi is the covariate dummy 
variable when coded as 0.  The final efavirenz model was based on the forward algorithm as 
the backward algorithm resulted in the base model.  The estimated clearance of efavirenz 
from the final model was 15.8 L/hr and after screening the covariates race and co-mediacted 
rifampicin accounted for a 56.4% and 2% change in efavirenz clearance respectively. 
 
In the lopinavir model, TMP-SMX, clotrimazole and isoniazid had a significant influence on 
lopinavir clearance at both the 5% (p = 0.05) and 1% (p = 0.01) levels and were included in 
the final model.  The relationship was defined such that ( )i1 θ+= baseCLCL , where θi is the 
covariate dummy variable when coded as 0.  In the forward algorithm, additional covariates 
that were significant at the 0.05 level were serum creatinine, CYP3A and body mass index.  
The corresponding objective function of the forward model was 1116.652.  The estimated 
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clearance of lopinavir from the final model was 4.27 L/hr. The concurrent use of 
antituberculosis agents accounted for a 46.4% change in lopinavir clearance. 
 
The nevirapine data obtained in the present study comprised of a very extensive spread of 
drug serum concentrations. No significant covariates were observed in the nevirapine model 
and the estimated clearance, obtained from the base model, was 4.56 L/hr. 
 
4.3.4 Model validation 
The degenerate visual predictive check results are shown in Figures 25 to 27 for efavirenz, 
nevirapine and lopinavir, respectively.  The results were generated from 500 simulations.  
The 90% prediction interval of the simulated results contained the individual concentration-
time profiles from the pooled data relative to the time of their steady state dose.  The 
simulated profiles were able to capture all the observed data, supporting the validity of the 
model. 
 
Patients taking rifampicin had lower serum efavirenz concentrations, except for the three 
outliers, as shown by the red filled circles the left panel in Figure 25.  In the right panel of 
Figure 25, coloured patients marked by red filled circles had an overall lower efavirenz 
concentration compared to black patients represented by black empty circles. 
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Figure 25:  Degenerate visual predictive check showing the median (red line) and the 95% prediction 
interval (blue shade) of 500 simulated profiles for patients taking efavirenz.  The left panel shows the 
actual efavirenz concentration from patients with (red solid circles) and without (black empty circles) 
rifampicin concomitant medication.  The right panel shows the actual efavirenz concentration from 
black (black empty circles) and coloured (red solid circles) patients respectively. 
 
 
Patients that were not taking TMP-SMX tended to have a smaller spread of serum lopinavir 
concentrations, as shown by the black empty circles the left panel in Figure 26.  In the right 
panel of Figure 26, patients who were administered either isoniazid and pyrazinamide as part 
of their TB treatment, indicated by the red filled circles, had higher lopinavir concentrations.  
This was possibly due to their inhibiting effect on CYP3A isoenzymes.  Because patients on 
isoniazid or pyrazinamide had higher peak lopinavir concentrations, and observed lower 
concentrations at the later time intervals, such as the 12-hour time point, this translates to the 
effect of the covariate on both V and CL parameters. 
 
A simulation of 500 nevirapine concentrations is shown in a visual predictive check in Figure 
27. 
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Figure 26:  Degenerate visual predictive check showing the median (red line) and the 95% prediction 
interval (shaded blue) of 500 simulated profiles for patients taking lopinavir.  The left panel shows the 
actual lopinavir concentration from patients with (red solid circles) and without (black empty circles) 
TMP-SMX concomitant medication.  The right panel shows the actual lopinavir concentration in 
patients who had isoniazid and pyrazinamide as concomitant medication (red solid circles) and those 
that did not (black empty circles). 
 
 
 
 
 
 
 
 
 
 
 
Figure 27:  Degenerate visual predictive check showing the median (red line) and the 95% prediction 
interval (shaded blue) of 500 simulated profiles for patients taking nevirapine. 
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5.0 Discussion 
In developing countries, HIV positive patients with late stage disease significantly contribute 
to the total burden of disease.  There is an estimated 5.5 million South-Africans living with 
HIV; contributing 17% to the global HIV/AIDS epidemic (Jarvis et al., 2010).  The 
occurrence of opportunistic infections in these patients has decreased significantly after the 
emergence of combination antiretroviral therapy (cART), but additional treatment is still 
required (Seden et al., 2009; Ruhnke, 2004).  Polypharmacy has therefore become a more 
common practice to manage one or multiple pathologies.  The risk for experiencing DDIs, 
whether pharmacokinetic or pharmacodynamic in nature, is extensive due to high pill burden, 
concomitant diseases, age, gender and ethnicity (Evans-Jones et al., 2010; Lazarou et al., 
1998).  The outcome of DDIs may vary.  Co-administration could result in decreased serum 
concentrations which can lead to treatment failure and potential drug resistance or an 
interaction following concomitant use may result in elevated blood concentrations and 
development of adverse drug reactions (Seden et al., 2009; Robertson et al., 2005; Tseng et 
al., 1997). 
 
In this thesis the potential pharmacokinetic DDIs between the antifungal, FCZ (200 mg qd), 
prescribed as maintenance therapy and prophylaxis for cryptococcal meningitis and as 
treatment for oropharyngeal candidiasis, and any of the studied antiretroviral agents; 
efavirenz (600 mg qd), nevirapine (200 mg bd) and lopinavir/ritonavir (400/100 mg bd), was 
investigated.  Theoretically pharmacokinetic DDIs between these agents primarily involve 
interaction in common metabolic pathways, particularly CYP3A4 and CYP2C9, the 
isoenzymes inhibited by FCZ. 
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Furthermore, the population pharmacokinetic method used in this study for pharmacokinetic 
analysis also allowed for the evaluation of other significant co-factors which may affect the 
pharmacokinetics of the investigated ARVs. 
 
5.1 Patient characteristics 
In order to allow valid comparisons between the study groups, the control group and the 
treatment group should be comparable regarding drug regimens and patient characteristics. 
Age and height did not differ significantly between the two groups, however, body weight 
and body mass index were significantly higher in the control group.  A larger body weight is 
associated with a greater volume of distribution and clearance, especially for highly lipophilic 
drugs, and this would result in lower serum concentrations of the drug (Guo et al., 2010).  
When looking at weight and gender it is usually thought that males have a greater body 
weight than females.  In this study, however, males and females in the both the control and 
treatment group actually had very similar average body weights (69.7 and 69.9 kg versus 60.8 
and 61.0 kg, respectively).  There was a tendency for patients in the control group to have 
lower, but not significantly different, efavirenz serum concentrations, which is consistent 
with the concept that an increased body weight is associated with decreased serum 
concentrations.  The nevirapine and lopinavir serum concentrations, although not 
significantly different, tended to be greater in the treatment group which deviates from the 
aforementioned notion. 
 
With regards to the clinical test results related to the HIV infection, patients in the treatment 
group had significantly lower CD4 values (p<0.0001), indicative of the patients’ more 
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pronounced severity of the illness.  Once diagnosed, patients are clinically staged (I-IV) 
according to the World Health Organisation (WHO) disease staging system which is valuable 
in establishing the severity of illness and determining an appropriate treatment regimen 
(WHO, 2009).  Twenty one out of twenty six patients in the treatment group had previously 
been diagnosed with cryptococcal meningitis.  Cryptococcal meningitis is characterised as 
one of the AIDS-defining illnesses and patients are assigned as stage IV severity according to 
the WHO.  It was therefore expected and re-established that the treatment group would have a 
higher degree of immune suppression (lower CD4 values) when compared to the control 
group (227 ± 175 cells/µl vs 412 ± 227 cells/µl).  When comparing the severity of illness in 
the two study groups the following was ascertained; 5.6% of patients in the control were 
stage I, whereas no patients in the treatment group were; 27.8% of the control group were 
stage II versus only 3.8% of the treatment group; the largest percentage (51.9%) of the 
control group were stage III compared to the 7.6% of the treatment group; 14.8% of patients 
in the control group were stage IV versus 88.4% of the treatment group.  This confirms that 
patients in the treatment group were more ill, as expected. 
 
The viral load of a patient gives an indication of the number of HIV-RNA copies per 
millilitre plasma; therefore a lower than the detectable limit (LDL) viral load is desirable.  
Only 64.5 and 46.0 percent of patients were virally suppressed in the control and treatment 
group respectively (Table 15).  This could be a possible indication of treatment failure due to 
poor adherence or the patients’ may have developed resistance to one or more ARVs in their 
treatment regimen.  Drug resistance is multifactorial and may be a result of a lack of 
compliance or sub-therapeutic drug levels originating from DDIs between co-administered 
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drugs and therefore receiving a sub-therapeutic dose (Robertson et al., 2005; de Maat et al., 
2003; Back et al., 2000). 
 
In this study, two patients in the control group had an ALT three times the upper limit of 
normal (3 X ULN); one patient as a result of non-ARV drug-induced hepatitis and the other 
due to alcohol-induced hepatitis.  Continuous use and elevated concentration of co-
administered drugs that may cause hepatotoxicity can worsen the condition.  Drug-induced 
hepatotoxicity is an adverse drug reaction associated with a variety of drugs, including ARVs 
and FCZ.  The majority of drugs must first be converted into a more ionized or polar form, 
via the two phases of metabolism, in order to be more easily excreted. The main metabolic 
pathway involves the CYP enzyme family.  Hepatotoxicity may occur when reactive 
intermediates in this process accumulate and cause liver cell damage.  All of the investigated 
antiretrovirals undergo hepatic metabolism via the CYP enzyme system.  Furthermore, 
hepatotoxicity is listed as a side effect of nevirapine and lopinavir/ritonavir as well as the 
study drug, FCZ (Guo et al., 2010; Canta et al., 2005; Sanna et al., 2005; Stern et al., 2003). 
 
5.2 Drug serum concentrations 
Therapeutic drug monitoring of efavirenz and nevirapine has been the subject of great debate 
(Pretorius et al., 2011).  The deliberation is that steady state NNRTI drug levels do not vary 
greatly during a dosing interval as the drugs have considerably long half lives (40-55 hours 
and 25-30 hours, respectively) and that serum levels remain relatively constant (Back et al., 
2003; Smith et al., 2001).  It has been shown, however, that great inter- and intraindividual 
variability exists in NNRTI serum levels.  This can partly be explained by genetic variations 
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and polymorphisms in the expression of CYP isoenzymes.  As shown in Figure 1, CYP3A4 is 
the most abundant and prominent isoenzyme involved in drug metabolism.  Furthermore, this 
isoenzyme is also responsible for the metabolism of approximately 50% of all marketed 
drugs (Zhang et al., 2001).  CYP3A4 as opposed to other CYP3A isoenzymes (CYP3A5 and 
CYP3A7) is not subject to major genetic polymorphisms, but rather influenced by a variety 
of environmental factors (Wojnowski et al., 2006).  Altered serum concentrations of drugs 
that are metabolised by CYP3A4 may therefore be presumed to result from interindividual 
variation in the level of CYP gene expression.  Gene expression may be influenced by 
homeostatic mechanisms, disease states and environmental factors such as smoking, diet and 
concomitant drug use (Lamba et al., 2002). 
 
A visual representation of the spread of drug serum concentrations for efavirenz, nevirapine 
and lopinavir/ritonavir (Figures 18-20) shows that a greater percentage of patients, in both the 
control and treatment group, had drug concentrations within or above the recommended 
therapeutic range (73.4, 82.2 and 90.0% versus 74.4, 72.7 and 81.0% respectively).  When 
investigating non-adherence of the ARVs, defined as a serum concentration lower than the 
limit of quantification (<LLOQ), in the control and treatment group it was found that 0.6% 
and 5.1% had LLOQ serum concentrations, respectively. 
 
One of the main mechanisms of pharmacokinetic DDIs is interference within common 
metabolic pathways involving the CYP enzyme system (Kakuda et al., 2008; Tseng et al., 
1997).  DDIs can result in altered serum concentrations of the associated ARVs.  This is, 
however, not evident at first sight from the raw data obtained as the study made use of a 
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random sampling schedule and the concentrations cannot be directly compared since there 
were different timeframes between dose intake and blood sampling.  Furthermore, a 
straightforward comparison of ARV serum concentrations with the recommended therapeutic 
range would be misleading for nevirapine and lopinavir/ritonavir, since the therapeutic range 
refers to trough concentrations which were not obtained in this study (Pretorius et al., 2011).  
The therapeutic range can therefore only be used as a reference point for illustrative purposes.  
To better establish a link between ARV serum concentrations and concurrent drug use or 
various patient characteristics, a population pharmacokinetic approach was therefore 
employed including modelling of the data. 
 
Although the focus of this thesis was to investigate the effects of FCZ on the 
pharmacokinetics of ARVs, FCZ serum concentrations were measured by a newly developed 
HPLC method.  This determination, in part, was to identify whether any observed DDI was 
directly related to FCZ serum concentrations and to establish whether the patients were 
adherent to their antifungal treatment.  Moreover, verification of whether FCZ serum 
concentrations were in the recommended therapeutic range for maintenance/prophylactic 
treatment of cryptococcal meningitis and treatment of oropharyngeal candidiasis could also 
be done. 
 
5.3 Population pharmacokinetics 
To investigate the potential DDI between efavirenz, nevirapine or lopinavir/ritonavir and 
FCZ, a one-compartment pharmacokinetic model was developed, using a non-linear mixed 
effects modelling program (NONMEM), to establish whether differences in the random 
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serum concentrations obtained for each of the two study groups could be as a result of an 
interaction between the aforementioned drugs.  FCZ was incorporated as a categorical 
variable in the covariate model, along with all the other concomitant medications, according 
to their effects on specific CYP isoenzymes (Table 17). 
 
5.3.1 Efavirenz 
The efavirenz model delivered two significant covariates at the 5% level (p = 0.05); 
concomitant use of the antimycobacterial rifampicin as well as ethnicity.  Rifampicin is a 
potent inhibitor of CYP3A4, which besides a sizeable contribution of CYP2B6, is partly 
responsible for metabolism of efavirenz (Ståhle et al., 2004; Back et al., 2003).  Concomitant 
use of this antimycobacterial agent and efavirenz was associated with only a minor (2%) and 
clinically not significant, increase in efavirenz clearance.  This covariate was not significant 
in the backward elimination process, an automatic algorithm to remove non-significant 
variables, of the population pharmacokinetic model at the 1% level (p = 0.01).  A DDI 
between efavirenz and rifampicin was expected as the drugs share a common metabolic 
pathway via CYP3A4 and CYP2B6.  According to the literature, however, a more 
pronounced interaction between efavirenz and rifampicin has been demonstrated in other 
HIV-infected cohorts (Decloedt et al., 2011; Elsherbiny et al., 2009).  Eventhough efavirenz 
is metabolised by CYP3A4, no DDI was found between this ARV and FCZ, a CYP3A4 
inhibitor, which is consistent with literature from a number of studies (Robertson et al., 2005; 
de Maat et al., 2003; Dahri et al., 1998). 
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Of note, however, is that one coloured female patient in the treatment group had significantly 
elevated efavirenz levels on both sampling occasions; 33 023 ng/ml, 29 859 ng/ml and 33 622 
ng/ml taken at 8.83, 10.52 and 12.50 hours post-dose.  Corresponding FCZ serum 
concentrations were <LLOQ, 2 873 ng/ml and 2 663 ng/ml.  Concomitant medications 
included FCZ, TMP-SMX and vitamin B complex.  The patient was also diagnosed with 
abdominal TB and treatment consisted of rifampicin, isoniazid, ethambutol and 
pyrazinamide.  Potential reasons for this elevation may be a DDI with FCZ and/or isoniazid 
or the patient may be a poor metaboliser of efavirenz, most likely for the CYP2B6 pathway.  
Elevated efavirenz levels have been correlated to an increased risk of developing central 
nervous system side effects, but this patient did not present with any adverse effects.  Isolated 
case studies have been reported where the concomitant use of FCZ and efavirenz has led to 
increased concentrations of the ARV (Hasse et al., 2005; Robertson et al., 2005; de Maat et 
al., 2003).  The contribution of FCZ to the significantly elevated efavirenz levels in this study 
is, however, questionable.  In this specific case the patient had a FCZ serum concentration 
that was <LLOQ at the time of first blood sampling which shows that the drug had not been 
taken for at least 4 to 5 days.  Efavirenz levels were at their maximum at this point. 
 
The most probable reason for increased efavirenz concentrations in the abovementioned 
patient could be a genetic variation in CYP2B6.  Hasse et al. (2005) described a case of a 
female Thai woman, taking FCZ, found to be homozygous for the CYP2B6 G516T allele that 
had a plasma efavirenz concentration 30 times the normal limit.  A pharmacogenetic study 
performed in HIV-infected patients in the International Medical Centre of Japan illustrated 
that patients homozygous for CYP2B6 *6/*6 (Q172H and K262R) had a significantly higher 
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mean efavirenz plasma concentration when compared to patients heterozygous or without the 
*6 allele (Tsuchiya et al., 2004).   
 
Ethnicity was found to have the most significant effect on efavirenz pharmacokinetics.  In the 
covariate model race accounted for a 56.8% increase in efavirenz clearance and subsequent 
decreased efavirenz concentrations observed in coloured patients.  This data supports and 
adds important information to previously published data.  Effects of race on efavirenz 
pharmacokinetics have been well documented and this effect can most likely largely be 
explained by differences in CYP2B6 expression in the different patient populations, as 
discussed above. 
 
Stöhr and colleagues (2008) combined data from the Liverpool Therapeutic Drug Monitoring 
(TDM) register with the UK Collaborative HIV Cohort (CHIC) study to ascertain the effect 
of ethnicity on NNRTI plasma levels.  The outcome of the study was that black patients, 
comprising 34% of the study population, had a 59% increase in efavirenz plasma levels (p < 
0.001) showing a clear association between race and efavirenz plasma concentrations.  
During an exploratory analysis to correlate the effect of efavirenz plasma concentrations and 
the development of central nervous system adverse effects in European-American, African-
American and Hispanic patients, recruited to the Adult AIDS Clinical Trial Group Study in 
the USA, Haas et al. (2004) found that a CYP2B6 G516T polymorphism was more common 
in African-American patients (20%) than in European-Americans (3%).  This corresponded 
to significantly increased efavirenz plasma concentrations (p < 0.0001) and decreased drug 
clearance. 
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A UK-based study of Ugandan and Zimbabwean adult HIV-positive patients reported similar 
findings when investigating the genetic link between race and CYP2B6 in efavirenz 
pharmacokinetics (Jamshidi et al., 2010).  It has been well documented that the 
polymorphisms resulting in a loss of function (LoF) of the CYP2B6 gene are associated with 
elevated efavirenz concentrations and corresponding decrease in clearance (Haas et al., 2004; 
Tsuchiya et al., 2004).  The frequency of these LoF alleles in the UK study were found to be 
65% in Zimbabweans, 39% in Ugandan Nilotics and 22% in Ugandan Bantus and may 
therefore influence efavirenz pharmacokinetics in these African populations. 
The conclusion drawn from all of these studies is that varying efavirenz plasma 
concentrations in different ethnic populations may be due to differences in gene expression, 
particularly of CYP2B6.  This thesis adds data that supports the hypothesis that race and 
efavirenz plasma concentrations are linked.  Moreover, the present study illustrates a new 
finding that, in the South African context, coloured patients have significantly decreased 
efavirenz serum concentrations which may be related to a polymorphism of the CYP2B6 
gene resulting in a gain of function as opposed to the LoF commonly seen in black patients. 
 
Investigating the adherence, as measured by a pill count, shows no statistical difference 
between black patients (93.4%, n=41) and coloured patients (89.7, n=38) when taking both 
the control and treatment groups into account. 
 
Currently efavirenz is uniformly dosed as 600 mg once daily.  The present findings may, 
however, suggest that dosage adjustments according to race could be beneficial to avoid side 
effects associated with increased efavirenz levels in black patients or to ensure that coloured 
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patients are achieving high enough plasma levels for viral suppression and prevent the 
development of drug resistance and ultimately treatment failure. 
 
5.3.2 Nevirapine 
The primary CYP isoenzymes responsible for metabolism of nevirapine are CYP3A4 and 
CYP2B6 (Elsherbiny et al., 2009; de Maat et al., 2003).  As suggested by the literature, co-
administration of nevirapine and FCZ was expected to be associated with a significant DDI, 
as a result of the inhibition of CYP3A4 by FCZ, resulting in elevated nevirapine 
concentrations.  Kishimoto et al. (2000) described a 7.4 times increase in the AUC of 
nevirapine following concomitant use with FCZ, while Wakeman et al. (2010) reported a 
29% increase in AUC and approximately 10% decrease in nevirapine clearance in HIV-
positive Ugandan patients when nevirapine was co-administered with FCZ.  The nevirapine 
serum concentration data in both patient groups in the present study showed substantial 
variation, ranging from 1 007 – 14 400 ng/ml over a time period of 0.08 – 11.66 hours post-
dose.  This created some problems in model convergence.  To overcome the problem of 
extensive spread of nevirapine concentrations, they were converted to a log-scale with the 
base 10 to condense and collapse all the data which can then be handled by NONMEM and 
gives assurance that the model can converge.  No significant covariates were, however, 
observed in this model.   
 
Large inter- and intraindividual variability has been described in nevirapine concentrations 
because of the large extent of genetic variations in CYP2B6, CYP2C9 and CYP2D6 (Haas et 
al., 2006).  This may be the reason for the wide spread of concentrations seen as no DDI has 
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been established between nevirapine and FCZ or any other co-administered agents in the 
present study. 
 
In the aforementioned CHIC study, Stöhr et al. (2008) also investigated the effect of ethnicity 
on nevirapine plasma concentrations.  They found that black patients, comprising 27% of the 
study population, had a significant increase (p = 0.002) of 39% in nevirapine levels.  From 
the present study, however, no clear tendencies could be established between race and 
nevirapine serum concentrations. 
 
It is estimated that between 6 and 30% of patients on a nevirapine containing regimen 
experience serious adverse effects involving the liver and this may lead to the discontinuation 
of therapy (Sulkowski et al., 2002).  A nested study within the Gilead study, protocol FTC-
302, investigated the association between genetic polymorphisms of nevirapine metabolising 
CYP isoenzymes and the development of hepatotoxicity in 385 South African patients (Haas 
et al., 2006).  Contrary to previous reports and finding that CYP2B6 G516T polymorphisms 
influence efavirenz plasma levels, no association was found with nevirapine concentrations or 
with development of hepatotoxicity (Rotger et al., 2005).  Significant co-factors for the risk 
of developing hepatotoxicity was previously established in the Gilead study, these included 
female sex, increased body mass index, serum albumin concentration, plasma HIV RNA 
copies, lactate dehydrogenase level and aspartate aminotransferase level (Haas et al., 2006).  
In the present study 83.3% of the patients on a nevirapine-based regimen were female.  In 
keeping with the literature, nevirapine serum concentrations tended to be higher in female 
patients which are associated with an increased risk for hepatotoxicity. 
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5.3.3 Lopinavir 
The lopinavir model delivered the most extensive list of covariates that affected drug serum 
concentrations.  Concomitant use of TMP-SMX, isoniazid or clotrimazole, an antifungal 
given to treat vaginal and oral candidiasis, was found to significantly affect lopinavir serum 
concentrations at both the 1% (p =0.001) and 5% (p = 0.005) levels.  Other covariates that 
influenced lopinavir pharmacokinetics at the 5% significance level in the present study 
included serum creatinine, body mass index and coadministration of CYP3A inhibitors, 
which was already accounted for by isoniazid and clotrimazole.  These factors were however 
not included in the final model (Table 16). 
 
TMP-SMX is a combination antibiotic administered as prophylaxis for a variety of infections, 
including urinary tract infections, bronchitis, traveler’s diarrhoea and Pneumocystis carnii 
pneumonia (Wen et al., 2002).  Use of this drug was recorded in 56.3% of the study 
population.  Trimethoprim and sulfamethoxazole are both inhibitors of CYP2C8 and 2C9, 
respectively (Wen et al., 2002).  Concomitant use of TMP-SMX and lopinavir resulted in a 
greater spread of serum lopinavir concentrations (Figure 28).  A DDI between lopinavir and 
TMP-SMX was not expected as lopinavir is mainly metabolised by CYP3A4 with a limited 
contribution by CYP2D6 (Cvetkovic et al., 2003). 
 
The antituberculosis drug isoniazid is a strong inhibitor of CYP3A4 which is responsible for 
the largest portion of lopinavir metabolism.  Co-administration of CYP 3A4 inhibitors would 
be expected to result in increased serum lopinavir levels and a corresponding decrease in drug 
clearance.  TB treatment in all patients receiving lopinavir, however, also included 
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pyrazinamide, a CYP2C19 inhibitor, and rifampicin, a potent inducer of CYP3A4, 2B6, 
2C8,9,19 and 2D6 (Table 17).  The latter of which would result in decreased lopinavir serum 
concentrations and an increase in drug clearance via CYP3A4 induction.  The final 
population pharmacokinetic model, however, shows that the abovementioned antituberculosis 
combination results in a 46.4% decrease in lopinavir clearance when compared to patients 
that were not taking antituberculosis agents (Figure 26).  To tease out the contributing effect 
of each of these drugs is rather improbable.  Furthermore, clotrimazole also contributed to the 
aforementioned decrease in lopinavir clearance which can be explained by its properties as an 
inhibitor of CYP 3A4, 3A5 and 3A7. 
 
5.4 Study limitations and future work 
There were a number of limitations in the study.  The ideal study design for investigating 
potential DDIs between approved drugs is a randomised cross-over design. However such a 
design would not be feasible in a patient population that is receiving the investigated drugs as 
a part of their treatment regimen.  A random, sparse sampling approach was utilized in order 
to recruit more patients and not to interfere with routine clinical venepuncture.  Another 
caveat of the study is the limited sample size and number of blood samples, particularly in the 
nevirapine and FCZ treatment group.  According to the literature the most probable DDI 
would result from the concomitant use of nevirapine and FCZ (Wakeman et al., 2010; 
Manosuthi et al., 2007).  Although the use of a pharmacometric model contributed to the 
study design as predictions and simulations could be made based on all the data obtained 
from this study as well as data from various other studies and sources, the clinical 
significance of an interaction will require further data from a larger patient population. 
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From a practical perspective future work would be to increase blood sampling, create a more 
rigid blood sampling time schedule and increase the sample size of groups.  The covariates 
affecting ARV pharmacokinetics that were identified in the present study had not been pre-
specified prospectively, but were only identified retrospectively.  A confirmatory study 
would therefore be needed to verify the data.  Two major concerns raised in the study, 
namely the racial difference in EFV clearance and the identified interaction between lopinavir 
and the anti-tuberculosis agents (INH/PZA), will require further investigation considering 
South Africa’s patient population and the extent of HIV and TB co-infection.  Finally, 
problems with adherence should be addressed at the patient and caregiver level.  Improved 
methods of measuring adherence should be considered and further counselling might be 
necessary to keep patients motivated. 
 
A next step in the pharmacometric evaluation of the outcome of the present study could be 
the development of a pharmacodynamic model of the data in order to correlate the link 
between patient characteristics, serum drug concentrations and CD4 and viral load data. 
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6.0 Conclusion 
Given the limitations of the sample size in the present study, due to practical reasons, no 
statistical significant effect of FCZ on the pharmacokinetics of the investigated ARVs could 
be demonstrated. 
 
A retrospective analysis of the data showed various co-factors that influence the 
pharmacokinetics of the investigated ARVs.  Efavirenz clearance was increased by 56.8% in 
coloured patients which was previously not known and resulted in lower serum 
concentrations.  Concomitant use of efavirenz and rifampicin although significant, resulted in 
only a minor (2%) increase in efavirenz clearance.  No significant covariates were established 
in the nevirapine model.  Co-adminstration of combination antituberculosis agents including 
rifampicin, isoniazid and pyrazinamide, resulted in an overall decrease in lopinavir clearance 
by 46.4%. 
 
The data obtained and the significant covariates identified in this study need to be confirmed 
in a prospective study as these results are appropriate for management of HIV-infected 
patients in the South African context. 
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Appendix A 
Drug-drug interactions encountered with nevirapine, efavirenz and lopinavir/ritonavir.  
Interactions are graded as follows: drugs should not be co-administered •; potential for 
interaction ∆ ; no clinically significant interaction expected ◊ and too little or no clear data 
on possible interaction ◊ .  Adapted from www.hiv-druginteractions.org. 
Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Analgesics      
Aspirin ◊ ◊ ◊ 
Diclofenac ◊ ◊ ◊ 
Fentanyl ∆ ∆ ∆ 
Ibuprofen ◊ ◊ ◊ 
Methadone ∆ ∆ ∆ 
Morphine ◊ ◊ ∆ 
Paracetamol ◊ ◊ ◊ 
Tramadol ∆ ∆ ∆ 
Antiarrhythmics    
Amiodarone ∆ ∆ • 
Lidocaine ∆ ∆ ∆ 
Quinidine ∆ ∆ ∆ 
Antibacterials    
Amoxicillin ◊ ◊ ◊ 
Ciprofloxacillin ◊ ◊ ◊ 
Clarithromycin ∆ ∆ ∆ 
Clavulanic acid ◊ ◊ ◊ 
Dapsone ◊ ◊ ◊ 
Erythromycin ∆ ◊ ∆ 
Ethambutol ◊ ◊ ◊ 
Isoniazid ◊ ◊ ◊ 
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Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Antibacterials (cont)    
Metronidazole ◊ ◊ ∆ 
Moxifloxacin ◊ ◊ ∆ 
Penicillins ◊ ◊ ◊ 
Pyrazinamide ◊ ◊ ◊ 
Rifabutin ∆ ∆ ∆ 
Rifampicin • ∆ • 
Streptomycin ◊ ◊ ◊ 
Tetracyclines ◊ ◊ ◊ 
Trimethoprim-Sulfamethoxazole ◊ ◊ ∆ 
Anticonvulsants    
Carbamazepine ∆ ∆ ∆ 
Clonazepam ∆ ∆ ∆ 
Phenobarbital ∆ ∆ ∆ 
Phenytoin ∆ ∆ ∆ 
Valproate ∆ ◊ ∆ 
Antidepressants    
Amitryptiline ◊ ◊ ∆ 
Bupropion ∆ ∆ ∆ 
Lithium ◊ ◊ ◊ 
Mirtazapine ∆ ∆ ∆ 
Trazadone ∆ ∆ ∆ 
Anti-diabetics    
Gliclazide ∆ ∆ ∆ 
Insulin ◊ ◊ ◊ 
Metformin ◊ ◊ ◊ 
Pioglitazone ∆ ∆ ∆ 
Antifungals    
Amphotericin B ◊ ◊ ◊ 
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Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Antifungals (cont)    
Fluconazole ∆ ◊ ◊ 
Itraconazole • ∆ ∆ 
Ketoconazole • ∆ ∆ 
Voriconazole ∆ ∆ ∆ 
Antihistamines    
Loratidine ◊ ∆ ∆ 
Promethazine ∆ ∆ ∆ 
Anti-coagulent    
Warfarin ∆ ∆ ∆ 
Antiprotozoals    
Artemisinin ∆ ∆ ◊ 
Chloroquine ◊ ◊ ◊ 
Mefloquine ◊ ◊ ∆ 
Primaquine ◊ ◊ ◊ 
Proguanil ◊ ◊ ∆ 
Pyrimethamine ◊ ◊ ◊ 
Quinine ∆ ∆ ∆ 
Antipsychotics/Neuroleptics    
Chlorpromazine ◊ ◊ ∆ 
Clozapine ◊ ◊ ∆ 
Haloperidol ∆ ∆ ∆ 
Risperidone ◊ ◊ ◊ 
Antivirals    
Aciclovir ◊ ◊ ◊ 
Amantadine ◊ ◊ ◊ 
Oseltamivir ◊ ◊ ◊ 
Rimantidine ◊ ◊ ◊ 
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Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Erectile dysfunction agents    
Sildenafil ∆ ∆ ∆ 
Gastrointestinal agents    
Antacids ◊ ◊ ◊ 
Cimetidine ◊ ◊ ◊ 
Cisapride ∆ • • 
Lansoprazole ◊ ◊ ◊ 
Metoclopramide ◊ ◊ ◊ 
Omeprazole ◊ ◊ ◊ 
Ondansetron ◊ ◊ ◊ 
Pantoprazole ◊ ◊ ◊ 
Prochlorperazine ◊ ◊ ◊ 
Ranitidine ◊ ◊ ◊ 
General aneasthetics    
Halothane ◊ ◊ ◊ 
Ketamine ∆ ∆ ◊ 
Herbals/Supplements/Vitamins    
Folic acid ◊ ◊ ◊ 
Garlic ∆ ∆ ∆ 
Grapefruit juice ◊ ◊ ◊ 
Hops ∆ ∆ ∆ 
Milk thistle ∆ ∆ ∆ 
St. John's wort • • • 
Vitamin E ◊ ◊ ◊ 
Hypertension/Heart failure 
agents 
 
  
Amiloride ◊ ◊ ◊ 
Candesartan ◊ ◊ ◊ 
Enalapril ◊ ◊ ◊ 
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Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Hypertension/ Heart failure 
(cont) 
   
Furosumide ∆ ∆ ∆ 
Ramipril ◊ ◊ ◊ 
Sildenafil ∆ ∆ • 
Valsartan ◊ ◊ ◊ 
Illicit/Recreational    
Alcohol ◊ ◊ ◊ 
Cocaine ∆ ∆ ∆ 
Gamma-hydroxybutyrate ◊ ◊ ∆ 
Marijuana ◊ ◊ ∆ 
MDMA (ecstasy) ◊ ◊ ∆ 
Methamphetamine ◊ ◊ ∆ 
Immune modulators    
Interferon alpha ◊ ◊ ◊ 
Interleukin-2 ◊ ◊ ◊ 
Immunosuppressants    
Azothioprine ◊ ◊ ◊ 
Cyclosporine ∆ ∆ ∆ 
Tacrolimus ∆ ∆ ∆ 
Lipid lowering agents    
Atorvastatin ∆ ∆ ∆ 
Fish oils ◊ ◊ ◊ 
Simvastatin ∆ ∆ • 
Other    
Allopurinol ◊ ◊ ◊ 
Caffeine ◊ ◊ ◊ 
Calcium ◊ ◊ ◊ 
Digoxin ∆ ∆ ∆ 
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Coadministered drug Nevirapine Efavirenz Lopinavir/ritonavir 
Other (cont)    
Disulfiram ◊ ◊ ∆ 
Levodopa ◊ ◊ ◊ 
Potassium ◊ ◊ ◊ 
Pramipexole ◊ ◊ ◊ 
Spironolactone ◊ ◊ ◊ 
Tamsulosin ∆ ∆ ∆ 
Steroids    
Budesonide ◊ ◊ ∆ 
Dexamethasone ∆ ∆ ∆ 
Hydrocortisone (oral) ∆ ∆ ∆ 
Hydrocortisone (topical) ◊ ◊ ◊ 
Prednisolone ∆ ∆ ∆ 
Testosterone ∆ ∆ ∆ 
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Appendix B 
Drug-drug interactions encountered with fluconazole.  Interactions are graded as follows: 
drugs should not be co-administered •; potential for interaction ∆ ; no clinically significant 
interaction expected ◊ and too little or no clear data on possible interaction ◊ . 
Adapted from www.drugs.com/drug-interactions and www.medscape.com/drug-interactions  
 
Coadministered drug Fluconazole 
Analgesics   
Aspirin ∆ 
Diclofenac ◊ 
Fentanyl • 
Ibuprofen ◊ 
Methadone • 
Morphine ∆ 
Paracetamol ◊ 
Tramadol ◊ 
Antiarrhythmics  
Amiodarone • 
Lidocaine ∆ 
Quinidine • 
Antibacterials  
Amoxicillin ◊ 
Ciprofloxacin ∆ 
Clarithromycin ◊ 
Clavulanic acid ◊ 
Dapsone ◊ 
Erythromycin ∆ 
Ethambutol ◊ 
Isoniazid ∆ 
Stellenbosch University http://scholar.sun.ac.za
Appendix B                                                                     168 
 
Coadministered drug Fluconazole 
Antibacterials (cont)  
Metronidazole ◊ 
Moxifloxacin • 
Penicillins ◊ 
Pyrazinamide ◊ 
Rifabutin ∆ 
Rifampicin ∆ 
Streptomycin ∆ 
Tetracyclines ◊ 
Trimethoprim-Sulfamethoxazole ◊ 
Anticonvulsants  
Carbamazepine ∆ 
Clonazepam ◊ 
Phenobarbital ∆ 
Phenytoin ∆ 
Valproate ◊ 
Antidepressants  
Amitryptiline ∆ 
Bupropion ◊ 
Lithium ∆ 
Mirtazapine ◊ 
Trazodone • 
Anti-diabetics  
Gliclazide ∆ 
Insulin ◊ 
Metformin ∆ 
Pioglitazone ∆ 
Antifungals  
Amphotericin B ◊ 
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Coadministered drug Fluconazole 
Antifungals (cont)  
Voriconazole ∆ 
Antihistamines  
Loratidine ◊ 
Promethazine ∆ 
Anti-coagulent  
Warfarin • 
Antiprotozoals  
Artemisinin • 
Chloroquine ∆ 
Mefloquine ∆ 
Primaquine ◊ 
Proguanil ◊ 
Pyrimethamine ◊ 
Quinine ∆ 
Antipsychotics/Neuroleptics  
Chlorpromazine • 
Clozapine ∆ 
Haloperidol • 
Risperidone ∆ 
Antiretrovirals  
Efavirenz ◊ 
Lopinavir/ritonavir ◊ 
Nevirapine ∆ 
Zidovudine ∆ 
Anxiolytics/Hypnotics/Sedatives  
Diazepam ∆ 
Lorazepam ◊ 
Zolpidem ◊ 
Zopiclone ◊ 
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Coadministered drug Fluconazole 
Beta blockers  
Atenolol ◊ 
Carvedilol ∆ 
Metoprolol ◊ 
Propranolol ◊ 
Bronchodilators  
Salbutamol ◊ 
Salmeterol ∆ 
Theophylline ∆ 
Calcium channel blockers  
Amlodipine ∆ 
Diltiazem ∆ 
Verapamil ∆ 
Contraceptives  
Estradiol ∆ 
Ethinylestradiol ∆ 
Levenorgestrel ∆ 
Medroxyprogesterone (IM) ◊ 
Medroxyprogesterone (oral) ∆ 
Cytotoxics  
Cyclophosphamide ◊ 
Doxirubicin ∆ 
Tamoxifen ∆ 
Vinblastine ∆ 
Vincristine ∆ 
Erectile dysfunction agents  
Sildenafil ∆ 
Gastrointestinal agents  
Antacids ◊ 
Cimetidine ◊ 
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Coadministered drug Fluconazole 
Gastrointestinal agents cont.  
Cisapride • 
Lansoprazole ◊ 
Metoclopramide ◊ 
Omeprazole ∆ 
Ondansetron ∆ 
Pantoprazole ◊ 
Prochlorperazine • 
Ranitidine ◊ 
General aneasthetics  
Halothane ∆ 
Ketamine ∆ 
Herbals/Supplements/Vitamins  
Folic acid ◊ 
Garlic ◊ 
Grapefruit juice ◊ 
Hops ◊ 
Milk thistle ◊ 
St. John's wort • 
Vitamin E ◊ 
Hypertension/Heart failure agents  
Amiloride ◊ 
Candesartan ◊ 
Enalapril ◊ 
Furosumide ◊ 
Ramipril ◊ 
Sildenafil ∆ 
Valsartan ◊ 
Illicit/Recreational  
Alcohol ◊ 
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Coadministered drug Fluconazole 
Illicit/Recreational cont.  
Cocaine ◊ 
Gamma-hydroxybutyrate ◊ 
Marijuana ◊ 
MDMA (ecstasy) ◊ 
Methamphetamine ◊ 
Immune modulators  
Interferon alpha ◊ 
Interleukin-2 ◊ 
Immunosuppressants  
Azothioprine ◊ 
Cyclosporine ∆ 
Tacrolimus • 
Lipid lowering agents  
Atorvastatin • 
Fish oils ◊ 
Simvastatin • 
Other  
Allopurinol ◊ 
Caffeine ◊ 
Calcium ◊ 
Digoxin ◊ 
Steroids  
Budesonide ∆ 
Dexamethasone ∆ 
Hydrocortisone (oral) ∆ 
Hydrocortisone (topical) ◊ 
Prednisolone ∆ 
Testosterone ∆ 
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INTRODUCTION  
Effective treatment of the human immunodefiency virus (HIV) has become more complicated over 
the years as patients require antiretroviral (ARV) regimens that consist of a combination of agents 
that target different stages of the viral replication cycle.  Highly active antiretroviral therapy (HAART) 
involves concomitant administration of three or more agents from different pharmacological classes  
(O.Kis et al., 2009).  Most of these agents are either inducers or inhibitors, as well as substrates of 
the human cytochrome P450 (CYP) enzyme system in the liver and/or the gastrointestinal mucosa, 
and can therefore influence or alter the metabolism of co-administered agents resulting in drug 
interactions  (T.N. Kakuda et al., 2008).  
 
In developing countries, HIV positive patients with late stage disease significantly contribute to the 
total burden of disease.  There is an estimated 5.5 million South Africans living with HIV; 
contributing 17 % to the global HIV/AIDS epidemic (J.N. Jarvis et al., 2010).  The compounding 
problem is the late stage patients that are likely to develop a variety of opportunistic infections as the 
virus, characterized by a reduction in T-lymphocytes, renders the host immunocompromised and 
susceptible to a variety of pathogens.  Opportunistic infections (OIs) are defined as infections that 
would rarely cause disease in healthy individuals.  Although the occurrence of OIs have decreased 
significantly after the emergence of HAART in developed countries, OIs still pose a major hurdle 
with regards to morbidity and mortality in HIV-infected individuals in developing countries such as 
South Africa (P. Willemot et al., 2004, M Ruhnke, 2004). 
 
Mycobacterium tuberculosis (TB) is thought to be the deadliest infection that arises in patients living 
with HIV/AIDS (M.S. Sánchez et al, 2010).  Tuberculosis was diagnosed in 27%-34 % of HIV-
infected adults admitted to tertiary hospitals in Kwa-Zulu Natal, South Africa during 2001 (C.B. 
Holmes et al., 2003).  Since 2001 the number of patients co-infected with HIV and TB has 
increased, with Cape Town having the second largest patient population.  Other OIs such as 
pneumocystis pneumonia (PCP), caused by the fungus pneumocystis jiroveci, remains a common 
life-threatening infection seen in both treatment-naive and treatment-experienced patients (T. 
Enomoto et al., 2010).  PCP typically affects patients with a CD4 count of less than 200 cells/µl, 
however, patients with a CD4 count of less than 300 cells/µl and a history of previous OIs, are also 
at risk and may require prophylactic treatment (M.W. Hull et al., 2008).  The yeast-like fungus, 
candida, is present in the system of most people, however, in immunocompromised patients the 
body’s immune system cannot keep the fungus at bay resulting in disease (candidiasis).  Candida 
can infect the mouth, throat or vagina and is one of the more common and less severe opportunistic 
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infections seen during the early stages of infection.  The parasite toxoplasma gondii causes in an 
infection known as toxoplasmosis which frequently manifests in the brain resulting in encephalitis.  
Patients with CD4 count of less than 100 cells/µl are at risk. 
 
Oropharyngeal candidiasis and cryptococcal meningitis are the two most prevalent infections seen 
in late stage HIV/AIDS patients (J.E Gallant et al., 1994).  This necessitates further treatment or 
prophylaxis with antifungal agents.  A great potential for drug-drug interactions (DDIs) therefore 
exists in treated HIV/AIDS patients which in turn increases a patient’s probability of experiencing 
adverse drug reactions (ADRs) (K. Seden et al., 2009). 
 
Cryptococcal meningitis is a life-threatening fungal infection commonly seen in patients with HIV.  
The prevalence of HIV in the Sub-Saharan Africa region is approximately 22 500 000 with a 
reported estimate of 720 000 cases of cryptococcal meningitis per year, which demonstrates the 
impact of the disease (D.J. Sloan et al., 2009).  Research has also shown that in HIV infected 
individuals, the cryptococcal infection has a very high rate of relapse (30-50 %) following treatment 
(M. Ruhnke, 2004).  Management of the infection in patients therefore routinely involves lifelong 
antifungal therapy in addition to the antiretroviral therapy.  With the emergence of immune 
reconstitution inflammatory syndrome (IRIS), a condition seen in HAART-treated patients, there is a 
paradoxical deterioration in the patients’ clinical status as the recovering immune system responds 
to a previously acquired opportunistic infection which in turn worsens the symptoms of infection  (M. 
Ruhnke, 2004).  Management for this condition includes continuation of both antifungal therapy and 
HAART. 
 
Cryptococcal meningitis is diagnosed by performing a lumbar puncture and is one of the key 
indicators of the development of acquired immunodeficiency syndrome (AIDS) (D.J. Sloan et al., 
2009).  The disease generally affects adult patients and patients with a CD4 cell count of 100 
cells/µl or less.  Current South African guidelines outline three treatment categories for cryptococcal 
meningitis in HIV patients (K. McCarthy et al., 2007): 
• A 2 week induction phase with amphotericin B (IV) at a dose of 1-1.5 mg/kg/day 
• The consolidation phase consists of po. fluconazole, 400 mg po. daily for 8 weeks 
• Secondary prophylaxis (long term maintenance) with po. fluconazole 200 mg/day for life or 
until CD4 count is greater than 200 cells/mm3 for more than 6 months on ART (at least 12 
months on fluconazole in total) 
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The most commonly encountered opportunistic infection in patients with HIV/AIDS, oropharyngeal 
candidiasis (OPC), is reported to occur in approximately 90% of infected patients (O.J.M. Hamza et 
al., 2008).  Moreover, OPC remains the most frequent HIV-associated oral disease in sub-Saharan 
Africa in patients with a CD4 count of < 250 cells/µl (F.M. Durden et al., 1997).  OPC is treated with 
either single dose fluconazole (750mg po.) or 2-week therapy with oral fluconazole (150mg/day).  
Studies have found that there are no statistically significant differences between the efficacies of 
these two regimens. 
 
Drug-drug interactions (DDIs) are typically classified as either pharmacokinetic or pharmacodynamic 
interactions.  Pharmacokinetic interactions involve changes in blood concentrations of either agent 
due to the effect of interacting drugs on processes such as the absorption, distribution, metabolism 
and excretion of the drug (G.K. Dresser et al., 2000, S.M. Robertson et al., 2005).  Most DDIs are 
pharmacokinetic in nature and are attributed to the interaction of drugs in common metabolic 
pathways.  Pharmacodynamic interactions, conversely, arise from an additive/synergistic or 
antagonistic effect that occurs in response to co-administration of certain drugs (E. Albengres et al., 
1998).  An alteration in the pharmacological response (efficacy and/or toxicity) may result. 
 
Pharmacokinetic DDIs have a number of possible outcomes.  Drug levels of either the ARVs or the 
concomitant medication may be lowered thereby achieving sub-therapeutic levels which may lead to 
treatment failure as well as the development of drug resistance.  Alternatively, DDIs may elevate the 
concentrations of ARVs or co-administered medication resulting in drug toxicity and an increase in 
the severity and risk of developing adverse effects. 
 
The polyene antifungal amphotericin B is used mainly in the treatment of life-threatening systemic 
fungal infections (such as cryptococcal meningitis), as it has a narrow therapeutic index.  
Interactions between amphotericin B and antiretrovirals are pharmacodynamic in nature and may 
result in nephrotoxicity, blood dyscrasias and hypokalaemia (E. Albengres et al., 1998).  
Fluconazole is a triazole antifungal agent that inhibits the isoenzymes CYP2C9 and CYP3A4 of the 
human cytochrome P450 system.  In theory it therefore decreases the metabolism and increases 
the plasma concentration of co-administered drugs that are metabolised by the CYP P450 system. 
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ARVs are among the drug classes that have the greatest potential to develop DDIs (K. Seden et al., 
2009).  ARVs are potent inhibitors or inducers of liver enzymes (cytochrome P450 isoenzymes) 
which are responsible for the metabolism of a wide range of other drugs.  Ritonavir is a protease 
inhibitor which is predominantly metabolised by CYP3A isoenzymes and, to a lesser extent, by 
CYP2D6.  In addition to this, ritonavir is also a potent inhibitor of hepatic CYP3A4 as well as the 
ATP-dependent plasma membrane transporter, P-glycoprotein (Pgp)  (A. Hsu et al., 1998).  
Ritonavir has a very high affinity for CYP3A and therefore other CYP3A inhibitors have little effect 
on ritonavir metabolism.  Ritonavir, therefore, inhibits the metabolism of other agents metabolised by 
CYP3A leading to an increase in the corresponding concentrations (Table 1).  The non-nucleoside 
reverse transcriptase inhibitors, nevirapine and efavirenz, are metabolised by CYP3A and CYP2B6 
and CYP2B6 respectively (K. Dahri et al., 2007).  Interference therefore exists between the 
metabolic pathways of the antiretrovirals and the antifungals, potentially resulting in drug-drug 
interactions. 
 
The azole antifungal, fluconazole, is a potent inhibitor of both CYP3A4 and P-gp.  Concomitant 
administration of fluconazole and the protease inhibitors (PIs), therefore, results in higher PI levels 
due to inhibition of their metabolism and delayed excretion (D. Pal et al., 2006).  Fluconazole 
increases ritonavir concentrations, but the effect of ritonavir on fluconazole levels is unknown (Table 
1).  The effect of fluconazole on ritonavir-boosted lopinavir is also unknown.  It has been shown, 
however, that ketoconazole decreases the boosted-lopinavir levels and the ketoconazole levels 
conversely increase (M.M.R de Maat et al., 2003, D. Pal et al., 2006).  Efavirenz is both an inhibitor 
and an inducer of CYP3A4 and therefore its effect on concomitant agents is unpredictable (S.M. 
Robertson et al., 2005).  Coadministration of efavirenz and fluconazole results in elevated efavirenz 
levels (M.M.R. de Maat et al., 2003).  In vitro studies have shown that azole antifungals, including 
fluconazole, are expected to increase blood concentration of nevirapine, an inducer of CYP3A4 
activity (E. Albengres et al., 1998). 
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Table 1:  Known drug-drug interactions between fluconazole and the studied ARVs. 
       
  Inducer/Inhibitor 
 FLC RTV EFV NVP LPV/r 
FLC 
 
Increases fluconazole 
AUC
f,h
 
Effect unknown
g
 
FLC AUC decreases
h
 
Effect unknown
e
 
Fluconazole AUC 
expected to decrease
h
 
Fluconazole AUC 
increases
d
 
RTV Increase in RTV AUC
c,f,j
 
 
RTV AUC increases
b
 
RTV AUC decreases
b
 
No significant change in 
levels
h
 
 
EFV EFV AUC increases
e,h
 EFV AUC increases
b
 
 
No clinical data available 
No significant changes in 
EFV levels
b,h
 
EFV AUC decreases
d
 
NVP NVP AUC expected to increase
a,i
 
No significant interaction/ 
change in levels
j
 
No clinical data available 
 
No significant changes in 
NVP levels
d
 
S
u
b
s
t
r
a
t
e
 
LPV/r Effect unknown
g
 
 
LPV AUC decreases 
unless LPV/r dose 
increased
b,h
 
Studies have found both 
no significant change as 
well as a decrease in LPV 
AUC
b,d,h
 
 
       
Legend: AUC Area under the drug concentration-time curve; FLC Fluconazole; RTV Ritonavir; EFV Efavirenz; NVP Nevirapine;  
LPV/r Lopinavir/ritonavir 
       
a
 E. Albengres et al., 1998; 
b
 L.M. Catanzaro et al., 2004;
 c
 A. Cato et al., 1997; 
d
 R.S. Cvetkovic et al., 2003; 
e
 M.M.R. De Maat et al., 2003;  
f
 A. Hsu et al., 1998; 
g
 D. Pal et al., 2006; 
h
 S.M. Robertson et al., 2005; 
i
 K. Seden et al., 2009; 
j
 A.L. Tseng et al., 1997 
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Drug-drug interactions between antifungals and antiretroviral agents become a concern 
when given concomitantly for a long period of time, as is the case when treating HIV positive 
patients with cryptococcal meningitis.  For some antifungals and antiretrovirals, a 
relationship has been established between the plasma drug concentration and the resulting 
antifungal or antiviral (reduction in viral load) effect (J.W.C. Alffenaar et al., 2010).  
Therapeutic drug monitoring (TDM) of both agents may be useful to predict or interpret the 
emergence of DDIs.  TDM involves routine monitoring of plasma drug levels, thereby 
individualizing and optimizing drug therapy by dosage adjustments, improving dosing 
schedules or even altering the drug regimen.  Information about the pharmacokinetics of 
these drugs and clinical co-variates that may have a possible influence on these parameters, 
including DDIs, is therefore important for the determination of the most appropriate dosing 
schedule in these patients.  
 
GAPS IN RESEARCH 
• Data pertaining to ARV pharmacokinetic drug interaction studies is restricted in 
resource limited countries such as South Africa. 
 
• Knowledge of DDIs between fluconazole and the ARVs is limited; the effect of 
fluconazole on nevirapine levels and the lopinavir/ritonavir combination in specific. 
 
• Pharmacokinetic studies that include patients with renal impairment are limited. 
 
• More recently HIV is being diagnosed in patients over 50 years of age.  It is therefore 
seen as a chronic condition requiring life-long treatment.  Formal pharmacokinetic 
study data, however, is limited with regards to PK parameters in elderly patients. 
 
AIM 
Drug-drug interactions may lead to elevated or sub therapeutic drug levels, resulting in 
toxicity or treatment failure as well as the development of drug resistance.  There is a large 
degree of inter- and intraindividual variation with regards to plasma drug concentrations due 
to individual differences in the expression of metabolizing enzymes.  We therefore plan to 
use a population pharmacokinetic approach to study the pharmacokinetics (alteration in PK) 
and potential DDIs between fluconazole and the ARVs nevirapine, efavirenz, 
lopinavir/ritonavir in adult patients. 
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The results of this study will provide evidence based guidance for the combined 
antiretroviral-antifungal treatment in patients with cryptococcal meningitis and oropharyngeal 
candidiasis as well as the covariates/patient characteristics that may influence optimal 
therapy. 
 
SIGNIFICANCE 
The data derived from this study will provide guidance to HIV/AIDS patients with regards to 
the appropriate dose and dosing schedule of co-administered ARVs and antifungal therapy, 
to identify patient populations at risk and to recommend an appropriate dosing schedule in 
such patients to avoid treatment failure or toxicity. 
 
METHOD 
Study design 
This is a prospective, open uncontrolled study in a treatment population (ARVs + FLC) and a 
matched control group (ARVs only).  
 
Inclusion criteria 
Treatment population 
• HIV-infected adults (≥ 18 yrs) diagnosed with cryptococcal meningitis and/or 
oropharyngeal candidiasis that are on antifungal therapy (fluconazole) and ARVs (at 
least one of the following: nevirapine, efavirenz, lopinavir/ritonavir) will be recruited 
from both outpatient and in-patient centres at Tygerberg Hospital (TBH), Karl Bremer 
Hospital (KBH) and the T.C. Newman Clinic (TCNC). 
• Patients that have already been treated with fluconazole by another hospital and then 
referred to TBH because of the severity of the condition will also be recruited. 
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Control group 
• HIV-infected adults (≥ 18 yrs) that are currently on antiretroviral therapy (at least one of 
the following: nevirapine, efavirenz, lopinavir/ritonavir) will be recruited from both 
outpatient and in-patient centres TBH, KBH and TCNC. 
 
Exclusion criteria 
• Patients with an altered mental status as measured by the Glasgow Coma Score 
(<15). 
• Patients whose medical condition is such as to make the drawing of blood inadvisable 
eg. patients with anaemia as well as patients with severe diarrhoea or dehydration. 
• Patients who are unwilling to participate in the study or sign the consent forms. 
 
Blood specimens 
Blood will be collected in 7.5 ml Vacuette tubes containing serum separating clot activator.  
The antiretroviral and antifungal drug specimens will be centrifuged and serum will be stored 
in the Pharmacology Division’s -70 °C freezer until being shipped to the Division of Infectious 
Diseases, University of Würzburg Medical Centre (Germany) for analysis.  As this is a 
population pharmacokinetic analysis, there are no specific time points where blood must be 
taken and so each patient may have blood taken at various time points after medication 
intake. 
 
Outpatients: 
A total of four (4) blood samples (5ml each, total volume of 20ml) will be taken from the 
outpatients over a span of two clinic visits.  The sampling schedule for all enrolled 
outpatients (treatment as well as their matched control group) will be divided into two 
categories according to the reason for fluconazole use; either cryptococcal meningitis or 
oropharyngeal candidiasis.  The actual sampling methods for both groups are the same, only 
the time frame between clinic visits differ (see table 2).  Once patients have been recruited, 
they will have a sample drawn on their arrival at the clinic after they have taken their 
medication.  Before the patient then leaves the clinic he/she will have another blood sample 
taken.  .  At this first visit the patient will also be asked to only take his/her medication at the 
clinic on the date of the second visit, after a trough level blood sample has been drawn.  The 
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timeframe for the cryptococcal meningitis- and their matched control group is at least one 
month between blood draws at the clinic visit as these patients receive at least 6 months 
fluconazole therapy.  The oropharyngeal candidiasis group and their matched controls have 
a one week period between clinic visits as they only receive a 14-day course of fluconazole. 
 
Table 2: Sampling blood volumes and guidelines for blood sampling in the outpatient 
population. 
*Approximate timeframe, depending on patients’ ability to visit clinic. 
 
 BLOOD SPECIMENS 
 
Volume per 
sample (ml) 
Number of samples 
Total volume of blood  
(ml) 
Treatment 
population 
5 4 20 
Control 
population 
5 4 20 
    
 SAMPLING SCHEDULES 
OPC pts and  
matched 
control 
Sampling Day 1 Sample no.1 On arrival 
  Sample no. 2 Before departure 
 ONE WEEK* 
 
Sampling Day 2 Sample no. 3 
On arrival  
(before medication taken) 
  Sample no. 4 Before departure 
    
CM pts and  
matched 
control 
Sampling Day 1 Sample no. 1 On arrival 
  Sample no. 2 Before departure 
 ONE MONTH* 
 
Sampling Day 2 Sample no. 3 
On arrival  
(before medication taken) 
  Sample no. 4 Before departure 
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Hospitalised patients 
For the purpose of the study a total of seven (7) blood samples (4 ml per sample) will be 
taken from each inpatient over his/her full stay in hospital.  The sampling schedule for 
hospitalised patients would be as follows: 0hr, 0.5hr, 1hr, 2hr, 4hr, 8hr and 12hr post dose 
samples.  
Sample size 
It is envisaged to enrol 100 patients (50 pts ARVs + FLC; 50 pts ARVs only) 
 
Site 
Blood sampling will be performed at three centres; Tygerberg Hospital, Karl Bremer Hospital 
and the T.C. Newman Clinic. 
Screening 
Patients will be recruited when meeting the inclusion criteria.  When a patient who fulfils the 
inclusion criteria is recruited from the out-patient clinics at either Tygerberg Hospital, Karl 
Bremer Hospital or T.C. Newman Clinic, the research nurse will be informed who will then 
inform the patient about the study.  If the patient agrees, written informed consent will be 
obtained. 
 
Methods 
The determination of plasma levels will be performed by High Pressure Liquid 
Chromatography (HPLC) and Gas-Chromatography (GC) as described by Langmann et al. 
(2002, 2006).  The fluconazole assay will be developed by the research group in Wuerzburg, 
Germany and determination of fluconazole plasma levels would then be performed 
according the method developed. 
 
Data recording and management 
Each patient will be allocated a study specific number and the following data will be recorded 
for each patient on a case report form (CRF1) at the time of admittance to the study and on 
the occasion of each blood sampling: 
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• Current HAART regimen 
• Current fluconazole treatment 
• Reason for fluconazole use 
• Concurrent drug therapy, including over-the-counter and herbal preparations 
• Estimated times of the last three ARV doses according to patient recall 
• Estimated times of the last three fluconazole doses according to patient recall 
• Date of birth 
• Gender 
• Body weight 
• Height 
• Nutritional classification 
The following information will also be obtained from the patient’s clinical file: 
• Latest viral load and CD4/CD8 count (with date and time) 
• Latest serum creatinine (with date) 
• Serum albumin (with date) 
• Serum ALT (with date) 
• Significant past medical history and laboratory parameters related to toxicity e.g. liver 
function tests  
 
At the time of each pharmacokinetic study (taking of a blood sample at admittance and the 
second visit) the following data will be recorded for each patient on a patient specific case 
record form (CRF2): 
• Patient randomization number 
• Current HAART regimen as well as the brand names and batch numbers of the drugs 
that the patient is taking. 
• Current fluconazole regimen as well as brand names and batch numbers of the drugs 
the patient is taking. 
• ARV dosing schedule. 
• Fluconazole dosing schedule. 
• Exact time of the last dose of ARV. 
• Exact time of the last dose of fluconazole. 
• Exact time of venepuncture. 
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In this study no specific drug or medical device will be investigated or tested on patients.  
Any potential study-related adverse events will be reported in the CRF by the Principal 
Investigator or a sub-investigator. 
 
Data monitoring 
Monitoring for data integrity will be performed quarterly and at the end of the study by the 
Division of Pharmacology (Stellenbosch University). 
 
Patient confidentiality and anonymity 
To protect patient confidentiality, especially the patients’ HIV status, a study number will be 
assigned to each patient.  Only the study number will be used as a reference in the database 
to protect patient confidentiality.  The study number and name will be kept in a separate 
database.  The electronic database will be password-protected and access restricted to the 
study investigators.  The blood samples will be allocated a sample barcode and linked to the 
patient through the individual subject barcode.  Personal information will only be found on 
the consent form, which will be stored separately from all other anonymous patient 
information, including the CRF.  As the proposed project is a co-operation between 
Stellenbosch University, University of Würzburg medical centre and the University of Florida, 
anonymized data will also be transmitted to these universities under strict obedience of data 
protection.  The reporting on patients from this study in any type of manuscript will be done 
anonymously. 
 
Laboratory method 
The plasma concentration of nevirapine, efavirenz, lopinavir, ritonavir and fluconazole will be 
performed by the Division of Infectious Diseases, University of Würzburg Medical Centre 
(Germany).  A material transfer agreement will be obtained for the transfer of blood samples.  
 
The population PK evaluation will be performed by the Division of Pharmacology 
(Stellenbosch University) in consultation with the Department of Pharmaceutics, University of 
Florida. 
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Data analysis and Statistical method 
The data will be captured using MS Excel whereafter a Nonlinear Mixed Effects Modelling 
(NONMEM) software program will be used to analyse drug pharmacokinetics in the study 
population through pooling data.  The specific population pharmacokinetic method as 
described by Barrett et al. (2005) and Sheiner and Ludden (1992) will be used to perform the 
pharmacokinetic (PK) evaluation.  This statistical method will generate population 
pharmacokinetic data using a sparse sampling scheme taken from a large number of 
individuals from the same population.  This will be done by the Department of Pharmaceutics 
(University of Florida) and the Division of Pharmacology (Stellenbosch University).   
 
A one-compartment model will be used to assess the following parameters in both the 
treatment and control group: absorption rate constant (ka), oral clearance (CL) and the area 
under the concentration-time curve (AUC).  After constructing a model for each of these 
patient populations, comparisons can be made with regards to abovementioned parameters. 
Serum concentration and all other data will also be analyzed by descriptive statistics and 
graphically presented. 
 
ETHICAL CONSIDERATIONS 
Written informed consent will be obtained from each patient when submitted to hospital.  The 
patient information and consent forms will be available in English, Afrikaans and Xhosa. 
 
Patients taking part in this study will not receive feedback about their drug plasma levels, 
since the plasma samples will be stored for a few weeks to a few months before being 
analyzed.  If, however, the results of the drug plasma concentration of specific patients show 
non-compliance to their ART or antifungal therapy or virus resistance is established, the 
patients will be informed and necessary support will be given to such a patient. 
 
This study will deliver benefit to future patients on the studied ARV’s and fluconazole, since 
the pharmacokinetic data and covariates that influence combined drug therapy will serve as 
guidance for safe and efficacious ART and antifungal treatment in the future. 
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This study will be conducted according to internationally accepted ethical standards and 
guidelines. 
 
FUNDING AND TIMELINE 
An MSc student fellowship has been provided by the International Research Training Group 
(IRTG).  Additional funding requests will be made.  A detailed budget is attached (Appendix 
1). 
It is estimated that the study will take approximately 2 years to complete.  We plan to start 
collecting specimens in 2010 as soon as ethics approval is granted. 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM - ARVs 
 
TITLE OF THE RESEARCH PROJECT: 
Pharmacokinetic study to assess potential drug-drug interactions between antiretroviral therapy 
and fluconazole in patients with HIV/AIDS diagnosed with cryptococcal meningitis and/or 
oropharyngeal candidiasis. 
 
REFERENCE NUMBER: N10/06/212 
 
PRINCIPAL INVESTIGATOR: 
Prof. Bernd Rosenkranz 
 
ADDRESS: 
Division of Pharmacology 
Department of Medicine 
University of Stellenbosch 
PO Box 19063 
Tygerberg, Cape Town, 7505 
South Africa 
 
CONTACT NUMBER: 
Phone: +27-21-938 9331 
Mobile: +27-82-955 0017 
Fax: +27- 21-932 6958 
 
Invitation Paragraph 
You are being invited to take part in a research project that possibly involves the long-term 
storage of blood.  Please take some time to read the information presented here, which will 
explain the details of this project.  Please ask the study staff or doctor any questions about any 
part of this project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be involved.  
Also, your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical research Council (MRC) Ethical Guidelines for Research. 
Pat-No    
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Thank you for reading this. 
 
 
 
Why is this study being done and why have you been invited 
to participate? 
You have been diagnosed to be HIV positive.  Nowadays, it is possible to treat the HIV-infection 
with antiretroviral (ARV) medication to help keep you healthy for a long time.  To achieve 
successful antiretroviral therapy, we have to be sure that the patient’s blood always contains a 
sufficient concentration of medication.  This will avoid virus replication and disease progression.  
It is therefore essential that the patient takes his/her medication regularly over a long period of 
time. 
 
 
The level of medication in the blood, however, differs from patient to patient.  This can be due to 
interaction with other drugs, food or other factors that affect the breakdown or absorption of the 
ARVs.  If the drug level in a patient’s blood is too high there is a greater risk of developing side 
effects.  On the other hand, patients may not have any clinical benefit from the medication or the 
virus might develop resistance against the medication if the drug concentration in the blood is 
too low. 
 
The purpose of this study is to investigate the medication level in your blood.  With this 
knowledge we can see if anything is interfering with the amount of medicine in your blood and 
then determine whether the dosage of your treatment is sufficient and not too low or too high. 
 
How many people will take part in the study? 
We are planning to recruit 100 patients. 
 
Who is conducting the study? 
The study is a cooperative project between Stellenbosch University (South Africa), University of 
Wuerzburg Medical Centre (Germany) and the University of Florida (USA). 
 
What will happen if I take part in this research study? 
For the purpose of this study 4 blood samples will be taken from you during your routine visits to 
the clinic.  If possible, these blood samples will be taken at the time of routine clinical sampling 
to minimize needle pricks.  All other normal investigations will be done as usual. 
 
If the results of the study show that the concentration of ARVs in your blood is too low, an 
adjustment of the drug dose or a change in the dosing schedule may have to occur, so that you 
will get the best treatment available.  The results will not be available immediately though since 
it will take time to measure the samples. 
 
Pat-No    
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What will be investigated in the blood sample? 
We will investigate: 
• Drug concentration 
 
The results of the investigations will be analyzed and published anonymously by the universities 
and co-workers. 
 
You may choose if you wish to get information about you personal results. 
 
Can I stop being in the study? 
Yes.  You can decide to stop at any time.  Tell the study nurse if you are thinking about stopping 
or have decided to stop.  Your data will then not be evaluated. 
 
What risks can I expect from being in the study? 
There are no risks because there are only 2 additional blood tubes taken per visit when blood is 
routinely drawn for clinical reasons.  You may experience minor pain or bruising at the site 
where blood is taken during the routine clinical sampling.  Other risks of drawing blood such as 
fainting or feeling light-headed and excessive bleeding rarely occur. There is no special 
treatment or any change of the treatment. 
 
If your blood is to be stored is there a chance that it will be 
used for other research? 
Your blood will only be used for research that is directly related to the investigation of the 
medication level in your blood.  If the researchers wish to use your stored blood for additional 
research in this field they will be required to apply for permission to do so from the Human 
Research Ethics Committee at Stellenbosch University. 
 
If you do not wish your blood specimen to be stored after this research study is completed, you 
will have the opportunity to request that it should be discarded when you sign the consent form. 
 
Are there benefits to taking part in the study? 
Taking part in this study can help us determine if the ARV concentration in your blood is at the 
correct level so as to be effective in treatment and not cause unwanted side effects.   There is 
no direct benefit to you at this point in the study, but this information will help us to treat HIV 
positive patients better and could therefore also help future patients. 
 
 
You will not receive feedback about your drug plasma levels, since the plasma samples will be 
stored for a few weeks to a few months before being analyzed.  If however, we have found that 
the drug concentration of your medication is too low or too high, we will let you know.  You may 
choose if you want to get this information or not. 
 
 
Pat-No    
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Will my medical information and me taking part in this study 
be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognized by a third party. 
 
Will you be paid to take part in this study and are there any 
costs involved? 
You will not be paid for taking part in this study.  You will not need to pay for any laboratory tests 
and examinations which are study specific procedures. 
 
What are my rights if I take part in this study?  
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
the study.  If you decide to take part in the study, you may leave the study at any time.  No 
matter what decision you make, there will be no penalty to you and you will not lose any of your 
regular benefits.  Leaving the study will not affect your medical care.  You can still get your 
medical care from our institution. 
 
We shall tell you about new information or changes in the study that may affect your health or 
your willingness to continue in the study. 
 
Who can answer my questions about the study? 
You may talk to Dr. Jantjie J. Taljaard (021 938 9645) or Dr. M. Zeier (021 938 5230) 
(Tygerberg Hospital), Dr. Z. Joubert (021 979 5463) (Karl Bremer Hospital) and Dr. D. 
Hagemeister (021 860 2621) (T.C. Newman Clinic) the study doctors, about any questions or 
concerns you have about this study. 
 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 
You will receive a copy of this information and consent form for your own records. 
 
 
Pat-No    
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Pat-No    
 
Declaration by participant 
 
By signing below, I .................................................................................... agree to take part in a 
research study entitled (insert title of study). 
 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language in which I am fluent and comfortable. 
 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 
• I may ask to leave the study before it has finished, if the study doctor or researcher feels 
it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
I agree that my blood or tissue sample can be stored, but I can choose to request at any 
time that my stored sample be destroyed.  I have the right to receive confirmation that 
my request has been carried out. 
 
OR 
 
Please destroy my blood sample as soon as the current research project has been 
completed.  (Tick the chosen option) 
 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
 
...............................................................                                .......................................................... 
Signature of participant     Signature of witness 
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Declaration by investigator 
 
I (name) ........................................................................................ declare that: 
 
• I explained the information in this document to .................................................................. 
 
• I encouraged him/her to ask questions and took adequate time to answer them. 
 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign 
the declaration below.) 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
 
...............................................................                                .......................................................... 
Signature of investigator  Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ........................................................................................ declare that: 
 
• I assisted the investigator (name) 
................................................................................... to explain the information in this 
document to (name of participant) ........................................................................... using 
the language medium of English/Afrikaans/Xhosa. 
 
• We encouraged him/her to ask questions and took 
adequate time to answer them. 
 
• I conveyed a factually correct version of what was related 
to me. 
 
Pat-No    
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• I am satisfied that the participant fully understands the 
content of this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
Signed at (place) ............................................................ on (date) .......................................2010. 
 
 
...............................................................                                 ......................................................... 
Signature of interpreter  Signature of witness
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM – ARVs + FCZ 
 
TITLE OF THE RESEARCH PROJECT: 
Pharmacokinetic study to assess potential drug-drug interactions between antiretroviral therapy 
and fluconazole in patients with HIV/AIDS diagnosed with cryptococcal meningitis and/or 
oropharyngeal candidiasis. 
REFERENCE NUMBER: N10/06/212 
 
PRINCIPAL INVESTIGATOR: 
Prof. Bernd Rosenkranz 
 
ADDRESS: 
Division of Pharmacology 
Department of Medicine 
University of Stellenbosch 
PO Box 19063 
Tygerberg, Cape Town, 7505 
South Africa 
 
CONTACT NUMBER: 
Phone: +27-21-938 9331 
Mobile: +27-82-955 0017 
Fax: +27- 21-932 6958 
 
Invitation Paragraph 
You are being invited to take part in a research project that possibly involves the long-term 
storage of blood.  Please take some time to read the information presented here, which will 
explain the details of this project.  Please ask the study staff or doctor any questions about any 
part of this project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be involved.  
Also, your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee  at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical research Council (MRC) Ethical Guidelines for Research. 
 
Thank you for reading this. 
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Pat-No    
 
Why is this study being done and why have you been invited 
to participate? 
You have been diagnosed to be HIV positive.  Nowadays, it is possible to treat the HIV-infection 
with antiretroviral (ARV) medication to help keep you healthy for a long time.  To achieve 
successful antiretroviral therapy, we have to be sure that the patient’s blood always contains a 
sufficient concentration of medication.  This will avoid virus replication and disease progression.  
It is therefore essential that the patient takes his/her medication regularly over a long period of 
time. 
 
Your immune system is compromised and therefore you are susceptible to a variety of other 
infections.  You have also been diagnosed with cryptococcal meningitis (fungal infection of the 
brain) and/or oropharyngeal candidiasis (fungal infection of the mouth and throat) which is 
treated with the antifungal, fluconazole.  Successful therapy also requires a sufficient amount of 
medication in the blood. 
 
The level of medication in the blood, however, differs from patient to patient.  This can be due to 
interference in the metabolism of either medication.  If the drug level in a patient’s blood is too 
high there is a greater risk of developing side effects.  On the other hand, patients may not have 
any clinical benefit from the medication or the virus might develop resistance against the 
medication if the drug concentration in the blood is too low. 
 
The purpose of this study is to investigate the medication level in your blood.  With this 
knowledge we can see if any interactions are occurring between your medications and then 
determine whether the dosage of your treatment is sufficient and not too low or too high. 
 
How many people will take part in the study? 
We are planning to recruit 100 patients. 
 
Who is conducting the study? 
The study is a cooperative project between Stellenbosch University (South Africa), University of 
Wuerzburg Medical Centre (Germany) and the University of Florida (USA). 
 
What will happen if I take part in this research study? 
For the purpose of this study 4 blood samples will be taken from you during your routine visits to 
the clinic.  If possible, these blood samples will be taken at the time of routine clinical sampling 
to minimize needle pricks.  All other normal investigations will be done as usual. 
 
If the results of the study show that the concentration of either drug (ARV or antifungal) in your 
blood is too low due to an interaction between the drugs, an adjustment of the drug dose or a 
change in the dosing schedule may have to occur, so that you will get the best treatment 
available.  The results will not be available immediately though since it will take time to measure 
the samples. 
 
What will be investigated in the blood sample? 
We will investigate: 
• Drug concentration 
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The results of the investigations will be analyzed and published anonymously by the universities 
and co-workers. 
You may choose if you wish to get information about you personal results. 
 
Can I stop being in the study? 
Yes.  You can decide to stop at any time.  Tell the study nurse if you are thinking about stopping 
or have decided to stop.  Your data will then not be evaluated. 
 
What risks can I expect from being in the study? 
There are no risks because there are only 2 additional blood tubes taken per visit when blood is 
routinely drawn for clinical reasons.  You may experience minor pain or bruising at the site 
where blood is taken during the routine clinical sampling.  Other risks of drawing blood such as 
fainting or feeling light-headed and excessive bleeding rarely occur. There is no special 
treatment or any change of the treatment. 
 
If your blood is to be stored is there a chance that it will be 
used for other research? 
Your blood will only be used for research that is directly related to the investigation of the 
medication level in your blood.  If the researchers wish to use your stored blood for additional 
research in this field they will be required to apply for permission to do so from the Human 
Research Ethics Committee at Stellenbosch University. 
 
If you do not wish your blood specimen to be stored after this research study is completed, you 
will have the opportunity to request that it should be discarded when you sign the consent form. 
 
Are there benefits to taking part in the study? 
Taking part in this study can help us determine if the ARV and antifungal medication are 
interfering with one another resulting in a change in the concentration of the medication in your 
blood.  There is no direct benefit to you at this point in the study, but this information will help us 
to treat HIV positive patients using the antifungal medication better and could therefore also 
help future patients. 
 
You will not receive feedback about your drug plasma levels, since the plasma samples will be 
stored for a few weeks to a few months before being analyzed.  If however, we have found that 
the drug concentration of either medication is too low or too high due to an interaction, we will 
let you know.  You may choose if you want to get this information or not. 
 
Will my medical information and me taking part in this study 
be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognized by a third party. 
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Will you be paid to take part in this study and are there any 
costs involved? 
You will not be paid for taking part in this study.  You will not need to pay for any laboratory tests 
and examinations which are study specific procedures. 
 
What are my rights if I take part in this study? 
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
the study.  If you decide to take part in the study, you may leave the study at any time.  No 
matter what decision you make, there will be no penalty to you and you will not lose any of your 
regular benefits.  Leaving the study will not affect your medical care.  You can still get your 
medical care from our institution. 
 
We shall tell you about new information or changes in the study that may affect your health or 
your willingness to continue in the study. 
 
Who can answer my questions about the study? 
You may talk to Dr. Jantjie J. Taljaard (021 938 9645) or Dr. M. Zeier (021 938 5230) 
(Tygerberg Hospital), Dr. Z. Joubert (021 979 5463) (Karl Bremer Hospital) and Dr. D. 
Hagemeister (021 860 2621) (T.C. Newman Clinic) the study doctors, about any questions or 
concerns you have about this study. 
 
You can contact the Health Research Ethics Committee  at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 
You will receive a copy of this information and consent form for your own records. 
 
 
Pat-No    
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Declaration by participant 
 
By signing below, I .................................................................................... agree to take part in a 
research study entitled (insert title of study). 
 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language in which I am fluent and comfortable. 
 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 
• I may ask to leave the study before it has finished, if the study doctor or researcher feels 
it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
I agree that my blood or tissue sample can be stored, but I can choose to request at any 
time that my stored sample be destroyed.  I have the right to receive confirmation that 
my request has been carried out. 
 
OR 
 
Please destroy my blood sample as soon as the current research project has been 
completed.  (Tick the chosen option) 
 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
 
...............................................................                                .......................................................... 
Signature of participant     Signature of witness 
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Declaration by investigator 
 
I (name) ........................................................................................ declare that: 
 
• I explained the information in this document to .................................................................. 
 
• I encouraged him/her to ask questions and took adequate time to answer them. 
 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign 
the declaration below.) 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
 
...............................................................                                .......................................................... 
Signature of investigator  Signature of witness 
 
 
 
Declaration by interpreter 
 
I (name) ........................................................................................ declare that: 
 
• I assisted the investigator (name) 
................................................................................... to explain the information in this 
document to (name of participant) ........................................................................... using 
the language medium of English/Afrikaans/Xhosa. 
 
• We encouraged him/her to ask questions and took 
adequate time to answer them. 
 
• I conveyed a factually correct version of what was related 
to me. 
 
Pat-No    
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• I am satisfied that the participant fully understands the 
content of this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
Signed at (place) ............................................................ on (date) .......................................2010. 
 
 
...............................................................                                 ......................................................... 
Signature of interpreter  Signature of witness
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM – ARVs + FCZ – Serial blood draw 
 
TITLE OF THE RESEARCH PROJECT: 
Pharmacokinetic study to assess potential drug-drug interactions between antiretroviral therapy 
and fluconazole in patients with HIV/AIDS diagnosed with cryptococcal meningitis and/or 
oropharyngeal candidiasis. 
 
REFERENCE NUMBER: N10/06/212 
 
PRINCIPAL INVESTIGATOR: 
Prof. Bernd Rosenkranz 
 
ADDRESS: 
Division of Pharmacology 
Department of Medicine 
University of Stellenbosch 
PO Box 19063 
Tygerberg, Cape Town, 7505 
South Africa 
 
CONTACT NUMBER: 
Phone: +27-21-938 9331 
Mobile: +27-82-955 0017 
Fax: +27- 21-932 6958 
 
Invitation Paragraph 
You are being invited to take part in a research project that possibly involves the long-term 
storage of blood.  Please take some time to read the information presented here, which will 
explain the details of this project.  Please ask the study staff or doctor any questions about any 
part of this project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be involved.  
Also, your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee  at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical research Council (MRC) Ethical Guidelines for Research. 
 
Thank you for reading this. 
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Why is this study being done and why have you been invited 
to participate? 
You have been diagnosed to be HIV positive.  Nowadays, it is possible to treat the HIV-infection 
with antiretroviral (ARV) medication to help keep you healthy for a long time.  To achieve 
successful antiretroviral therapy, we have to be sure that the patient’s blood always contains a 
sufficient concentration of medication.  This will avoid virus replication and disease progression.  
It is therefore essential that the patient takes his/her medication regularly over a long period of 
time. 
 
Your immune system is compromised and therefore you are susceptible to a variety of other 
infections.  You have also been diagnosed with cryptococcal meningitis (fungal infection of the 
brain) and/or oropharyngeal candidiasis (fungal infection of the mouth and throat) which is 
treated with the antifungal, fluconazole.  Successful therapy also requires a sufficient amount of 
medication in the blood. 
 
The level of medication in the blood, however, differs from patient to patient.  This can be due to 
interference in the metabolism of either medication.  If the drug level in a patient’s blood is too 
high there is a greater risk of developing side effects.  On the other hand, patients may not have 
any clinical benefit from the medication or the virus might develop resistance against the 
medication if the drug concentration in the blood is too low. 
 
The purpose of this study is to investigate the medication level in your blood.  With this 
knowledge we can see if any interactions are occurring between your medications and then 
determine whether the dosage of your treatment is sufficient and not too low or too high. 
 
How many people will take part in the study? 
We are planning to recruit 12 patients. 
 
Who is conducting the study? 
The study is a cooperative project between Stellenbosch University (South Africa), University of 
Wuerzburg Medical Centre (Germany) and the University of Florida (USA). 
 
What will happen if I take part in this research study? 
For the purpose of this study 8 blood samples will be taken from you during an 8 hour period at 
the clinic. 
 
What will be investigated in the blood sample? 
We will investigate: 
• Drug concentration 
 
Can I stop being in the study? 
Yes.  You can decide to stop at any time.  Tell the study nurse if you are thinking about stopping 
or have decided to stop.  Your data will then not be evaluated. 
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What risks can I expect from being in the study? 
 You may experience minor pain or bruising at the site where blood is taken during the routine 
clinical sampling.  Other risks of drawing blood such as fainting or feeling light-headed and 
excessive bleeding rarely occur. There is no special treatment or any change of the treatment. 
 
Are there benefits to taking part in the study? 
Taking part in this study can help us determine if the ARV and antifungal medication are 
interfering with one another resulting in a change in the concentration of the medication in your 
blood.  There is no direct benefit to you at this point in the study, but this information will help us 
to treat HIV positive patients using the antifungal medication better and could therefore also 
help future patients. 
 
You will not receive feedback about your drug plasma levels, since the plasma samples will be 
stored for a few weeks to a few months before being analyzed.  If however, we have found that 
the drug concentration of either medication is too low or too high due to an interaction, we will 
let you know.  You may choose if you want to get this information or not. 
 
Will my medical information and me taking part in this study 
be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognized by a third party. 
 
Will you be paid to take part in this study and are there any 
costs involved? 
You will be paid for taking part in this study.  You will not need to pay for any laboratory tests 
and examinations which are study specific procedures. 
 
What are my rights if I take part in this study? 
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
the study.  If you decide to take part in the study, you may leave the study at any time.  No 
matter what decision you make, there will be no penalty to you and you will not lose any of your 
regular benefits.  Leaving the study will not affect your medical care.  You can still get your 
medical care from our institution. 
 
We shall tell you about new information or changes in the study that may affect your health or 
your willingness to continue in the study. 
 
Pat-No    
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Who can answer my questions about the study? 
 You may talk to Dr. Jantjie J. Taljaard (021 938 9645) or Dr. M. Zeier (021 938 5230) 
(Tygerberg Hospital), Dr. Z. Joubert (021 979 5463) (Karl Bremer Hospital) and Dr. D. 
Hagemeister (021 860 2621) (T.C. Newman Clinic) the study doctors, about any questions or 
concerns you have about this study. 
 
You can contact the Health Research Ethics Committee  at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 
You will receive a copy of this information and consent form for your own records. 
 
 
Pat-No    
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Declaration by participant 
 
By signing below, I .................................................................................... agree to take part in a 
research study entitled (insert title of study). 
 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language in which I am fluent and comfortable. 
 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 
• I may ask to leave the study before it has finished, if the study doctor or researcher feels 
it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
I agree that my blood or tissue sample can be stored, but I can choose to request at any 
time that my stored sample be destroyed.  I have the right to receive confirmation that 
my request has been carried out. 
 
OR 
 
Please destroy my blood sample as soon as the current research project has been 
completed.  (Tick the chosen option) 
 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
 
...............................................................                                .......................................................... 
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Signature of participant     Signature of witness 
 
 
 
 
 
Declaration by investigator 
 
I (name) ........................................................................................ declare that: 
 
• I explained the information in this document to .................................................................. 
 
• I encouraged him/her to ask questions and took adequate time to answer them. 
 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above. 
 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign 
the declaration below.) 
 
Signed at (place) ............................................................ on (date) ...................................... 2010. 
 
 
...............................................................                                .......................................................... 
Signature of investigator  Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ........................................................................................ declare that: 
 
• I assisted the investigator (name) 
................................................................................... to explain the information in this 
document to (name of participant) ........................................................................... using 
the language medium of English/Afrikaans/Xhosa. 
 
• We encouraged him/her to ask questions and took 
adequate time to answer them. 
 
• I conveyed a factually correct version of what was related 
to me. 
 
• I am satisfied that the participant fully understands the 
content of this informed consent document and has had all his/her questions 
satisfactorily answered. 
Pat-No    
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Signed at (place) ............................................................ on (date) .......................................2010. 
 
...............................................................                                 ......................................................... 
Signature of interpreter  Signature of witness 
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Pat. –No.    
 
 
 
 
                DATE 
PATIENT CHARACTERISTICS 
 
Date of birth        Sex                                                        
                                                     
 
 
Date of informed consent 
 
 
 
 
Ethnic group            Smoke   
 
 
 
 
 
 
 
 
 
 
PHYSICAL EXAMINATION 
 
 
 
Weight    Height                                                                       
 
 
 
 
 
 
BODY WEIGHT CLASSIFICATION (ACCORDING TO BMI) 
 
 Underweight  
(< 18.5) 
Normal  
(18.5-24.99) 
Overweight  
(≥ 25.0) 
Obese  
(≥ 30.0) 
YES     
NO     
 
      
D D M M Y Y 
      
D D M M Y Y 
male  
female  
      
D D M M Y Y 
Black 
 
Coloured 
 
Indian/Asian 
 
White 
 
Other 
 
yes  
no  
    
 kg  
  
 cm  
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Pat. –No.    
 
 
 
HIV DIAGNOSIS 
 
Date of first    
diagnosis    
 
 
 
 
 
STAGING   (according to WHO: 1,2,3,4)                          Stage: 
 
 
CONCOMITANT DISEASES (significant)                                     None 
 
 Disease 
Date onset 
DDMMYY 
On going 
1    
2    
3    
4    
5    
6    
7    
 
 
CONCOMITANT MEDICATION                                None 
 
 Medication  Route Dosage 
Date onset 
DDMMYY 
On going 
1      
2      
3      
4      
5      
6      
7      
      
D D M M Y Y 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
Appendix G                                                                 217 
Protocol No. 1002 CRF I    Version 2.0    6 June 2010 
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Clinical Tests  
Standard 
Unit 
Other unit (if 
applicable) 
Value 
CD4 Cells 
 
      
D D M M Y Y 
    
h h m m 
Cells/µl   
Creatinine 
 
      
D D M M Y Y 
mg/dl   
Viral load 
 
      
D D M M Y Y 
Copies/ml   
Serum albumin 
 
      
D D M M Y Y 
mg/l   
Serum ALT 
 
      
D D M M Y Y 
Units/l   
 
 
 
 
COMMENTS           Yes                   No    
 
___________________________________________________________________________  
 
__________________________________________________________________________  
 
 
CASE REPORT FORM REVIEW 
 
I confirm that all Information reported for this patient is accurate and complete. 
  
  
_______________________________________ 
                                    Investigator Signature 
 
 
      
D D M M Y Y 
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               DATE 
 
HIV MEDICATION     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MISSING LAST 7 DAYS   None 
 
Number of days 
      
D D M M Y Y 
Medication  Formulation 
(T, C, S) 
Dosage Date of onset 
Time of medication intake prior to 
blood sampling 
   
 
      
D D M M Y Y  
    
h h m m 
      
D D M M Y Y 
   
      
D D M M Y Y 
    
h h m m 
      
D D M M Y Y 
   
      
D D M M Y Y 
    
h h m m 
      
D D M M Y Y 
   
      
D D M M Y Y 
    
h h m m 
      
D D M M Y Y 
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FLUCONAZOLE MEDICATION       N/A  
 
REASON FOR USE OF FLUCONAZOLE 
 
Cryptococcal meningitis   Oropharyngeal candidiasis   Other (please specify) 
 
MEAL PRIOR TO ARVs              _______________________ 
 
Heavy meal (eg. a full plate of food)  Medium meal (eg. a sandwich) 
 
Light meal (eg. a biscuit, cracker or fruit)            Time of meal 
 
No meal               
Medication  Formulation Dosage Date of onset Time of medication intake prior to 
blood sampling 
    
h h m m 
      
D D M M Y Y 
    
h h m m 
      
D D M M Y Y 
   
 
      
D D M M Y Y 
    
   
  
    
h h m m 
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LABORATORY – BLOOD SAMPLING 
 
 
1. First blood sample  
 
Collection time       Collection date 
 
 
 
 
 
 
2. Second blood sample (if applicable) 
 
Collection time 
 
 
 
 
 
 
 
COMMENTS  Yes   No   
 
 
 
 
 
 
 
 
CASE REPORT FORM REVIEW 
 
I confirm that all information reported for this patient is accurate and complete 
 
 
  ________________________________________ 
         Investigator Signature 
    
h h m m 
      
D D M M Y Y 
    
h h m m 
  
      
D D M M Y Y 
Stellenbosch University http://scholar.sun.ac.za
Appendix I                                                                       222 
 
 
 
Appendix I 
 
Interday precision of fluconazole 
 
Date Day 0.5 µg/ml 4  µg/ml 10  µg/ml 20  µg/ml 
19-07-2011 1 0.47 4.3 10.9 20.1 
20-07-2011 2 0.43 4.4 11 20 
26-07-2011 3 0.42 3.8 12.3 19.8 
27-07-2011 4 0.55 3.8 12 20 
28-07-2011 5 0.54 3.8 9.3 18.3 
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